assertion_id	disorder_id	disorder_name	source_file	section	section_index	name	description	category	frequency	diagnostic	context	subtype	role	presence	association	accession	age_range	background	base_model	classification	clinical_significance	consequence	data_type	de_novo_rate	definition_type	duration	effect	expressivity	features	genotype	incubation_days	incubation_years	markers	maximum_value	mean_range	minimum_value	model_format	model_id	model_software	model_type	notes	parent_of_origin_effect	penetrance	percentage	phase	platform	population	publication	repository_url	results	review_notes	sample_count	scope	sequence_length	severity	species	specificity	status	subtype_frequency	title	type	unit	scalar_fields_json	complex_fields_json	raw_json
24	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	has_subtypes	0	EML4-ALK NSCLC	EML4-ALK fusion is the most common ALK rearrangement in NSCLC (~90%), resulting from an inversion on chromosome 2p. Multiple EML4-ALK variants exist (V1, V2, V3a/b) differing in the EML4 breakpoint. V3 may have different resistance patterns.																																																								"{""description"": ""EML4-ALK fusion is the most common ALK rearrangement in NSCLC (~90%), resulting from an inversion on chromosome 2p. Multiple EML4-ALK variants exist (V1, V2, V3a/b) differing in the EML4 breakpoint. V3 may have different resistance patterns."", ""name"": ""EML4-ALK NSCLC""}"	{}	"{""description"": ""EML4-ALK fusion is the most common ALK rearrangement in NSCLC (~90%), resulting from an inversion on chromosome 2p. Multiple EML4-ALK variants exist (V1, V2, V3a/b) differing in the EML4 breakpoint. V3 may have different resistance patterns."", ""name"": ""EML4-ALK NSCLC""}"
25	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	has_subtypes	1	Non-EML4 ALK Fusion NSCLC	Rare ALK fusions with partners other than EML4, including KIF5B-ALK, TFG-ALK, and KLC1-ALK. Generally respond similarly to ALK TKIs.																																																								"{""description"": ""Rare ALK fusions with partners other than EML4, including KIF5B-ALK, TFG-ALK, and KLC1-ALK. Generally respond similarly to ALK TKIs."", ""name"": ""Non-EML4 ALK Fusion NSCLC""}"	{}	"{""description"": ""Rare ALK fusions with partners other than EML4, including KIF5B-ALK, TFG-ALK, and KLC1-ALK. Generally respond similarly to ALK TKIs."", ""name"": ""Non-EML4 ALK Fusion NSCLC""}"
71	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	0	ATTRm (hereditary)	Caused by mutations in the TTR gene, leading to misfolded transthyretin proteins and amyloid deposits in various tissues.																																																								"{""description"": ""Caused by mutations in the TTR gene, leading to misfolded transthyretin proteins and amyloid deposits in various tissues."", ""name"": ""ATTRm (hereditary)""}"	{}	"{""description"": ""Caused by mutations in the TTR gene, leading to misfolded transthyretin proteins and amyloid deposits in various tissues."", ""evidence"": [{""explanation"": ""The literature clearly states that mutations in the TTR gene lead to the misfolding of transthyretin proteins, which then aggregate into amyloid fibrils, supporting the statement."", ""reference"": ""PMID:25604431"", ""snippet"": ""Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to then misfold and aggregate into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms that hereditary cardiac amyloidosis results from the misfolding and accumulation of transthyretin due to mutations in the TTR gene."", ""reference"": ""PMID:34518987"", ""snippet"": ""Heritable cardiac amyloidosis (CA) ... results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports that hereditary ATTRm amyloidosis is caused by mutations in the TTR gene, which leads to the disease."", ""reference"": ""PMID:30486687"", ""snippet"": ""Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis, in which the disease is caused by mutant transthyretin (TTR)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms that familial amyloid polyneuropathies, a form of hereditary ATTR amyloidosis, are caused by mutated TTR leading to amyloid deposits."", ""reference"": ""PMID:22094129"", ""snippet"": ""Familial amyloid polyneuropathies (FAPs) are a group of life-threatening multisystem disorders transmitted as an autosomal dominant trait. Nerve lesions are induced by deposits of amyloid fibrils, most commonly due to mutated transthyretin (TTR)."", ""supports"": ""SUPPORT""}], ""name"": ""ATTRm (hereditary)""}"
72	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	1	ATTRwt (wild-type/senile)	Occurs without mutations in the TTR gene, commonly affecting older individuals, with amyloid deposits primarily in the heart.																																																								"{""description"": ""Occurs without mutations in the TTR gene, commonly affecting older individuals, with amyloid deposits primarily in the heart."", ""name"": ""ATTRwt (wild-type/senile)""}"	{}	"{""description"": ""Occurs without mutations in the TTR gene, commonly affecting older individuals, with amyloid deposits primarily in the heart."", ""evidence"": [{""explanation"": ""The study confirms that ATTR-wt occurs without mutations in the TTR gene and primarily affects the heart in older individuals."", ""reference"": ""PMID:31731233"", ""snippet"": ""Wild-type ATTR amyloidosis (ATTR-wt) is characterized by the accumulation of amyloid in the heart, leading to fatal heart failure and arrhythmia."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports that ATTRwt occurs without mutations in the TTR gene and primarily affects the heart, commonly in older individuals."", ""reference"": ""PMID:26048914"", ""snippet"": ""The non-hereditary form (ATTRwt) is caused by native or wild-type TTR and was previously referred to as senile systemic amyloidosis. ... The predominant effect of ATTRwt amyloidosis is on the heart"", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms that ATTRwt affects older individuals and involves amyloid deposits in the heart."", ""reference"": ""PMID:34390072"", ""snippet"": ""Cardiac ATTR deposition occurred after age 75 years and increased in an age-dependent manner."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature supports that ATTRwt occurs without TTR gene mutations and is age-related, affecting the heart."", ""reference"": ""PMID:32441155"", ""snippet"": ""Tissue accumulation of misfolded transthyretin (TTR) may occur because of TTR gene mutations (variant amyloid TTR amyloidosis, ATTRv), or as an age-related phenomenon (wild-type ATTR, ATTRwt)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports that ATTRwt commonly affects older individuals and involves the heart."", ""reference"": ""PMID:28329248"", ""snippet"": ""Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease predominantly of elderly male, characterized by concentric LV hypertrophy, preserved LVEF, and low QRS voltages."", ""supports"": ""SUPPORT""}], ""name"": ""ATTRwt (wild-type/senile)""}"
216	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	has_subtypes	0	AIDS-defining conditions	Presence of specific opportunistic infections or cancers signaling progression to AIDS.																																																								"{""description"": ""Presence of specific opportunistic infections or cancers signaling progression to AIDS."", ""name"": ""AIDS-defining conditions""}"	{}	"{""description"": ""Presence of specific opportunistic infections or cancers signaling progression to AIDS."", ""evidence"": [{""explanation"": ""The reference explicitly mentions that opportunistic infections and certain cancers (neoplasms) are part of the spectrum of AIDS, fitting the definition of AIDS-defining conditions provided in the statement."", ""reference"": ""PMID:3608570"", ""snippet"": ""Aside from opportunistic infections, several neoplasms have been identified as part of the spectrum of acquired immunodeficiency syndrome (AIDS) as defined by the Centers for Disease Control."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses specific opportunistic infections and cancers as initial AIDS-defining illnesses (ADIs), supporting the assertion that these conditions signal progression to AIDS."", ""reference"": ""PMID:18366449"", ""snippet"": ""The three most frequent initial ADIs were Pneumocystis carinii (jirovecii) pneumonia (PCP) (15.6%), oesophageal candidiasis (14.3%) and Kaposi's sarcoma (13.9%) in the pre-cART period."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights the role of opportunistic infections in patients with HIV/AIDS, which supports the statement about specific opportunistic infections being AIDS-defining conditions."", ""reference"": ""PMID:19584497"", ""snippet"": ""Opportunistic parasitic infection can cause severe morbidity and mortality."", ""supports"": ""SUPPORT""}], ""name"": ""AIDS-defining conditions""}"
284	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	0	Acute ATLL	Most aggressive form with leukemic presentation, hypercalcemia, organ infiltration, and opportunistic infections. Median survival is 6-10 months despite treatment. Characterized by high tumor burden and poor response to chemotherapy.																																																								"{""description"": ""Most aggressive form with leukemic presentation, hypercalcemia, organ infiltration, and opportunistic infections. Median survival is 6-10 months despite treatment. Characterized by high tumor burden and poor response to chemotherapy."", ""name"": ""Acute ATLL""}"	{}	"{""description"": ""Most aggressive form with leukemic presentation, hypercalcemia, organ infiltration, and opportunistic infections. Median survival is 6-10 months despite treatment. Characterized by high tumor burden and poor response to chemotherapy."", ""evidence"": [{""explanation"": ""Shimoyama classification study confirms acute ATLL has median survival of 6.2 months, supporting the poor prognosis described."", ""reference"": ""PMID:1751370"", ""snippet"": ""MST was 6.2 months for acute type"", ""supports"": ""SUPPORT""}], ""name"": ""Acute ATLL""}"
285	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	1	Lymphoma Type ATLL	Presents with lymphadenopathy without significant blood involvement. May have better prognosis than acute form if responsive to chemotherapy. Less frequently associated with hypercalcemia.																																																								"{""description"": ""Presents with lymphadenopathy without significant blood involvement. May have better prognosis than acute form if responsive to chemotherapy. Less frequently associated with hypercalcemia."", ""name"": ""Lymphoma Type ATLL""}"	{}	"{""description"": ""Presents with lymphadenopathy without significant blood involvement. May have better prognosis than acute form if responsive to chemotherapy. Less frequently associated with hypercalcemia."", ""evidence"": [{""explanation"": ""Shimoyama classification defines lymphoma type by lymphadenopathy without significant blood involvement."", ""reference"": ""PMID:1751370"", ""snippet"": ""Lymphoma type, no lymphocytosis, 1% or less abnormal T-lymphocytes, and histologically-proven lymphadenopathy with or without extranodal lesions."", ""supports"": ""SUPPORT""}], ""name"": ""Lymphoma Type ATLL""}"
286	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	2	Chronic ATLL	Indolent presentation with mild lymphocytosis and skin involvement. May remain stable for years before transforming to acute type. Better prognosis with median survival of several years.																																																								"{""description"": ""Indolent presentation with mild lymphocytosis and skin involvement. May remain stable for years before transforming to acute type. Better prognosis with median survival of several years."", ""name"": ""Chronic ATLL""}"	{}	"{""description"": ""Indolent presentation with mild lymphocytosis and skin involvement. May remain stable for years before transforming to acute type. Better prognosis with median survival of several years."", ""evidence"": [{""explanation"": ""Shimoyama study shows chronic type has median survival of 24.3 months, supporting the better prognosis described."", ""reference"": ""PMID:1751370"", ""snippet"": ""24.3 months for chronic type"", ""supports"": ""SUPPORT""}], ""name"": ""Chronic ATLL""}"
287	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	3	Smoldering ATLL	Most indolent form with minimal lymphocytosis (<5% abnormal cells) and often limited to skin lesions. May not require immediate treatment. Requires monitoring for transformation to aggressive disease.																																																								"{""description"": ""Most indolent form with minimal lymphocytosis (<5% abnormal cells) and often limited to skin lesions. May not require immediate treatment. Requires monitoring for transformation to aggressive disease."", ""name"": ""Smoldering ATLL""}"	{}	"{""description"": ""Most indolent form with minimal lymphocytosis (<5% abnormal cells) and often limited to skin lesions. May not require immediate treatment. Requires monitoring for transformation to aggressive disease."", ""evidence"": [{""explanation"": ""Shimoyama classification defines smoldering type by low abnormal cell counts and absence of hypercalcemia."", ""reference"": ""PMID:1751370"", ""snippet"": ""Smouldering type, 5% or more abnormal lymphocytes of T-cell nature in PB, normal lymphocyte level (less than 4 x 10(9)/l), no hypercalcaemia"", ""supports"": ""SUPPORT""}], ""name"": ""Smoldering ATLL""}"
344	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	has_subtypes	0	Dry AMD (Atrophic)	Gradual degeneration with drusen and geographic atrophy, 85-90% of cases.																																																								"{""description"": ""Gradual degeneration with drusen and geographic atrophy, 85-90% of cases."", ""name"": ""Dry AMD (Atrophic)""}"	{}	"{""description"": ""Gradual degeneration with drusen and geographic atrophy, 85-90% of cases."", ""name"": ""Dry AMD (Atrophic)""}"
345	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	has_subtypes	1	Wet AMD (Neovascular)	Abnormal blood vessel growth, causes rapid vision loss, 10-15% of cases.																																																								"{""description"": ""Abnormal blood vessel growth, causes rapid vision loss, 10-15% of cases."", ""name"": ""Wet AMD (Neovascular)""}"	{}	"{""description"": ""Abnormal blood vessel growth, causes rapid vision loss, 10-15% of cases."", ""name"": ""Wet AMD (Neovascular)""}"
384	15	Akinetopsia	Akinetopsia.yaml	has_subtypes	0	Cinematographic vision	Akinetopsia subtype characterized by perceiving motion as a series of discrete frames (cinematographic vision).																																																								"{""description"": ""Akinetopsia subtype characterized by perceiving motion as a series of discrete frames (cinematographic vision)."", ""name"": ""Cinematographic vision""}"	{}	"{""description"": ""Akinetopsia subtype characterized by perceiving motion as a series of discrete frames (cinematographic vision)."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report describes cinematographic vision as one of two reported akinetopsia subtypes."", ""reference"": ""PMID:31036340"", ""snippet"": ""Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects."", ""supports"": ""SUPPORT""}], ""name"": ""Cinematographic vision""}"
385	15	Akinetopsia	Akinetopsia.yaml	has_subtypes	1	Invisibility of moving objects	Akinetopsia subtype characterized by failure to perceive moving objects.																																																								"{""description"": ""Akinetopsia subtype characterized by failure to perceive moving objects."", ""name"": ""Invisibility of moving objects""}"	{}	"{""description"": ""Akinetopsia subtype characterized by failure to perceive moving objects."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report describes invisibility of moving objects as the second akinetopsia subtype."", ""reference"": ""PMID:31036340"", ""snippet"": ""Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects."", ""supports"": ""SUPPORT""}], ""name"": ""Invisibility of moving objects""}"
418	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	0	Early-Onset Alzheimer's Disease	Type of Alzheimer's that occurs in individuals younger than 65 and is often associated with genetic factors.																																																								"{""description"": ""Type of Alzheimer's that occurs in individuals younger than 65 and is often associated with genetic factors."", ""name"": ""Early-Onset Alzheimer's Disease""}"	{}	"{""description"": ""Type of Alzheimer's that occurs in individuals younger than 65 and is often associated with genetic factors."", ""evidence"": [{""explanation"": ""This reference clearly supports the definition of Early-Onset Alzheimer's Disease as occurring in individuals younger than 65 and being often associated with genetic factors."", ""reference"": ""PMID:30707186"", ""snippet"": ""Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics of early-onset AD in comparison to late-onset AD include a larger genetic predisposition (familial mutations and summed polygenic risk)"", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the idea that early-onset Alzheimer's disease can be hereditary, aligning with the statement's mention of genetic factors."", ""reference"": ""PMID:25998117"", ""snippet"": ""Young-onset dementia is hereditary, multifactorial, or sporadic. The most common hereditary dementias include Alzheimer disease."", ""supports"": ""SUPPORT""}], ""name"": ""Early-Onset Alzheimer's Disease""}"
419	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	1	Late-Onset Alzheimer's Disease	The most common form of Alzheimer's, occurring in those aged 65 and older.																																																								"{""description"": ""The most common form of Alzheimer's, occurring in those aged 65 and older."", ""name"": ""Late-Onset Alzheimer's Disease""}"	{}	"{""description"": ""The most common form of Alzheimer's, occurring in those aged 65 and older."", ""evidence"": [{""explanation"": ""The literature confirms that late-onset Alzheimer's Disease is the most common form of Alzheimer's and primarily affects those aged 65 and older."", ""reference"": ""PMID:24429902"", ""snippet"": ""In both cases, the disease results in severe cognitive dysfunction, among other problems, and the late-onset form of the disease is now considered to be the most common cause of dementia among the elderly."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study differentiates between young onset and late onset Alzheimer's Disease, with late onset typically affecting older adults."", ""reference"": ""PMID:34120901"", ""snippet"": ""BACKGROUND: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that late-onset Alzheimer's Disease is more prevalent compared to early-onset forms."", ""reference"": ""PMID:18667359"", ""snippet"": ""Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa."", ""supports"": ""SUPPORT""}], ""name"": ""Late-Onset Alzheimer's Disease""}"
482	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	has_subtypes	0	PAX3-FOXO1 Fusion-Positive	The most common and aggressive subtype, harboring the t(2;13)(q35;q14) translocation. Associated with older age at diagnosis, extremity primary sites, and inferior survival compared to other subtypes.																																																								"{""description"": ""The most common and aggressive subtype, harboring the t(2;13)(q35;q14) translocation. Associated with older age at diagnosis, extremity primary sites, and inferior survival compared to other subtypes."", ""name"": ""PAX3-FOXO1 Fusion-Positive""}"	{}	"{""description"": ""The most common and aggressive subtype, harboring the t(2;13)(q35;q14) translocation. Associated with older age at diagnosis, extremity primary sites, and inferior survival compared to other subtypes."", ""name"": ""PAX3-FOXO1 Fusion-Positive""}"
483	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	has_subtypes	1	PAX7-FOXO1 Fusion-Positive	Harbors the t(1;13)(p36;q14) translocation. Generally diagnosed at younger age and associated with better prognosis than PAX3-FOXO1 positive tumors.																																																								"{""description"": ""Harbors the t(1;13)(p36;q14) translocation. Generally diagnosed at younger age and associated with better prognosis than PAX3-FOXO1 positive tumors."", ""name"": ""PAX7-FOXO1 Fusion-Positive""}"	{}	"{""description"": ""Harbors the t(1;13)(p36;q14) translocation. Generally diagnosed at younger age and associated with better prognosis than PAX3-FOXO1 positive tumors."", ""name"": ""PAX7-FOXO1 Fusion-Positive""}"
484	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	has_subtypes	2	Fusion-Negative Alveolar Rhabdomyosarcoma	Approximately 20% of histologically defined ARMS lack PAX-FOXO1 fusions. These tumors have clinical behavior and molecular features more similar to embryonal rhabdomyosarcoma.																																																								"{""description"": ""Approximately 20% of histologically defined ARMS lack PAX-FOXO1 fusions. These tumors have clinical behavior and molecular features more similar to embryonal rhabdomyosarcoma."", ""name"": ""Fusion-Negative Alveolar Rhabdomyosarcoma""}"	{}	"{""description"": ""Approximately 20% of histologically defined ARMS lack PAX-FOXO1 fusions. These tumors have clinical behavior and molecular features more similar to embryonal rhabdomyosarcoma."", ""name"": ""Fusion-Negative Alveolar Rhabdomyosarcoma""}"
527	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	has_subtypes	0	Familial ALS	Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS.																																																								"{""description"": ""Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS."", ""name"": ""Familial ALS""}"	{}	"{""description"": ""Hereditary form of ALS accounting for 5-10% of cases, with mutations in genes such as SOD1, C9orf72, TARDBP, and FUS."", ""name"": ""Familial ALS""}"
528	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	has_subtypes	1	Sporadic ALS	Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology.																																																								"{""description"": ""Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology."", ""name"": ""Sporadic ALS""}"	{}	"{""description"": ""Non-hereditary form of ALS accounting for 90-95% of cases with unclear etiology."", ""name"": ""Sporadic ALS""}"
529	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	has_subtypes	2	Bulbar-onset ALS	ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement.																																																								"{""description"": ""ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement."", ""name"": ""Bulbar-onset ALS""}"	{}	"{""description"": ""ALS beginning with speech and swallowing difficulties due to bulbar motor neuron involvement."", ""name"": ""Bulbar-onset ALS""}"
530	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	has_subtypes	3	Limb-onset ALS	ALS beginning with limb weakness, the most common presentation.																																																								"{""description"": ""ALS beginning with limb weakness, the most common presentation."", ""name"": ""Limb-onset ALS""}"	{}	"{""description"": ""ALS beginning with limb weakness, the most common presentation."", ""name"": ""Limb-onset ALS""}"
582	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	0	Primary APS	occurs in the absence of any other related disease																																																								"{""description"": ""occurs in the absence of any other related disease"", ""name"": ""Primary APS""}"	{}	"{""description"": ""occurs in the absence of any other related disease"", ""evidence"": [{""explanation"": ""The passage supports the statement by indicating that APS can exist on its own without other related diseases, defining it as primary APS (PAPS)."", ""reference"": ""PMID:16338214"", ""snippet"": ""the condition can exist on its own. APS appears to represent a clinical spectrum, both in terms of APS features and the presence of other autoimmune conditions. The clinical and serological characteristics of 'primary' APS (PAPS) are similar to those of secondary APS, although the clinical features are more commonly recognised in the presence of another autoimmune or inflammatory condition."", ""supports"": ""SUPPORT""}, {""explanation"": ""This snippet reinforces that APS can exist independently as primary APS."", ""reference"": ""PMID:27550302"", ""snippet"": ""APS can be isolated (primary APS) or associated with other autoimmune diseases."", ""supports"": ""SUPPORT""}], ""name"": ""Primary APS""}"
583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	Secondary APS	occurs with other autoimmune diseases, such as systemic lupus erythematosus																																																								"{""description"": ""occurs with other autoimmune diseases, such as systemic lupus erythematosus"", ""name"": ""Secondary APS""}"	{}	"{""description"": ""occurs with other autoimmune diseases, such as systemic lupus erythematosus"", ""evidence"": [{""explanation"": ""This reference states that APS can occur with other autoimmune diseases, particularly systemic lupus erythematosus, which supports the statement regarding the subtype Secondary APS."", ""reference"": ""PMID:11014973"", ""snippet"": ""APS may be associated with another autoimmune disease (secondary APS), particularly systemic lupus erythematosus (SLE)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference explains that secondary APS is associated with another autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE), thus supporting the statement."", ""reference"": ""PMID:15507265"", ""snippet"": ""Primary utilized when there is no associated disorder, secondary with an associated autoimmune disorder such as systemic lupus erythematosus (SLE)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference provides context for primary APS being without other autoimmune diseases and implies that secondary APS, in contrast, involves other autoimmune disorders such as systemic lupus erythematosus."", ""reference"": ""PMID:19593144"", ""snippet"": ""Although originally described in the context of systemic lupus erythematosus, antiphospholipid syndrome was then recognized as a primary antiphospholipid syndrome without any underlying autoimmune disease in almost half of the cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article mentions secondary antiphospholipid syndrome in conjunction with systemic lupus erythematosus, supporting the existence of Secondary APS as a subtype of APS."", ""reference"": ""PMID:35896399"", ""snippet"": ""Systemic lupus erythematosus (SLE) and secondary anti-phospholipid syndrome (APS II) can cause increased morbidity and mortality of the fetus."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article gives data on secondary APS occurring along with systemic lupus erythematosus, thus supporting the statement about the existence of the Secondary APS subtype."", ""reference"": ""PMID:10866096"", ""snippet"": ""We retrospectively studied patients with APS and systemic lupus erythematosus (SLE)...39 patients had primary antiphospholipid syndrome (PAPS) and 69 secondary antiphospholipid syndrome (SAPS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article states that APS is common in SLE patients, indicating the close relationship between APS and SLE and supporting the subtype of Secondary APS."", ""reference"": ""PMID:26939208"", ""snippet"": ""BACKGROUND: The antiphospholipid syndrome (APS) is one of the most encountered autoimmunity in systemic lupus erythematosus (SLE) patients and pathogenesis of these two seems to be intricate"", ""supports"": ""SUPPORT""}], ""name"": ""Secondary APS""}"
584	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	2	Asymptomatic APS	individuals with antiphospholipid antibodies but no clinical symptoms																																																								"{""description"": ""individuals with antiphospholipid antibodies but no clinical symptoms"", ""name"": ""Asymptomatic APS""}"	{}	"{""description"": ""individuals with antiphospholipid antibodies but no clinical symptoms"", ""evidence"": [{""explanation"": ""The reference supports the existence of individuals with antiphospholipid antibodies but no clinical symptoms, which align with the description of Asymptomatic APS."", ""reference"": ""PMID:17145604"", ""snippet"": ""Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are increasingly being recognized in children. Transient non-pathogenic aPL are often seen after childhood infections, while thrombotic events seem rare in those with true aPL."", ""supports"": ""SUPPORT""}], ""name"": ""Asymptomatic APS""}"
690	28	Asthma	Asthma.yaml	has_subtypes	0	Allergic Asthma	Triggered by allergens such as pollen, pet dander, or dust mites.																																																								"{""description"": ""Triggered by allergens such as pollen, pet dander, or dust mites."", ""name"": ""Allergic Asthma""}"	{}	"{""description"": ""Triggered by allergens such as pollen, pet dander, or dust mites."", ""evidence"": [{""explanation"": ""The literature explicitly states that allergic asthma is triggered by allergens."", ""reference"": ""PMID:32037107"", ""snippet"": ""Allergic asthma is defined as asthma associated with sensitization to aeroallergens, which leads to asthma symptoms and airway inflammation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature confirms asthma can be triggered by mite allergens, consistent with the definition of allergic asthma."", ""reference"": ""PMID:24925403"", ""snippet"": ""Allergic diseases triggered by mite allergens include allergic rhinoconjunctivitis, asthma, atopic dermatitis and other skin diseases."", ""supports"": ""SUPPORT""}, {""explanation"": ""The document indicates that climate change contributes to the development of asthma, supporting the statement."", ""reference"": ""PMID:32589303"", ""snippet"": ""Respiratory health can be particularly affected by climate change, which contributes to the development of allergic respiratory diseases and asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature identifies atopic (allergic) asthma as initiated by allergens, which supports the statement."", ""reference"": ""PMID:30725285"", ""snippet"": ""Asthma is a heterogeneous chronic inflammatory disease of the airways. The most prevalent form is atopic asthma, which is initiated by the exposure to (inhaled) allergens."", ""supports"": ""SUPPORT""}], ""name"": ""Allergic Asthma""}"
691	28	Asthma	Asthma.yaml	has_subtypes	1	Non-Allergic Asthma	Triggered by factors such as stress, exercise, cold air, or respiratory infections.																																																								"{""description"": ""Triggered by factors such as stress, exercise, cold air, or respiratory infections."", ""name"": ""Non-Allergic Asthma""}"	{}	"{""description"": ""Triggered by factors such as stress, exercise, cold air, or respiratory infections."", ""evidence"": [{""explanation"": ""The reference discusses asthma subtypes triggered by exercise, cold air, and respiratory conditions, but does not explicitly mention stress or classify it specifically as 'Non-Allergic Asthma'."", ""reference"": ""PMID:11678516"", ""snippet"": ""Asthmatic attack in exercise-induced asthma is brought about by hyperventilation (not necessarily to exercise), cold air, and low humidity of the air breathed."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference mentions environmental exposures like cold dry air and non-allergic triggers, but does not explicitly identify stress or exercise specifically in relation to 'Non-Allergic Asthma'."", ""reference"": ""PMID:25439356"", ""snippet"": ""First, asthma phenotypes that are associated with environmental exposures (occupational agents, cigarette smoke, air pollution, cold dry air)..."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference corroborates that environmental pollutants are triggers for asthma exacerbations."", ""reference"": ""PMID:20176257"", ""snippet"": ""Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma."", ""supports"": ""SUPPORT""}], ""name"": ""Non-Allergic Asthma""}"
692	28	Asthma	Asthma.yaml	has_subtypes	2	Adult-Onset Asthma	Develops later in adult life and often triggered by environmental factors.																																																								"{""description"": ""Develops later in adult life and often triggered by environmental factors."", ""name"": ""Adult-Onset Asthma""}"	{}	"{""description"": ""Develops later in adult life and often triggered by environmental factors."", ""evidence"": [{""explanation"": ""The reference discusses subtypes of adult-onset asthma and emphasizes the importance of different risk factors, which supports that adult-onset asthma could have environmental triggers."", ""reference"": ""PMID:36833767"", ""snippet"": ""Only a few previous studies have investigated the subtypes of adult-onset asthma. No previous study has assessed whether these subtypes are different between men and women, or whether these subtypes have different risk factors."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study indicates that adult-onset asthma is often associated with specific triggers of onset, which aligns with the statement that it is often triggered by environmental factors."", ""reference"": ""PMID:30240884"", ""snippet"": ""Adult-onset asthma is an important asthma phenotype and, in contrast to childhood asthma, is often associated with specific triggers of onset."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature specifies that environmental factors such as pollutants can trigger adult asthma, further supporting the statement about environmental triggers."", ""reference"": ""PMID:20176257"", ""snippet"": ""Exposure to unusual substances at work causes occupational asthma, accounting for about 5% of asthma in adults. Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma."", ""supports"": ""SUPPORT""}], ""name"": ""Adult-Onset Asthma""}"
693	28	Asthma	Asthma.yaml	has_subtypes	3	Asthma-COPD Overlap	Features of both chronic obstructive pulmonary disease and asthma.																																																								"{""description"": ""Features of both chronic obstructive pulmonary disease and asthma."", ""name"": ""Asthma-COPD Overlap""}"	{}	"{""description"": ""Features of both chronic obstructive pulmonary disease and asthma."", ""evidence"": [{""explanation"": ""The article explicitly refers to the Asthma-COPD Overlap Syndrome, which indicates the presence of subtypes sharing features of both asthma and COPD."", ""reference"": ""PMID:26398072"", ""snippet"": ""Although in textbooks asthma and chronic obstructive pulmonary disease (COPD) are viewed as distinct disorders, there is increasing awareness that many patients have features of both. This article reviews the asthma-COPD overlap syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article acknowledges overlapping phenotypes between asthma and COPD, supporting the existence of a subtype with features of both diseases."", ""reference"": ""PMID:24507842"", ""snippet"": ""Asthma in childhood and COPD in smokers have their own phenotypic expression with underlying pathophysiological mechanisms that differ importantly. In older adults, asthma and COPD are more difficult to differentiate and there exists a bronchodilator response in most but not all patients with asthma and persistent airway obstruction in most but not all patients with COPD where even up to 50% have been reported to have some bronchodilator response as assessed with FEV1."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article clearly supports that there is an overlap between asthma and COPD, validating the statement about the Asthma-COPD Overlap subtype with shared features."", ""reference"": ""PMID:29713158"", ""snippet"": ""Asthma and COPD are heterogeneous diseases. Patients with both disease features (asthma-COPD overlap ...) are common."", ""supports"": ""SUPPORT""}], ""name"": ""Asthma-COPD Overlap""}"
694	28	Asthma	Asthma.yaml	has_subtypes	4	Exercise-Induced Asthma	Often triggered by physical exertion.																																												Added Exercise-Induced Asthma for a more comprehensive list of subtypes.												"{""description"": ""Often triggered by physical exertion."", ""name"": ""Exercise-Induced Asthma"", ""review_notes"": ""Added Exercise-Induced Asthma for a more comprehensive list of subtypes.""}"	{}	"{""description"": ""Often triggered by physical exertion."", ""evidence"": [{""explanation"": ""This reference explicitly lists exercise-induced asthma as a subtype of asthma, supporting the statement."", ""reference"": ""PMID:22794682"", ""snippet"": ""patients with asthma may be classified as allergic (IgE mediated), nonallergic (often triggered by viral upper respiratory tract infections or no apparent cause), occupational, aspirin-exacerbated respiratory disease, potentially (near) fatal, exercise induced, and cough variant asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study highlights exercise-induced asthma and provides insights into managing physical activities for those with this subtype."", ""reference"": ""PMID:5002114"", ""snippet"": ""This study indicates that swimming should be recommended in preference to running or cycling as an exercise programme for adults and children with asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study details the pathology of exercise-induced bronchoconstriction, commonly referred to as exercise-induced asthma, supporting the statement."", ""reference"": ""PMID:22157157"", ""snippet"": ""Exercise-induced bronchoconstriction (EIB) refers to acute airflow obstruction that is triggered by a period of physical exertion."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference recognizes the role of physical exertion as a trigger for asthma symptoms, aligning with the concept of exercise-induced asthma as a subtype."", ""reference"": ""PMID:37086818"", ""snippet"": ""Exercise is one of the most commonly reported symptom triggers for people with asthma."", ""supports"": ""SUPPORT""}], ""name"": ""Exercise-Induced Asthma"", ""review_notes"": ""Added Exercise-Induced Asthma for a more comprehensive list of subtypes.""}"
726	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	has_subtypes	0	Paroxysmal Atrial Fibrillation	Episodes terminate spontaneously within 7 days.																																																								"{""description"": ""Episodes terminate spontaneously within 7 days."", ""name"": ""Paroxysmal Atrial Fibrillation""}"	{}	"{""description"": ""Episodes terminate spontaneously within 7 days."", ""name"": ""Paroxysmal Atrial Fibrillation""}"
727	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	has_subtypes	1	Persistent Atrial Fibrillation	Episodes last longer than 7 days or require intervention.																																																								"{""description"": ""Episodes last longer than 7 days or require intervention."", ""name"": ""Persistent Atrial Fibrillation""}"	{}	"{""description"": ""Episodes last longer than 7 days or require intervention."", ""name"": ""Persistent Atrial Fibrillation""}"
728	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	has_subtypes	2	Long-standing Persistent Atrial Fibrillation	Continuous AF for more than 12 months.																																																								"{""description"": ""Continuous AF for more than 12 months."", ""name"": ""Long-standing Persistent Atrial Fibrillation""}"	{}	"{""description"": ""Continuous AF for more than 12 months."", ""name"": ""Long-standing Persistent Atrial Fibrillation""}"
729	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	has_subtypes	3	Permanent Atrial Fibrillation	AF accepted as permanent rhythm.																																																								"{""description"": ""AF accepted as permanent rhythm."", ""name"": ""Permanent Atrial Fibrillation""}"	{}	"{""description"": ""AF accepted as permanent rhythm."", ""name"": ""Permanent Atrial Fibrillation""}"
730	29	Atrial Fibrillation	Atrial_Fibrillation.yaml	has_subtypes	4	Valvular Atrial Fibrillation	AF associated with mitral stenosis or mechanical valves.																																																								"{""description"": ""AF associated with mitral stenosis or mechanical valves."", ""name"": ""Valvular Atrial Fibrillation""}"	{}	"{""description"": ""AF associated with mitral stenosis or mechanical valves."", ""name"": ""Valvular Atrial Fibrillation""}"
807	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	has_subtypes	0	Axenfeld-Rieger Syndrome Type 1 (RIEG1)	Caused by mutations in the PITX2 gene, characterized by ocular abnormalities and extra-ocular symptoms.																																																								"{""description"": ""Caused by mutations in the PITX2 gene, characterized by ocular abnormalities and extra-ocular symptoms."", ""name"": ""Axenfeld-Rieger Syndrome Type 1 (RIEG1)""}"	{}	"{""description"": ""Caused by mutations in the PITX2 gene, characterized by ocular abnormalities and extra-ocular symptoms."", ""evidence"": [{""explanation"": ""The literature confirms that Axenfeld-Rieger syndrome is associated with mutations in the PITX2 gene and is characterized by ocular abnormalities and extra-ocular symptoms."", ""reference"": ""PMID:22199394"", ""snippet"": ""Recent advances in molecular genetics have identified two major genes, PITX2 and FOXC1, demonstrating a wide spectrum of mutations, which aids in the molecular diagnosis of the disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by indicating that mutations in the PITX2 gene are linked to Axenfeld-Rieger syndrome, which includes ocular and systemic manifestations."", ""reference"": ""PMID:31341655"", ""snippet"": ""The PITX2 gene may be responsible for a significant portion of ARS with additional systemic defects in the Chinese population."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that Rieger syndrome, also known as Axenfeld-Rieger Syndrome Type 1 (RIEG1), involves ocular and extra-ocular abnormalities."", ""reference"": ""PMID:11092457"", ""snippet"": ""Rieger syndrome (RIEG 1; MIM 180500) is an autosomal dominant disorder of morphogenesis. It is a phenotypically heterogeneous disorder characterized by malformations of the eyes, teeth, and umbilicus."", ""supports"": ""SUPPORT""}], ""name"": ""Axenfeld-Rieger Syndrome Type 1 (RIEG1)""}"
808	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	has_subtypes	1	Axenfeld-Rieger Syndrome Type 3 (RIEG3)	Caused by mutations in the FOXC1 gene, associated with similar phenotypic features as Type 1.																																																								"{""description"": ""Caused by mutations in the FOXC1 gene, associated with similar phenotypic features as Type 1."", ""name"": ""Axenfeld-Rieger Syndrome Type 3 (RIEG3)""}"	{}	"{""description"": ""Caused by mutations in the FOXC1 gene, associated with similar phenotypic features as Type 1."", ""evidence"": [{""explanation"": ""This reference directly supports the statement that Axenfeld-Rieger Syndrome Type 3 (RIEG3) is caused by mutations in the FOXC1 gene and has similar phenotypic features."", ""reference"": ""PMID:32741584"", ""snippet"": ""Axenfeld-Rieger syndrome (ARS) type 3 is a rare autosomal dominant disease, characterized by anterior segment dysgenesis of the eye, hearing loss, and cardiac defects. ARS type 3 is highly associated with FOXC1 mutations, which induces developmental disorders of neural crest cells."", ""supports"": ""SUPPORT""}], ""name"": ""Axenfeld-Rieger Syndrome Type 3 (RIEG3)""}"
832	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	has_subtypes	0	BRAF V600E-Mutant PTC	Most common BRAF mutation, accounting for >95% of BRAF-mutant thyroid cancers. V600E causes constitutive kinase activation and is targetable with BRAF/MEK inhibitor combinations.																																																								"{""description"": ""Most common BRAF mutation, accounting for >95% of BRAF-mutant thyroid cancers. V600E causes constitutive kinase activation and is targetable with BRAF/MEK inhibitor combinations."", ""name"": ""BRAF V600E-Mutant PTC""}"	{}	"{""description"": ""Most common BRAF mutation, accounting for >95% of BRAF-mutant thyroid cancers. V600E causes constitutive kinase activation and is targetable with BRAF/MEK inhibitor combinations."", ""name"": ""BRAF V600E-Mutant PTC""}"
833	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	has_subtypes	1	BRAF V600K and Other BRAF Mutations	Rare non-V600E BRAF mutations occur in a small subset of thyroid cancers. May have different biological behavior and therapeutic implications.																																																								"{""description"": ""Rare non-V600E BRAF mutations occur in a small subset of thyroid cancers. May have different biological behavior and therapeutic implications."", ""name"": ""BRAF V600K and Other BRAF Mutations""}"	{}	"{""description"": ""Rare non-V600E BRAF mutations occur in a small subset of thyroid cancers. May have different biological behavior and therapeutic implications."", ""name"": ""BRAF V600K and Other BRAF Mutations""}"
850	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	has_subtypes	0	MSI-H BRAF V600E CRC	BRAF V600E mutation with concurrent microsatellite instability-high status, typically from MLH1 promoter hypermethylation. Better prognosis than MSS BRAF-mutant CRC, responds to immune checkpoint inhibitors.																																																								"{""description"": ""BRAF V600E mutation with concurrent microsatellite instability-high status, typically from MLH1 promoter hypermethylation. Better prognosis than MSS BRAF-mutant CRC, responds to immune checkpoint inhibitors."", ""name"": ""MSI-H BRAF V600E CRC""}"	{}	"{""description"": ""BRAF V600E mutation with concurrent microsatellite instability-high status, typically from MLH1 promoter hypermethylation. Better prognosis than MSS BRAF-mutant CRC, responds to immune checkpoint inhibitors."", ""name"": ""MSI-H BRAF V600E CRC""}"
851	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	has_subtypes	1	MSS BRAF V600E CRC	BRAF V600E mutation with microsatellite stable (MSS) status. Represents the majority of BRAF-mutant CRC with aggressive behavior, poor response to chemotherapy, and need for targeted therapy approaches.																																																								"{""description"": ""BRAF V600E mutation with microsatellite stable (MSS) status. Represents the majority of BRAF-mutant CRC with aggressive behavior, poor response to chemotherapy, and need for targeted therapy approaches."", ""name"": ""MSS BRAF V600E CRC""}"	{}	"{""description"": ""BRAF V600E mutation with microsatellite stable (MSS) status. Represents the majority of BRAF-mutant CRC with aggressive behavior, poor response to chemotherapy, and need for targeted therapy approaches."", ""name"": ""MSS BRAF V600E CRC""}"
868	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	has_subtypes	0	BRAF V600E Adenocarcinoma	The majority of BRAF V600E NSCLC presents as adenocarcinoma histology. V600E is a class I BRAF mutation causing RAS-independent RAF dimerization.																																																								"{""description"": ""The majority of BRAF V600E NSCLC presents as adenocarcinoma histology. V600E is a class I BRAF mutation causing RAS-independent RAF dimerization."", ""name"": ""BRAF V600E Adenocarcinoma""}"	{}	"{""description"": ""The majority of BRAF V600E NSCLC presents as adenocarcinoma histology. V600E is a class I BRAF mutation causing RAS-independent RAF dimerization."", ""name"": ""BRAF V600E Adenocarcinoma""}"
869	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	has_subtypes	1	BRAF Non-V600 Mutant NSCLC	Non-V600 BRAF mutations (class II and III) account for approximately 50% of BRAF mutations in NSCLC. These have different mechanisms and do not respond to BRAF V600E-specific inhibitors.																																																								"{""description"": ""Non-V600 BRAF mutations (class II and III) account for approximately 50% of BRAF mutations in NSCLC. These have different mechanisms and do not respond to BRAF V600E-specific inhibitors."", ""name"": ""BRAF Non-V600 Mutant NSCLC""}"	{}	"{""description"": ""Non-V600 BRAF mutations (class II and III) account for approximately 50% of BRAF mutations in NSCLC. These have different mechanisms and do not respond to BRAF V600E-specific inhibitors."", ""name"": ""BRAF Non-V600 Mutant NSCLC""}"
900	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	has_subtypes	0	BRCA2-Mutant Prostate Cancer	More common than BRCA1 mutations, occurring in approximately 5% of mCRPC. BRCA2 mutations confer higher sensitivity to PARP inhibitors and platinum chemotherapy.																																																								"{""description"": ""More common than BRCA1 mutations, occurring in approximately 5% of mCRPC. BRCA2 mutations confer higher sensitivity to PARP inhibitors and platinum chemotherapy."", ""name"": ""BRCA2-Mutant Prostate Cancer""}"	{}	"{""description"": ""More common than BRCA1 mutations, occurring in approximately 5% of mCRPC. BRCA2 mutations confer higher sensitivity to PARP inhibitors and platinum chemotherapy."", ""name"": ""BRCA2-Mutant Prostate Cancer""}"
901	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	has_subtypes	1	BRCA1-Mutant Prostate Cancer	Less common than BRCA2 mutations in prostate cancer. Also predicts response to PARP inhibition and platinum chemotherapy.																																																								"{""description"": ""Less common than BRCA2 mutations in prostate cancer. Also predicts response to PARP inhibition and platinum chemotherapy."", ""name"": ""BRCA1-Mutant Prostate Cancer""}"	{}	"{""description"": ""Less common than BRCA2 mutations in prostate cancer. Also predicts response to PARP inhibition and platinum chemotherapy."", ""name"": ""BRCA1-Mutant Prostate Cancer""}"
972	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	0	BBS1	The most common subtype caused by mutations in the BBS1 gene.																																																								"{""description"": ""The most common subtype caused by mutations in the BBS1 gene."", ""name"": ""BBS1""}"	{}	"{""description"": ""The most common subtype caused by mutations in the BBS1 gene."", ""evidence"": [{""explanation"": ""This supports the claim that mutations in the BBS1 gene are a common subtype of Bardet-Biedl syndrome."", ""reference"": ""PMID:37612261"", ""snippet"": ""This study reports variants in BBS1 and BBS7 in patients with Bardet-Biedl syndrome from the Canadian Maritime provinces. The BBS1 variant NM_024649.5:c.1169T>G was identified as a recurrent variant in Prince Edward Island."", ""supports"": ""SUPPORT""}, {""explanation"": ""This explains the critical role of BBS1 in the assembly of the BBSome, further implicating it in Bardet-Biedl syndrome."", ""reference"": ""PMID:32759308"", ""snippet"": ""More than half of BBS patients carry mutations in one of eight genes encoding for subunits of a protein complex, the BBSome, which mediates trafficking of ciliary cargoes. ... We show that the pre-BBSome is nucleated by BBS4 and assembled at pericentriolar satellites, followed by the translocation of the BBSome into the ciliary base mediated by BBS1."", ""supports"": ""SUPPORT""}], ""name"": ""BBS1""}"
973	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	1	BBS2	Caused by mutations in the BBS2 gene, associated with similar features but can show some phenotypic variability.																																																								"{""description"": ""Caused by mutations in the BBS2 gene, associated with similar features but can show some phenotypic variability."", ""name"": ""BBS2""}"	{}	"{""description"": ""Caused by mutations in the BBS2 gene, associated with similar features but can show some phenotypic variability."", ""evidence"": [{""explanation"": ""The study shows that a mutation in the BBS2 gene can indeed cause Bardet-Biedl syndrome and the associated phenotypic variability in clinical findings."", ""reference"": ""PMID:36672825"", ""snippet"": ""Patient 3 had Bardet-Biedl syndrome and carried a heterozygous mutation (c.389_390delAC; p.Asn130ThrfsTer4) in BBS7 and a homozygous mutation in BBS2 (c.209G>A; p.Ser70Asn). Her clinical findings included global developmental delay, disproportionate short stature, myopia, retinitis pigmentosa, obesity, pyometra with vaginal atresia, bilateral hydronephrosis with ureteropelvic junction obstruction, bilateral genu valgus, post-axial polydactyly feet, and small and thin fingernails and toenails, tooth agenesis, microdontia, taurodontism, and impaired dentin formation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study supports that mutations in the BBS2 gene can cause Bardet-Biedl syndrome, along with a spectrum of associated features, reinforcing the idea of phenotypic variability."", ""reference"": ""PMID:34364070"", ""snippet"": ""Bardet-Biedl syndrome is a autosomal recessive hereditary disorder characterized by polydactyly, multiple renal cysts, retinal cone-rod dystrophy, obesity, and variable neural development or cognitive impairment"", ""supports"": ""SUPPORT""}], ""name"": ""BBS2""}"
974	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	2	Other BBS Subtypes	Caused by mutations in various other BBS genes, including BBS3, BBS4, BBS5, and more.																																																								"{""description"": ""Caused by mutations in various other BBS genes, including BBS3, BBS4, BBS5, and more."", ""name"": ""Other BBS Subtypes""}"	{}	"{""description"": ""Caused by mutations in various other BBS genes, including BBS3, BBS4, BBS5, and more."", ""evidence"": [{""explanation"": ""This reference acknowledges the genetic heterogeneity of Bardet-Biedl Syndrome and mentions multiple BBS genes."", ""reference"": ""PMID:12876834"", ""snippet"": ""BBS is defined by the association of retinopathy, obesity, hypogonadism, renal dysfunction, postaxial polydactyly and mental retardation. This clinically complex syndrome is genetically heterogeneous with linkage to more than 6 loci, and 4 genes have been cloned so far."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference focuses on BBS3, it contributes to the recognition of different BBS subtypes caused by mutations in various BBS genes."", ""reference"": ""PMID:27170093"", ""snippet"": ""Bardet-Biedl Syndrome (BBS) is an autosomal recessive disorder and is classified as one of the ciliopathy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference highlights the heterogeneity of BBS and mentions the existence of multiple types of the syndrome, caused by different genetic mutations."", ""reference"": ""PMID:32165602"", ""snippet"": ""Bardet-Biedl syndrome (BBS) is a rare heterogenous autosomal recessive disease due to defects in primary cilia which until now, up to 21 types have been detected."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study identifies mutations in multiple BBS genes, supporting the statement that BBS comprises various subtypes caused by different genetic mutations."", ""reference"": ""PMID:36325687"", ""snippet"": ""Mutation screening demonstrated four novel mutations: c.613C>T; p.Q205* in the BBS5 gene, c.1391C>G; p.S464* in the BBS10 gene, and c.155delC; p.S52* and c.1584T>G; p.Y528* in the BBS12 gene."", ""supports"": ""SUPPORT""}], ""name"": ""Other BBS Subtypes""}"
1006	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	has_subtypes	0	Nodular Basal Cell Carcinoma	Most common BCC subtype (60-80%), presenting as a pearly, dome-shaped nodule with telangiectasias and rolled borders. May develop central ulceration (rodent ulcer).																																																								"{""description"": ""Most common BCC subtype (60-80%), presenting as a pearly, dome-shaped nodule with telangiectasias and rolled borders. May develop central ulceration (rodent ulcer)."", ""name"": ""Nodular Basal Cell Carcinoma""}"	{}	"{""description"": ""Most common BCC subtype (60-80%), presenting as a pearly, dome-shaped nodule with telangiectasias and rolled borders. May develop central ulceration (rodent ulcer)."", ""name"": ""Nodular Basal Cell Carcinoma""}"
1007	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	has_subtypes	1	Superficial Basal Cell Carcinoma	Second most common subtype (10-15%), presenting as a thin, erythematous scaly plaque. Often occurs on the trunk and may be multifocal. Generally less aggressive than nodular type.																																																								"{""description"": ""Second most common subtype (10-15%), presenting as a thin, erythematous scaly plaque. Often occurs on the trunk and may be multifocal. Generally less aggressive than nodular type."", ""name"": ""Superficial Basal Cell Carcinoma""}"	{}	"{""description"": ""Second most common subtype (10-15%), presenting as a thin, erythematous scaly plaque. Often occurs on the trunk and may be multifocal. Generally less aggressive than nodular type."", ""name"": ""Superficial Basal Cell Carcinoma""}"
1008	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	has_subtypes	2	Morpheaform (Sclerosing) Basal Cell Carcinoma	Aggressive subtype with ill-defined borders and scar-like appearance. Shows extensive subclinical extension and higher recurrence rates. Requires wide excision margins.																																																								"{""description"": ""Aggressive subtype with ill-defined borders and scar-like appearance. Shows extensive subclinical extension and higher recurrence rates. Requires wide excision margins."", ""name"": ""Morpheaform (Sclerosing) Basal Cell Carcinoma""}"	{}	"{""description"": ""Aggressive subtype with ill-defined borders and scar-like appearance. Shows extensive subclinical extension and higher recurrence rates. Requires wide excision margins."", ""name"": ""Morpheaform (Sclerosing) Basal Cell Carcinoma""}"
1009	41	Basal Cell Carcinoma	Basal_Cell_Carcinoma.yaml	has_subtypes	3	Infiltrative Basal Cell Carcinoma	Aggressive variant with thin strands of tumor cells infiltrating the dermis. Often has poorly defined clinical margins and higher recurrence rates.																																																								"{""description"": ""Aggressive variant with thin strands of tumor cells infiltrating the dermis. Often has poorly defined clinical margins and higher recurrence rates."", ""name"": ""Infiltrative Basal Cell Carcinoma""}"	{}	"{""description"": ""Aggressive variant with thin strands of tumor cells infiltrating the dermis. Often has poorly defined clinical margins and higher recurrence rates."", ""name"": ""Infiltrative Basal Cell Carcinoma""}"
1100	46	Bipolar Disorder	Bipolar_Disorder.yaml	has_subtypes	0	Bipolar I Disorder	Characterized by manic episodes, with or without depressive episodes.																																																								"{""description"": ""Characterized by manic episodes, with or without depressive episodes."", ""name"": ""Bipolar I Disorder""}"	{}	"{""description"": ""Characterized by manic episodes, with or without depressive episodes."", ""name"": ""Bipolar I Disorder""}"
1101	46	Bipolar Disorder	Bipolar_Disorder.yaml	has_subtypes	1	Bipolar II Disorder	Characterized by hypomanic and depressive episodes, no full mania.																																																								"{""description"": ""Characterized by hypomanic and depressive episodes, no full mania."", ""name"": ""Bipolar II Disorder""}"	{}	"{""description"": ""Characterized by hypomanic and depressive episodes, no full mania."", ""name"": ""Bipolar II Disorder""}"
1102	46	Bipolar Disorder	Bipolar_Disorder.yaml	has_subtypes	2	Cyclothymic Disorder	Chronic fluctuating mood with hypomanic and depressive symptoms.																																																								"{""description"": ""Chronic fluctuating mood with hypomanic and depressive symptoms."", ""name"": ""Cyclothymic Disorder""}"	{}	"{""description"": ""Chronic fluctuating mood with hypomanic and depressive symptoms."", ""name"": ""Cyclothymic Disorder""}"
1142	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	has_subtypes	0	Recurrent chronic bird fancier's lung	Chronic BFL with recurrent acute episodes that progress to interstitial pulmonary fibrosis.																																																								"{""description"": ""Chronic BFL with recurrent acute episodes that progress to interstitial pulmonary fibrosis."", ""name"": ""Recurrent chronic bird fancier's lung""}"	{}	"{""description"": ""Chronic BFL with recurrent acute episodes that progress to interstitial pulmonary fibrosis."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract defines a recurrent chronic BFL subtype marked by recurrent acute episodes and fibrotic progression."", ""reference"": ""PMID:12839317"", ""snippet"": ""One subgroup of patients develops interstitial pulmonary fibrosis after recurrent acute episodes (recurrent BFL)"", ""supports"": ""SUPPORT""}], ""name"": ""Recurrent chronic bird fancier's lung""}"
1143	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	has_subtypes	1	Insidious chronic bird fancier's lung	Chronic BFL with slowly progressive respiratory disease without a history of acute episodes.																																																								"{""description"": ""Chronic BFL with slowly progressive respiratory disease without a history of acute episodes."", ""name"": ""Insidious chronic bird fancier's lung""}"	{}	"{""description"": ""Chronic BFL with slowly progressive respiratory disease without a history of acute episodes."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract defines an insidious subtype with slow progression and no acute episode history."", ""reference"": ""PMID:12839317"", ""snippet"": ""the other subgroup of patients has no history of acute episodes but has slowly progressive chronic respiratory disease (insidious BFL)."", ""supports"": ""SUPPORT""}], ""name"": ""Insidious chronic bird fancier's lung""}"
1221	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	has_subtypes	0	Endemic Burkitt Lymphoma	African variant strongly associated with EBV infection (>95% EBV-positive), occurring predominantly in children in equatorial Africa. Classically presents as jaw or facial tumors. Geographic distribution correlates with malaria endemicity, suggesting chronic immune activation as a cofactor.																																																								"{""description"": ""African variant strongly associated with EBV infection (>95% EBV-positive), occurring predominantly in children in equatorial Africa. Classically presents as jaw or facial tumors. Geographic distribution correlates with malaria endemicity, suggesting chronic immune activation as a cofactor."", ""name"": ""Endemic Burkitt Lymphoma""}"	{}	"{""description"": ""African variant strongly associated with EBV infection (>95% EBV-positive), occurring predominantly in children in equatorial Africa. Classically presents as jaw or facial tumors. Geographic distribution correlates with malaria endemicity, suggesting chronic immune activation as a cofactor."", ""name"": ""Endemic Burkitt Lymphoma""}"
1222	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	has_subtypes	1	Sporadic Burkitt Lymphoma	Occurs worldwide without geographic restriction. Less commonly EBV-associated (15-30% in developed countries). Typically presents with abdominal masses, often involving the ileocecal region. More common in children and young adults.																																																								"{""description"": ""Occurs worldwide without geographic restriction. Less commonly EBV-associated (15-30% in developed countries). Typically presents with abdominal masses, often involving the ileocecal region. More common in children and young adults."", ""name"": ""Sporadic Burkitt Lymphoma""}"	{}	"{""description"": ""Occurs worldwide without geographic restriction. Less commonly EBV-associated (15-30% in developed countries). Typically presents with abdominal masses, often involving the ileocecal region. More common in children and young adults."", ""name"": ""Sporadic Burkitt Lymphoma""}"
1223	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	has_subtypes	2	Immunodeficiency-Associated Burkitt Lymphoma	Occurs in patients with HIV/AIDS or other immunodeficiency states. EBV association is intermediate (25-40%). May present as the initial AIDS-defining illness. Requires concurrent management of underlying immunodeficiency.																																																								"{""description"": ""Occurs in patients with HIV/AIDS or other immunodeficiency states. EBV association is intermediate (25-40%). May present as the initial AIDS-defining illness. Requires concurrent management of underlying immunodeficiency."", ""name"": ""Immunodeficiency-Associated Burkitt Lymphoma""}"	{}	"{""description"": ""Occurs in patients with HIV/AIDS or other immunodeficiency states. EBV association is intermediate (25-40%). May present as the initial AIDS-defining illness. Requires concurrent management of underlying immunodeficiency."", ""name"": ""Immunodeficiency-Associated Burkitt Lymphoma""}"
1366	58	Cervical Cancer	Cervical_Cancer.yaml	has_subtypes	0	Squamous Cell Carcinoma	The most common histologic type, accounting for approximately 70-80% of cases. Arises from the squamous epithelium of the ectocervix, typically at the transformation zone where squamous and glandular epithelia meet.																																																								"{""description"": ""The most common histologic type, accounting for approximately 70-80% of cases. Arises from the squamous epithelium of the ectocervix, typically at the transformation zone where squamous and glandular epithelia meet."", ""name"": ""Squamous Cell Carcinoma""}"	{}	"{""description"": ""The most common histologic type, accounting for approximately 70-80% of cases. Arises from the squamous epithelium of the ectocervix, typically at the transformation zone where squamous and glandular epithelia meet."", ""name"": ""Squamous Cell Carcinoma""}"
1367	58	Cervical Cancer	Cervical_Cancer.yaml	has_subtypes	1	Adenocarcinoma	Accounts for 20-25% of cervical cancers. Arises from the glandular epithelium of the endocervical canal. Often HPV-18 associated. May be more difficult to detect by cytology screening.																																																								"{""description"": ""Accounts for 20-25% of cervical cancers. Arises from the glandular epithelium of the endocervical canal. Often HPV-18 associated. May be more difficult to detect by cytology screening."", ""name"": ""Adenocarcinoma""}"	{}	"{""description"": ""Accounts for 20-25% of cervical cancers. Arises from the glandular epithelium of the endocervical canal. Often HPV-18 associated. May be more difficult to detect by cytology screening."", ""name"": ""Adenocarcinoma""}"
1368	58	Cervical Cancer	Cervical_Cancer.yaml	has_subtypes	2	Adenosquamous Carcinoma	Mixed tumors with both squamous and glandular differentiation. Generally associated with worse prognosis than pure squamous cell carcinoma.																																																								"{""description"": ""Mixed tumors with both squamous and glandular differentiation. Generally associated with worse prognosis than pure squamous cell carcinoma."", ""name"": ""Adenosquamous Carcinoma""}"	{}	"{""description"": ""Mixed tumors with both squamous and glandular differentiation. Generally associated with worse prognosis than pure squamous cell carcinoma."", ""name"": ""Adenosquamous Carcinoma""}"
1495	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	has_subtypes	0	Diabetic Nephropathy	CKD caused by long-standing diabetes mellitus.																																																								"{""description"": ""CKD caused by long-standing diabetes mellitus."", ""name"": ""Diabetic Nephropathy""}"	{}	"{""description"": ""CKD caused by long-standing diabetes mellitus."", ""name"": ""Diabetic Nephropathy""}"
1496	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	has_subtypes	1	Hypertensive Nephrosclerosis	CKD caused by chronic hypertension.																																																								"{""description"": ""CKD caused by chronic hypertension."", ""name"": ""Hypertensive Nephrosclerosis""}"	{}	"{""description"": ""CKD caused by chronic hypertension."", ""name"": ""Hypertensive Nephrosclerosis""}"
1497	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	has_subtypes	2	Glomerulonephritis	CKD from primary or secondary glomerular diseases.																																																								"{""description"": ""CKD from primary or secondary glomerular diseases."", ""name"": ""Glomerulonephritis""}"	{}	"{""description"": ""CKD from primary or secondary glomerular diseases."", ""name"": ""Glomerulonephritis""}"
1498	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	has_subtypes	3	Polycystic Kidney Disease	Inherited form of CKD with multiple kidney cysts.																																																								"{""description"": ""Inherited form of CKD with multiple kidney cysts."", ""name"": ""Polycystic Kidney Disease""}"	{}	"{""description"": ""Inherited form of CKD with multiple kidney cysts."", ""name"": ""Polycystic Kidney Disease""}"
1525	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	has_subtypes	0	IGHV Mutated CLL	CLL with somatic hypermutation of immunoglobulin heavy chain variable region genes (at least 2% deviation from germline). Associated with favorable prognosis, lower risk of progression, and better responses to chemoimmunotherapy. Represents post-germinal center B-cell origin.																																																								"{""description"": ""CLL with somatic hypermutation of immunoglobulin heavy chain variable region genes (at least 2% deviation from germline). Associated with favorable prognosis, lower risk of progression, and better responses to chemoimmunotherapy. Represents post-germinal center B-cell origin."", ""name"": ""IGHV Mutated CLL""}"	{}	"{""description"": ""CLL with somatic hypermutation of immunoglobulin heavy chain variable region genes (at least 2% deviation from germline). Associated with favorable prognosis, lower risk of progression, and better responses to chemoimmunotherapy. Represents post-germinal center B-cell origin."", ""name"": ""IGHV Mutated CLL""}"
1526	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	has_subtypes	1	IGHV Unmutated CLL	CLL without significant IGHV somatic hypermutation (less than 2% deviation from germline). Associated with more aggressive course, higher risk of progression, and inferior outcomes with chemoimmunotherapy. May benefit particularly from novel targeted agents.																																																								"{""description"": ""CLL without significant IGHV somatic hypermutation (less than 2% deviation from germline). Associated with more aggressive course, higher risk of progression, and inferior outcomes with chemoimmunotherapy. May benefit particularly from novel targeted agents."", ""name"": ""IGHV Unmutated CLL""}"	{}	"{""description"": ""CLL without significant IGHV somatic hypermutation (less than 2% deviation from germline). Associated with more aggressive course, higher risk of progression, and inferior outcomes with chemoimmunotherapy. May benefit particularly from novel targeted agents."", ""name"": ""IGHV Unmutated CLL""}"
1582	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	0	Chronic Bronchitis	Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.																																																								"{""description"": ""Inflammation of the bronchial tubes leading to increased mucus production and chronic cough."", ""name"": ""Chronic Bronchitis""}"	{}	"{""description"": ""Inflammation of the bronchial tubes leading to increased mucus production and chronic cough."", ""evidence"": [{""explanation"": ""The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough."", ""reference"": ""PMID:23204254"", ""snippet"": ""Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis."", ""reference"": ""PMID:27264777"", ""snippet"": ""Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis."", ""reference"": ""PMID:22753831"", ""snippet"": ""Chronic cough and sputum production: a clinical COPD phenotype?"", ""supports"": ""SUPPORT""}], ""name"": ""Chronic Bronchitis""}"
1583	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	1	Emphysema	Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.																																																								"{""description"": ""Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange."", ""name"": ""Emphysema""}"	{}	"{""description"": ""Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange."", ""evidence"": [{""explanation"": ""This reference reiterates the point that emphysema is a recognized subtype of COPD."", ""reference"": ""PMID:33926668"", ""snippet"": ""Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms that emphysema is considered a subtype of COPD, further supporting the statement."", ""reference"": ""PMID:21178627"", ""snippet"": ""Latest studies further support the association of emphysema and COPD with coal dust exposure."", ""supports"": ""SUPPORT""}], ""name"": ""Emphysema""}"
1649	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	has_subtypes	0	VHL-associated ccRCC	Hereditary form occurring in Von Hippel-Lindau disease patients with germline VHL mutations. Tumors are typically bilateral and multifocal. Patients also develop hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors.																																																								"{""description"": ""Hereditary form occurring in Von Hippel-Lindau disease patients with germline VHL mutations. Tumors are typically bilateral and multifocal. Patients also develop hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors."", ""name"": ""VHL-associated ccRCC""}"	{}	"{""description"": ""Hereditary form occurring in Von Hippel-Lindau disease patients with germline VHL mutations. Tumors are typically bilateral and multifocal. Patients also develop hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors."", ""name"": ""VHL-associated ccRCC""}"
1650	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	has_subtypes	1	Sporadic ccRCC	Comprises 95% of ccRCC cases. Somatic VHL inactivation occurs through mutation, deletion, or promoter hypermethylation. Additional mutations in chromatin remodeling genes (PBRM1, BAP1, SETD2) affect prognosis.																																																								"{""description"": ""Comprises 95% of ccRCC cases. Somatic VHL inactivation occurs through mutation, deletion, or promoter hypermethylation. Additional mutations in chromatin remodeling genes (PBRM1, BAP1, SETD2) affect prognosis."", ""name"": ""Sporadic ccRCC""}"	{}	"{""description"": ""Comprises 95% of ccRCC cases. Somatic VHL inactivation occurs through mutation, deletion, or promoter hypermethylation. Additional mutations in chromatin remodeling genes (PBRM1, BAP1, SETD2) affect prognosis."", ""name"": ""Sporadic ccRCC""}"
1669	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	has_subtypes	0	Classic Clear Cell Sarcoma	The typical form arising in deep soft tissues of extremities, associated with tendons and aponeuroses. Characterized by nests of pale cells with melanocytic differentiation.																																																								"{""description"": ""The typical form arising in deep soft tissues of extremities, associated with tendons and aponeuroses. Characterized by nests of pale cells with melanocytic differentiation."", ""name"": ""Classic Clear Cell Sarcoma""}"	{}	"{""description"": ""The typical form arising in deep soft tissues of extremities, associated with tendons and aponeuroses. Characterized by nests of pale cells with melanocytic differentiation."", ""name"": ""Classic Clear Cell Sarcoma""}"
1670	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	has_subtypes	1	Clear Cell Sarcoma of the Gastrointestinal Tract	A related but distinct entity arising in the gastrointestinal tract, most commonly stomach or small intestine. Harbors EWSR1-CREB1 fusion and has different clinical behavior.																																																								"{""description"": ""A related but distinct entity arising in the gastrointestinal tract, most commonly stomach or small intestine. Harbors EWSR1-CREB1 fusion and has different clinical behavior."", ""name"": ""Clear Cell Sarcoma of the Gastrointestinal Tract""}"	{}	"{""description"": ""A related but distinct entity arising in the gastrointestinal tract, most commonly stomach or small intestine. Harbors EWSR1-CREB1 fusion and has different clinical behavior."", ""name"": ""Clear Cell Sarcoma of the Gastrointestinal Tract""}"
1750	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	has_subtypes	0	AML with t(8;21)(q22;q22) RUNX1-RUNX1T1	AML characterized by the t(8;21) translocation fusing RUNX1 (formerly AML1) on chromosome 21 with RUNX1T1 (formerly ETO) on chromosome 8. Typically shows maturation to promyelocyte/myelocyte stage. Associated with Auer rods, CD19 expression, and loss of chromosome Y or del(9q). Favorable prognosis with intensive chemotherapy.																																																								"{""description"": ""AML characterized by the t(8;21) translocation fusing RUNX1 (formerly AML1) on chromosome 21 with RUNX1T1 (formerly ETO) on chromosome 8. Typically shows maturation to promyelocyte/myelocyte stage. Associated with Auer rods, CD19 expression, and loss of chromosome Y or del(9q). Favorable prognosis with intensive chemotherapy."", ""name"": ""AML with t(8;21)(q22;q22) RUNX1-RUNX1T1""}"	{}	"{""description"": ""AML characterized by the t(8;21) translocation fusing RUNX1 (formerly AML1) on chromosome 21 with RUNX1T1 (formerly ETO) on chromosome 8. Typically shows maturation to promyelocyte/myelocyte stage. Associated with Auer rods, CD19 expression, and loss of chromosome Y or del(9q). Favorable prognosis with intensive chemotherapy."", ""name"": ""AML with t(8;21)(q22;q22) RUNX1-RUNX1T1""}"
1751	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	has_subtypes	1	AML with inv(16)(p13.1q22) or t(16;16) CBFB-MYH11	AML characterized by inv(16) or t(16;16) fusing CBFB (core binding factor beta) with MYH11 (smooth muscle myosin heavy chain). Associated with abnormal bone marrow eosinophils containing abnormal granules. Typically presents with younger age and may have extramedullary disease. Favorable prognosis.																																																								"{""description"": ""AML characterized by inv(16) or t(16;16) fusing CBFB (core binding factor beta) with MYH11 (smooth muscle myosin heavy chain). Associated with abnormal bone marrow eosinophils containing abnormal granules. Typically presents with younger age and may have extramedullary disease. Favorable prognosis."", ""name"": ""AML with inv(16)(p13.1q22) or t(16;16) CBFB-MYH11""}"	{}	"{""description"": ""AML characterized by inv(16) or t(16;16) fusing CBFB (core binding factor beta) with MYH11 (smooth muscle myosin heavy chain). Associated with abnormal bone marrow eosinophils containing abnormal granules. Typically presents with younger age and may have extramedullary disease. Favorable prognosis."", ""name"": ""AML with inv(16)(p13.1q22) or t(16;16) CBFB-MYH11""}"
1822	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	0	Ileal Crohn's Disease	Involves inflammation of the ileum, the latter part of the small intestine.																																																								"{""description"": ""Involves inflammation of the ileum, the latter part of the small intestine."", ""name"": ""Ileal Crohn's Disease""}"	{}	"{""description"": ""Involves inflammation of the ileum, the latter part of the small intestine."", ""evidence"": [{""explanation"": ""This reference supports the statement that Crohn's disease involves inflammation of the ileum, and specifies this subtype as Ileal Crohn's Disease."", ""reference"": ""PMID:37377591"", ""snippet"": ""In CD, the ileum is frequently affected and about one third of patients presents with a pure ileal type."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the claim that Crohn's disease can involve the ileum, characterizing it distinctly as terminal ileitis which is a known feature of Ileal Crohn's Disease."", ""reference"": ""PMID:30882291"", ""snippet"": ""Gastroscopy revealed severe aphthous pangastritis with biopsies showing a focal active and chronic gastritis with presence of granulomas... coloscopy showing an aphthous terminal ileum... concordant with a slightly active, mildly chronic terminal ileitis typical for Crohn's disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights that Crohn's disease can manifest as inflammation of the ileum, aligning with the subtype of Ileal Crohn's Disease."", ""reference"": ""PMID:31960900"", ""snippet"": ""Crohn''s disease patients with unequivocal imaging findings of ileal inflammation at enterography despite negative ileoscopy and biopsy are likely to have active inflammatory Crohn''s disease."", ""supports"": ""SUPPORT""}], ""name"": ""Ileal Crohn's Disease""}"
1823	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	1	Colonic Crohn's Disease	Affects the colon (large intestine) with skip lesions.																																																								"{""description"": ""Affects the colon (large intestine) with skip lesions."", ""name"": ""Colonic Crohn's Disease""}"	{}	"{""description"": ""Affects the colon (large intestine) with skip lesions."", ""evidence"": [{""explanation"": ""The literature indicates that Crohn's disease can affect the colon and often presents with discontinuous, patchy inflammation. However, it is typically not limited to the colon and often involves the terminal ileum."", ""reference"": ""PMID:38437854"", ""snippet"": ""Commonly affecting the terminal ileum and proximal colon, Crohn's disease inflammation is often discontinuous and patchy, segmental, and transmural."", ""supports"": ""PARTIAL""}, {""explanation"": ""This study shows that Crohn's disease can indeed affect the colon specifically, supporting the subtype known as Colonic Crohn's Disease."", ""reference"": ""PMID:11271896"", ""snippet"": ""The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient. Typical small intestinal CD occurred in four of seven patients with marked aphthous lesions of the small intestine, whereas colonic CD occurred in two of eight patients with such aphthous lesions of the colon."", ""supports"": ""SUPPORT""}, {""explanation"": ""The focus is on terminal ileitis, commonly seen in Crohns disease. It suggests that Crohn's disease frequently involves the ileum, but does not refute that the colon can also be involved."", ""reference"": ""PMID:26906301"", ""snippet"": ""Although ileitis can be seen in HSP, terminal ileitis is virtually pathognomonic for Crohn disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""This study focuses on small intestine involvement in Crohn's disease but does not refute colonic involvement with skip lesions."", ""reference"": ""PMID:33278326"", ""snippet"": ""Changes in absorptive capacity and first-pass metabolism in the small intestine affect oral drug bioavailability."", ""supports"": ""PARTIAL""}, {""explanation"": ""Findings indicate that Crohn's Disease can have varying and discontinuous involvement, including potentially just the colon, thereby supporting the subtype."", ""reference"": ""PMID:28379745"", ""snippet"": ""Nearly half (36/73, 49%) of the patients with normal or nonspecific findings at ileocolonoscopy had radiologically active disease with a median length of SB involvement of 20 cm (range, 1 to > 100 cm)."", ""supports"": ""SUPPORT""}], ""name"": ""Colonic Crohn's Disease""}"
1824	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	2	Ileocolonic Crohn's Disease	Involves both the small intestine (ileum) and the colon.																																																								"{""description"": ""Involves both the small intestine (ileum) and the colon."", ""name"": ""Ileocolonic Crohn's Disease""}"	{}	"{""description"": ""Involves both the small intestine (ileum) and the colon."", ""evidence"": [{""explanation"": ""Although the literature acknowledges different manifestations of Crohn's disease involving the ileum and colon, it primarily discusses the broader differentiation between small-intestinal and colonic Crohn's Disease without naming or detailing specific subtypes such as Ileocolonic Crohn's Disease."", ""reference"": ""PMID:33712743"", ""snippet"": ""Crohn's disease can affect any part of the gastrointestinal tract; however, current European and national guidelines worldwide do not differentiate between small-intestinal and colonic Crohn's disease for medical treatment."", ""supports"": ""PARTIAL""}, {""explanation"": ""This provides clinical evidence of Crohn's Disease affecting both the ileum and colon in patients but does not explicitly label it as Ileocolonic Crohn's Disease."", ""reference"": ""PMID:11271896"", ""snippet"": ""The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient."", ""supports"": ""PARTIAL""}, {""explanation"": ""This literature reference supports the statement by noting that 20% of Crohn's disease cases involve both the small and large intestines, which corresponds to the description of Ileocolonic Crohn's Disease."", ""reference"": ""PMID:38294885"", ""snippet"": ""The terminal ileum and small bowel (SB) are involved in 30-45% of patients with Crohn's disease, while 20% have both small and large bowel involvement."", ""supports"": ""SUPPORT""}], ""name"": ""Ileocolonic Crohn's Disease""}"
1931	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	has_subtypes	0	Classic CF	Severe disease with pancreatic insufficiency and progressive lung disease.																																																								"{""description"": ""Severe disease with pancreatic insufficiency and progressive lung disease."", ""name"": ""Classic CF""}"	{}	"{""description"": ""Severe disease with pancreatic insufficiency and progressive lung disease."", ""name"": ""Classic CF""}"
1932	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	has_subtypes	1	Atypical CF	Milder phenotype, often pancreatic sufficient, variable lung involvement.																																																								"{""description"": ""Milder phenotype, often pancreatic sufficient, variable lung involvement."", ""name"": ""Atypical CF""}"	{}	"{""description"": ""Milder phenotype, often pancreatic sufficient, variable lung involvement."", ""name"": ""Atypical CF""}"
1933	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	has_subtypes	2	CFTR-Related Metabolic Syndrome	Inconclusive diagnosis with some CFTR dysfunction but not meeting CF criteria.																																																								"{""description"": ""Inconclusive diagnosis with some CFTR dysfunction but not meeting CF criteria."", ""name"": ""CFTR-Related Metabolic Syndrome""}"	{}	"{""description"": ""Inconclusive diagnosis with some CFTR dysfunction but not meeting CF criteria."", ""name"": ""CFTR-Related Metabolic Syndrome""}"
1986	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	has_subtypes	0	Classic DFSP	The typical form presenting as a slow-growing, indurated plaque that progressively develops a multinodular or protuberant appearance. Low metastatic potential.																																																								"{""description"": ""The typical form presenting as a slow-growing, indurated plaque that progressively develops a multinodular or protuberant appearance. Low metastatic potential."", ""name"": ""Classic DFSP""}"	{}	"{""description"": ""The typical form presenting as a slow-growing, indurated plaque that progressively develops a multinodular or protuberant appearance. Low metastatic potential."", ""name"": ""Classic DFSP""}"
1987	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	has_subtypes	1	Fibrosarcomatous DFSP	A higher-grade variant with fibrosarcomatous transformation in approximately 10-15% of cases. Associated with increased local recurrence and metastatic potential. May lose imatinib sensitivity.																																																								"{""description"": ""A higher-grade variant with fibrosarcomatous transformation in approximately 10-15% of cases. Associated with increased local recurrence and metastatic potential. May lose imatinib sensitivity."", ""name"": ""Fibrosarcomatous DFSP""}"	{}	"{""description"": ""A higher-grade variant with fibrosarcomatous transformation in approximately 10-15% of cases. Associated with increased local recurrence and metastatic potential. May lose imatinib sensitivity."", ""name"": ""Fibrosarcomatous DFSP""}"
1988	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	has_subtypes	2	Pigmented DFSP (Bednar Tumor)	A variant containing melanin-producing dendritic cells, giving the tumor a pigmented appearance. Shares the same COL1A1-PDGFB fusion and clinical behavior as classic DFSP.																																																								"{""description"": ""A variant containing melanin-producing dendritic cells, giving the tumor a pigmented appearance. Shares the same COL1A1-PDGFB fusion and clinical behavior as classic DFSP."", ""name"": ""Pigmented DFSP (Bednar Tumor)""}"	{}	"{""description"": ""A variant containing melanin-producing dendritic cells, giving the tumor a pigmented appearance. Shares the same COL1A1-PDGFB fusion and clinical behavior as classic DFSP."", ""name"": ""Pigmented DFSP (Bednar Tumor)""}"
2020	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	has_subtypes	0	Intra-Abdominal DSRCT	The classic presentation with multiple peritoneal implants studding the abdominal cavity. Primary tumor may arise from the peritoneum, omentum, or mesentery.																																																								"{""description"": ""The classic presentation with multiple peritoneal implants studding the abdominal cavity. Primary tumor may arise from the peritoneum, omentum, or mesentery."", ""name"": ""Intra-Abdominal DSRCT""}"	{}	"{""description"": ""The classic presentation with multiple peritoneal implants studding the abdominal cavity. Primary tumor may arise from the peritoneum, omentum, or mesentery."", ""name"": ""Intra-Abdominal DSRCT""}"
2021	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	has_subtypes	1	Extra-Abdominal DSRCT	Rare cases arising in other locations including paratesticular region, ovary, pleura, or soft tissues. Shares the same EWSR1-WT1 fusion and histologic features.																																																								"{""description"": ""Rare cases arising in other locations including paratesticular region, ovary, pleura, or soft tissues. Shares the same EWSR1-WT1 fusion and histologic features."", ""name"": ""Extra-Abdominal DSRCT""}"	{}	"{""description"": ""Rare cases arising in other locations including paratesticular region, ovary, pleura, or soft tissues. Shares the same EWSR1-WT1 fusion and histologic features."", ""name"": ""Extra-Abdominal DSRCT""}"
2058	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	has_subtypes	0	Germinal Center B-cell (GCB) Type	DLBCL with gene expression profile resembling normal germinal center B cells. Characterized by expression of GCB markers (CD10, BCL6, GCET1). Often harbors BCL2 translocation and EZH2 mutations. Better prognosis than ABC type with R-CHOP, with approximately 60-70% cure rates.																																																								"{""description"": ""DLBCL with gene expression profile resembling normal germinal center B cells. Characterized by expression of GCB markers (CD10, BCL6, GCET1). Often harbors BCL2 translocation and EZH2 mutations. Better prognosis than ABC type with R-CHOP, with approximately 60-70% cure rates."", ""name"": ""Germinal Center B-cell (GCB) Type""}"	{}	"{""description"": ""DLBCL with gene expression profile resembling normal germinal center B cells. Characterized by expression of GCB markers (CD10, BCL6, GCET1). Often harbors BCL2 translocation and EZH2 mutations. Better prognosis than ABC type with R-CHOP, with approximately 60-70% cure rates."", ""name"": ""Germinal Center B-cell (GCB) Type""}"
2059	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	has_subtypes	1	Activated B-cell (ABC) Type	DLBCL with gene expression profile resembling activated peripheral B cells. Shows constitutive NF-kB activation, often through mutations in CD79A/B, CARD11, MYD88, or deletions of A20. Inferior prognosis with standard R-CHOP. May benefit from targeted agents inhibiting NF-kB pathway.																																																								"{""description"": ""DLBCL with gene expression profile resembling activated peripheral B cells. Shows constitutive NF-kB activation, often through mutations in CD79A/B, CARD11, MYD88, or deletions of A20. Inferior prognosis with standard R-CHOP. May benefit from targeted agents inhibiting NF-kB pathway."", ""name"": ""Activated B-cell (ABC) Type""}"	{}	"{""description"": ""DLBCL with gene expression profile resembling activated peripheral B cells. Shows constitutive NF-kB activation, often through mutations in CD79A/B, CARD11, MYD88, or deletions of A20. Inferior prognosis with standard R-CHOP. May benefit from targeted agents inhibiting NF-kB pathway."", ""name"": ""Activated B-cell (ABC) Type""}"
2060	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	has_subtypes	2	High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements	Double-hit lymphoma (DHL) with concurrent MYC and BCL2 translocations, or triple-hit with MYC, BCL2, and BCL6 rearrangements. Highly aggressive with poor outcomes to standard R-CHOP. Requires intensified therapy.																																																								"{""description"": ""Double-hit lymphoma (DHL) with concurrent MYC and BCL2 translocations, or triple-hit with MYC, BCL2, and BCL6 rearrangements. Highly aggressive with poor outcomes to standard R-CHOP. Requires intensified therapy."", ""name"": ""High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements""}"	{}	"{""description"": ""Double-hit lymphoma (DHL) with concurrent MYC and BCL2 translocations, or triple-hit with MYC, BCL2, and BCL6 rearrangements. Highly aggressive with poor outcomes to standard R-CHOP. Requires intensified therapy."", ""name"": ""High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements""}"
2151	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	has_subtypes	0	Classic Duchenne	Complete absence of dystrophin, onset by age 5, wheelchair-dependent by early teens.																																																								"{""description"": ""Complete absence of dystrophin, onset by age 5, wheelchair-dependent by early teens."", ""name"": ""Classic Duchenne""}"	{}	"{""description"": ""Complete absence of dystrophin, onset by age 5, wheelchair-dependent by early teens."", ""name"": ""Classic Duchenne""}"
2152	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	has_subtypes	1	Intermediate DMD	Partial dystrophin expression, intermediate severity between DMD and Becker.																																																								"{""description"": ""Partial dystrophin expression, intermediate severity between DMD and Becker."", ""name"": ""Intermediate DMD""}"	{}	"{""description"": ""Partial dystrophin expression, intermediate severity between DMD and Becker."", ""name"": ""Intermediate DMD""}"
2189	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	has_subtypes	0	EGFR Exon 19 Deletion NSCLC	In-frame deletions in exon 19 (most commonly delE746-A750) account for approximately 45% of EGFR mutations. Generally associated with better response to TKIs and longer progression-free survival than L858R.																																																								"{""description"": ""In-frame deletions in exon 19 (most commonly delE746-A750) account for approximately 45% of EGFR mutations. Generally associated with better response to TKIs and longer progression-free survival than L858R."", ""name"": ""EGFR Exon 19 Deletion NSCLC""}"	{}	"{""description"": ""In-frame deletions in exon 19 (most commonly delE746-A750) account for approximately 45% of EGFR mutations. Generally associated with better response to TKIs and longer progression-free survival than L858R."", ""name"": ""EGFR Exon 19 Deletion NSCLC""}"
2190	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	has_subtypes	1	EGFR L858R Mutant NSCLC	Point mutation substituting arginine for leucine at codon 858 in exon 21. Accounts for approximately 40% of EGFR mutations. Sensitive to EGFR TKIs though potentially less so than exon 19 deletions.																																																								"{""description"": ""Point mutation substituting arginine for leucine at codon 858 in exon 21. Accounts for approximately 40% of EGFR mutations. Sensitive to EGFR TKIs though potentially less so than exon 19 deletions."", ""name"": ""EGFR L858R Mutant NSCLC""}"	{}	"{""description"": ""Point mutation substituting arginine for leucine at codon 858 in exon 21. Accounts for approximately 40% of EGFR mutations. Sensitive to EGFR TKIs though potentially less so than exon 19 deletions."", ""name"": ""EGFR L858R Mutant NSCLC""}"
2191	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	has_subtypes	2	EGFR Exon 20 Insertion NSCLC	In-frame insertions in exon 20 account for 5-10% of EGFR mutations. Most are resistant to first- through third-generation TKIs. Amivantamab and mobocertinib approved specifically for this population.																																																								"{""description"": ""In-frame insertions in exon 20 account for 5-10% of EGFR mutations. Most are resistant to first- through third-generation TKIs. Amivantamab and mobocertinib approved specifically for this population."", ""name"": ""EGFR Exon 20 Insertion NSCLC""}"	{}	"{""description"": ""In-frame insertions in exon 20 account for 5-10% of EGFR mutations. Most are resistant to first- through third-generation TKIs. Amivantamab and mobocertinib approved specifically for this population."", ""name"": ""EGFR Exon 20 Insertion NSCLC""}"
2192	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	has_subtypes	3	EGFR T790M Resistance NSCLC	T790M gatekeeper mutation emerges in ~50-60% of patients progressing on first/second-generation TKIs. Sensitive to third-generation TKI osimertinib.																																																								"{""description"": ""T790M gatekeeper mutation emerges in ~50-60% of patients progressing on first/second-generation TKIs. Sensitive to third-generation TKI osimertinib."", ""name"": ""EGFR T790M Resistance NSCLC""}"	{}	"{""description"": ""T790M gatekeeper mutation emerges in ~50-60% of patients progressing on first/second-generation TKIs. Sensitive to third-generation TKI osimertinib."", ""name"": ""EGFR T790M Resistance NSCLC""}"
2212	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	has_subtypes	0	Luminal A Breast Cancer	ER+/HER2- with low proliferation (Ki-67 <20%). Best prognosis among breast cancer subtypes with high endocrine sensitivity and low recurrence rates. Often does not require chemotherapy.																																																								"{""description"": ""ER+/HER2- with low proliferation (Ki-67 <20%). Best prognosis among breast cancer subtypes with high endocrine sensitivity and low recurrence rates. Often does not require chemotherapy."", ""name"": ""Luminal A Breast Cancer""}"	{}	"{""description"": ""ER+/HER2- with low proliferation (Ki-67 <20%). Best prognosis among breast cancer subtypes with high endocrine sensitivity and low recurrence rates. Often does not require chemotherapy."", ""evidence"": [{""explanation"": ""Study establishes that luminal A tumors have lower proliferation and better prognosis than luminal B, supporting the subtype distinction."", ""reference"": ""PMID:19436038"", ""snippet"": ""Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors."", ""supports"": ""SUPPORT""}], ""name"": ""Luminal A Breast Cancer""}"
2213	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	has_subtypes	1	Luminal B Breast Cancer	ER+/HER2- with high proliferation (Ki-67 20%) or ER+/HER2+. Higher recurrence risk than luminal A, often benefits from chemotherapy in addition to endocrine therapy.																																																								"{""description"": ""ER+/HER2- with high proliferation (Ki-67 20%) or ER+/HER2+. Higher recurrence risk than luminal A, often benefits from chemotherapy in addition to endocrine therapy."", ""name"": ""Luminal B Breast Cancer""}"	{}	"{""description"": ""ER+/HER2- with high proliferation (Ki-67 20%) or ER+/HER2+. Higher recurrence risk than luminal A, often benefits from chemotherapy in addition to endocrine therapy."", ""evidence"": [{""explanation"": ""Study demonstrates significantly worse 10-year survival for luminal B (64%) compared to luminal A (79%) with tamoxifen monotherapy."", ""reference"": ""PMID:19436038"", ""snippet"": ""the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B"", ""supports"": ""SUPPORT""}], ""name"": ""Luminal B Breast Cancer""}"
2236	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	0	Zaire Ebolavirus	The most common and deadliest strain, responsible for the majority of Ebola outbreaks.																																																								"{""description"": ""The most common and deadliest strain, responsible for the majority of Ebola outbreaks."", ""name"": ""Zaire Ebolavirus""}"	"{""geography"": [""Democratic Republic of Congo"", ""Gabon""]}"	"{""description"": ""The most common and deadliest strain, responsible for the majority of Ebola outbreaks."", ""evidence"": [{""explanation"": ""The Zaire ebolavirus is indeed one of the subtypes of Ebola virus. It is highlighted as a significant strain causing major concern during outbreaks."", ""reference"": ""PMID:8800808"", ""snippet"": ""The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide sensation, since it struck after a sensibilization on the danger of Ebola virus disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference highlights the re-emergence of outbreaks in the specified locations and underscores the high mortality rates associated with the Zaire strain of the Ebola virus."", ""reference"": ""PMID:23327370"", ""snippet"": ""The re-emergence of EHF outbreaks in Gabon and Republic of the Congo were concomitant with an increase in mortality amongst gorillas and chimpanzees infected with ZEBOV."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that the virus responsible for the outbreak is a strain of Zaire Ebola virus, supporting the statement's claim about the locations and the strain."", ""reference"": ""PMID:24795448"", ""snippet"": ""The causative agent has now been identified as an outlier strain of Zaire Ebola virus."", ""supports"": ""SUPPORT""}], ""geography"": [""Democratic Republic of Congo"", ""Gabon""], ""name"": ""Zaire Ebolavirus""}"
2237	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	1	Sudan Ebolavirus	Second most prevalent strain, associated with large outbreaks in Africa.																																																								"{""description"": ""Second most prevalent strain, associated with large outbreaks in Africa."", ""name"": ""Sudan Ebolavirus""}"	"{""geography"": [""Sudan"", ""Uganda""]}"	"{""description"": ""Second most prevalent strain, associated with large outbreaks in Africa."", ""evidence"": [{""explanation"": ""This reference indicates that Sudan virus disease (SVD), one of the strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda."", ""reference"": ""PMID:37750724"", ""snippet"": ""Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that the Sudan virus (SUDV) is a known subtype of Ebola virus disease."", ""reference"": ""PMID:28643203"", ""snippet"": ""Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Ta Forest virus"", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference lists Sudan ebolavirus as one of the species in the genus Ebolavirus, supporting the statement that it is a subtype."", ""reference"": ""PMID:31806422"", ""snippet"": ""The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the history of outbreaks in Sudan, correlating with the Sudan ebolavirus strain."", ""reference"": ""PMID:37355146"", ""snippet"": ""In 1976, the disease emerged in two simultaneous outbreaks in Sudan and the Democratic Republic of Congo."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference does not specifically mention Sudan ebolavirus, it alludes to significant EVD outbreaks in Africa, indirectly supporting the assertion about large outbreaks."", ""reference"": ""PMID:34420499"", ""snippet"": ""The second largest Ebola virus disease (EVD) epidemic occurred in the Democratic Republic of the Congo (DRC) from 2018-20."", ""supports"": ""SUPPORT""}], ""geography"": [""Sudan"", ""Uganda""], ""name"": ""Sudan Ebolavirus""}"
2238	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	2	Bundibugyo Ebolavirus	Identified in Uganda, this strain has caused smaller outbreaks.																																																								"{""description"": ""Identified in Uganda, this strain has caused smaller outbreaks."", ""name"": ""Bundibugyo Ebolavirus""}"	"{""geography"": [""Uganda""]}"	"{""description"": ""Identified in Uganda, this strain has caused smaller outbreaks."", ""evidence"": [{""explanation"": ""This reference supports the statement by confirming the occurrence of a Bundibugyo Ebola virus outbreak in Uganda."", ""reference"": ""PMID:21122234"", ""snippet"": ""The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference also supports the statement by citing outbreaks of Bundibugyo Ebola virus in Uganda."", ""reference"": ""PMID:34467242"", ""snippet"": ""Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo."", ""supports"": ""SUPPORT""}], ""geography"": [""Uganda""], ""name"": ""Bundibugyo Ebolavirus""}"
2239	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	3	Ta Forest Ebolavirus	Known for a single outbreak in the Ivory Coast.																																																								"{""description"": ""Known for a single outbreak in the Ivory Coast."", ""name"": ""Ta Forest Ebolavirus""}"	"{""geography"": [""Ivory Coast""]}"	"{""description"": ""Known for a single outbreak in the Ivory Coast."", ""evidence"": [{""explanation"": ""The literature states that Tai Forest virus is indeed one of the ebolaviruses and mentions its association with human Ebola virus disease (EVD), supporting the claim of a known outbreak in Ivory Coast."", ""reference"": ""PMID:28643203"", ""snippet"": ""Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Ta Forest virus"", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference lists Tai Forest ebolavirus as one of the species within the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus disease."", ""reference"": ""PMID:31806422"", ""snippet"": ""The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Ta Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus)"", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the Sudan virus disease outbreak in Uganda in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory Coast."", ""reference"": ""PMID:37750724"", ""snippet"": ""Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated."", ""supports"": ""NO_EVIDENCE""}], ""geography"": [""Ivory Coast""], ""name"": ""Ta Forest Ebolavirus""}"
2240	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	4	Reston Ebolavirus	Only strain identified outside Africa; found in the Philippines and has not caused disease in humans.																																																								"{""description"": ""Only strain identified outside Africa; found in the Philippines and has not caused disease in humans."", ""name"": ""Reston Ebolavirus""}"	"{""geography"": [""Philippines""]}"	"{""description"": ""Only strain identified outside Africa; found in the Philippines and has not caused disease in humans."", ""evidence"": [{""explanation"": ""The reference supports that Reston ebolavirus was identified outside of Africa in the Philippines and that it had not caused disease in humans, but it does not affirmatively state that it is the only strain identified outside of Africa."", ""reference"": ""PMID:21987747"", ""snippet"": ""Reston ebolavirus infection event in domestic pigs has triggered continuing epidemiologic investigations among Philippine health and veterinary agencies... The first one in 1989 was the first-ever Ebola virus that emerged outside of Africa and was also the first known natural infection of Ebola virus in nonhuman primates."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference supports the claim that Reston ebolavirus has not caused disease in humans."", ""reference"": ""PMID:28643203"", ""snippet"": ""To date, no documented cases of human disease have been associated with Reston virus."", ""supports"": ""SUPPORT""}], ""geography"": [""Philippines""], ""name"": ""Reston Ebolavirus""}"
2286	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	0	Classical EDS (cEDS)	Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility.																																																								"{""description"": ""Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility."", ""name"": ""Classical EDS (cEDS)""}"	{}	"{""description"": ""Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility."", ""evidence"": [{""explanation"": ""This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring."", ""reference"": ""PMID:28192633"", ""snippet"": ""Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising."", ""supports"": ""SUPPORT""}], ""name"": ""Classical EDS (cEDS)""}"
2287	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	1	Hypermobile EDS (hEDS)	Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain.																																																								"{""description"": ""Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain."", ""name"": ""Hypermobile EDS (hEDS)""}"	{}	"{""description"": ""Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain."", ""evidence"": [{""explanation"": ""While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic."", ""reference"": ""PMID:20301456"", ""snippet"": ""Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising..."", ""supports"": ""PARTIAL""}, {""explanation"": ""This article supports the characterization of hEDS with generalized joint hypermobility, recurrent joint dislocations, and chronic pain."", ""reference"": ""PMID:31582002"", ""snippet"": ""Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance"", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS."", ""reference"": ""PMID:28145611"", ""snippet"": ""The hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue manifestations.\"""", ""supports"": ""SUPPORT""}], ""name"": ""Hypermobile EDS (hEDS)""}"
2288	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	2	Vascular EDS (vEDS)	Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility.																																																								"{""description"": ""Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility."", ""name"": ""Vascular EDS (vEDS)""}"	{}	"{""description"": ""Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility."", ""evidence"": [{""explanation"": ""This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus."", ""reference"": ""PMID:33650410"", ""snippet"": ""The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility."", ""reference"": ""PMID:32941194"", ""snippet"": ""Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS."", ""reference"": ""PMID:29709596"", ""snippet"": ""Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt indirectly supports the statement by describing a patient with vEDS having translucent skin, which aligns with the defining characteristics of vEDS mentioned in the statement."", ""reference"": ""PMID:30534875"", ""snippet"": ""Ehlers Danlos Syndrome comprises a heterogeneous group of genetic disorders of the connective tissue, due to defects in collagen or its modifying enzymes. We report a 21 years old male presenting with translucent skin revealing the subcutaneous venous pattern."", ""supports"": ""SUPPORT""}], ""name"": ""Vascular EDS (vEDS)""}"
2289	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	3	Kyphoscoliotic EDS (kEDS)	Characterized by kyphoscoliosis, hypotonia, and ocular fragility																																												Added an additional clinically relevant subtype.												"{""description"": ""Characterized by kyphoscoliosis, hypotonia, and ocular fragility"", ""name"": ""Kyphoscoliotic EDS (kEDS)"", ""review_notes"": ""Added an additional clinically relevant subtype.""}"	{}	"{""description"": ""Characterized by kyphoscoliosis, hypotonia, and ocular fragility"", ""evidence"": [{""explanation"": ""The reference describes the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) as having kyphoscoliosis and hypotonia."", ""reference"": ""PMID:18155911"", ""snippet"": ""The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference explicitly lists kyphoscoliosis, hypotonia, and ocular abnormalities as characteristics of PLOD1-kEDS."", ""reference"": ""PMID:20301635"", ""snippet"": ""PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin fragility, and ocular abnormality."", ""supports"": ""SUPPORT""}], ""name"": ""Kyphoscoliotic EDS (kEDS)"", ""review_notes"": ""Added an additional clinically relevant subtype.""}"
2344	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	has_subtypes	0	Botryoid Embryonal Rhabdomyosarcoma	A variant that grows as grape-like polypoid masses in mucosal-lined hollow organs such as the bladder, vagina, and nasopharynx. Has the best prognosis among ERMS variants.																																																								"{""description"": ""A variant that grows as grape-like polypoid masses in mucosal-lined hollow organs such as the bladder, vagina, and nasopharynx. Has the best prognosis among ERMS variants."", ""name"": ""Botryoid Embryonal Rhabdomyosarcoma""}"	{}	"{""description"": ""A variant that grows as grape-like polypoid masses in mucosal-lined hollow organs such as the bladder, vagina, and nasopharynx. Has the best prognosis among ERMS variants."", ""name"": ""Botryoid Embryonal Rhabdomyosarcoma""}"
2345	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	has_subtypes	1	Spindle Cell Embryonal Rhabdomyosarcoma	A variant with elongated spindle-shaped cells. When arising in paratesticular region, has excellent prognosis. Some cases harbor MYOD1 mutations.																																																								"{""description"": ""A variant with elongated spindle-shaped cells. When arising in paratesticular region, has excellent prognosis. Some cases harbor MYOD1 mutations."", ""name"": ""Spindle Cell Embryonal Rhabdomyosarcoma""}"	{}	"{""description"": ""A variant with elongated spindle-shaped cells. When arising in paratesticular region, has excellent prognosis. Some cases harbor MYOD1 mutations."", ""name"": ""Spindle Cell Embryonal Rhabdomyosarcoma""}"
2346	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	has_subtypes	2	Anaplastic Embryonal Rhabdomyosarcoma	A variant with marked nuclear pleomorphism and anaplasia. Associated with TP53 mutations and carries a worse prognosis.																																																								"{""description"": ""A variant with marked nuclear pleomorphism and anaplasia. Associated with TP53 mutations and carries a worse prognosis."", ""name"": ""Anaplastic Embryonal Rhabdomyosarcoma""}"	{}	"{""description"": ""A variant with marked nuclear pleomorphism and anaplasia. Associated with TP53 mutations and carries a worse prognosis."", ""name"": ""Anaplastic Embryonal Rhabdomyosarcoma""}"
2400	105	Epilepsy	Epilepsy.yaml	has_subtypes	0	Focal Epilepsy	Seizures originate from a localized brain region.																																																								"{""description"": ""Seizures originate from a localized brain region."", ""name"": ""Focal Epilepsy""}"	{}	"{""description"": ""Seizures originate from a localized brain region."", ""name"": ""Focal Epilepsy""}"
2401	105	Epilepsy	Epilepsy.yaml	has_subtypes	1	Generalized Epilepsy	Seizures involve both hemispheres from onset.																																																								"{""description"": ""Seizures involve both hemispheres from onset."", ""name"": ""Generalized Epilepsy""}"	{}	"{""description"": ""Seizures involve both hemispheres from onset."", ""name"": ""Generalized Epilepsy""}"
2402	105	Epilepsy	Epilepsy.yaml	has_subtypes	2	Temporal Lobe Epilepsy	Most common focal epilepsy, often with mesial temporal sclerosis.																																																								"{""description"": ""Most common focal epilepsy, often with mesial temporal sclerosis."", ""name"": ""Temporal Lobe Epilepsy""}"	{}	"{""description"": ""Most common focal epilepsy, often with mesial temporal sclerosis."", ""name"": ""Temporal Lobe Epilepsy""}"
2403	105	Epilepsy	Epilepsy.yaml	has_subtypes	3	Juvenile Myoclonic Epilepsy	Generalized epilepsy with myoclonic, absence, and tonic-clonic seizures.																																																								"{""description"": ""Generalized epilepsy with myoclonic, absence, and tonic-clonic seizures."", ""name"": ""Juvenile Myoclonic Epilepsy""}"	{}	"{""description"": ""Generalized epilepsy with myoclonic, absence, and tonic-clonic seizures."", ""name"": ""Juvenile Myoclonic Epilepsy""}"
2404	105	Epilepsy	Epilepsy.yaml	has_subtypes	4	Childhood Absence Epilepsy	Frequent brief absence seizures beginning in childhood.																																																								"{""description"": ""Frequent brief absence seizures beginning in childhood."", ""name"": ""Childhood Absence Epilepsy""}"	{}	"{""description"": ""Frequent brief absence seizures beginning in childhood."", ""name"": ""Childhood Absence Epilepsy""}"
2467	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	has_subtypes	0	Osseous Ewing Sarcoma	Primary tumors arising in bone, most commonly the pelvis, femur, and other long bones. Accounts for approximately 80% of Ewing sarcoma cases. Typically presents with localized pain and swelling.																																																								"{""description"": ""Primary tumors arising in bone, most commonly the pelvis, femur, and other long bones. Accounts for approximately 80% of Ewing sarcoma cases. Typically presents with localized pain and swelling."", ""name"": ""Osseous Ewing Sarcoma""}"	{}	"{""description"": ""Primary tumors arising in bone, most commonly the pelvis, femur, and other long bones. Accounts for approximately 80% of Ewing sarcoma cases. Typically presents with localized pain and swelling."", ""name"": ""Osseous Ewing Sarcoma""}"
2468	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	has_subtypes	1	Extraosseous Ewing Sarcoma	Primary tumors arising in soft tissues outside of bone. Can occur in chest wall, paravertebral region, or extremities. Shares the same EWS-FLI1 fusion and treated similarly to osseous disease.																																																								"{""description"": ""Primary tumors arising in soft tissues outside of bone. Can occur in chest wall, paravertebral region, or extremities. Shares the same EWS-FLI1 fusion and treated similarly to osseous disease."", ""name"": ""Extraosseous Ewing Sarcoma""}"	{}	"{""description"": ""Primary tumors arising in soft tissues outside of bone. Can occur in chest wall, paravertebral region, or extremities. Shares the same EWS-FLI1 fusion and treated similarly to osseous disease."", ""name"": ""Extraosseous Ewing Sarcoma""}"
2508	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	has_subtypes	0	FGFR3-Mutant Urothelial Carcinoma	Most common FGFR alteration type, with activating point mutations in FGFR3 including S249C, Y373C, and R248C. These mutations cause constitutive receptor dimerization and activation.																																																								"{""description"": ""Most common FGFR alteration type, with activating point mutations in FGFR3 including S249C, Y373C, and R248C. These mutations cause constitutive receptor dimerization and activation."", ""name"": ""FGFR3-Mutant Urothelial Carcinoma""}"	{}	"{""description"": ""Most common FGFR alteration type, with activating point mutations in FGFR3 including S249C, Y373C, and R248C. These mutations cause constitutive receptor dimerization and activation."", ""name"": ""FGFR3-Mutant Urothelial Carcinoma""}"
2509	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	has_subtypes	1	FGFR2/3-Fusion Positive Urothelial Carcinoma	Gene fusions involving FGFR2 or FGFR3, most commonly FGFR3-TACC3, lead to constitutive kinase activation through dimerization mediated by the fusion partner.																																																								"{""description"": ""Gene fusions involving FGFR2 or FGFR3, most commonly FGFR3-TACC3, lead to constitutive kinase activation through dimerization mediated by the fusion partner."", ""name"": ""FGFR2/3-Fusion Positive Urothelial Carcinoma""}"	{}	"{""description"": ""Gene fusions involving FGFR2 or FGFR3, most commonly FGFR3-TACC3, lead to constitutive kinase activation through dimerization mediated by the fusion partner."", ""name"": ""FGFR2/3-Fusion Positive Urothelial Carcinoma""}"
2551	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	has_subtypes	0	FLT3-ITD Mutated AML	AML with internal tandem duplications in the juxtamembrane domain of FLT3. ITD mutations cause ligand-independent receptor dimerization and constitutive activation. Associated with leukocytosis, high blast percentage, and poor prognosis, particularly when the ITD allelic ratio is high. Represents the most clinically significant FLT3 mutation subtype.																																																								"{""description"": ""AML with internal tandem duplications in the juxtamembrane domain of FLT3. ITD mutations cause ligand-independent receptor dimerization and constitutive activation. Associated with leukocytosis, high blast percentage, and poor prognosis, particularly when the ITD allelic ratio is high. Represents the most clinically significant FLT3 mutation subtype."", ""name"": ""FLT3-ITD Mutated AML""}"	{}	"{""description"": ""AML with internal tandem duplications in the juxtamembrane domain of FLT3. ITD mutations cause ligand-independent receptor dimerization and constitutive activation. Associated with leukocytosis, high blast percentage, and poor prognosis, particularly when the ITD allelic ratio is high. Represents the most clinically significant FLT3 mutation subtype."", ""name"": ""FLT3-ITD Mutated AML""}"
2552	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	has_subtypes	1	FLT3-TKD Mutated AML	AML with point mutations in the tyrosine kinase domain of FLT3, most commonly at codon D835. TKD mutations cause constitutive kinase activation but have a less adverse prognostic impact than ITD mutations. May co-occur with other mutations including NPM1.																																																								"{""description"": ""AML with point mutations in the tyrosine kinase domain of FLT3, most commonly at codon D835. TKD mutations cause constitutive kinase activation but have a less adverse prognostic impact than ITD mutations. May co-occur with other mutations including NPM1."", ""name"": ""FLT3-TKD Mutated AML""}"	{}	"{""description"": ""AML with point mutations in the tyrosine kinase domain of FLT3, most commonly at codon D835. TKD mutations cause constitutive kinase activation but have a less adverse prognostic impact than ITD mutations. May co-occur with other mutations including NPM1."", ""name"": ""FLT3-TKD Mutated AML""}"
2596	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	has_subtypes	0	Classic FAP	Characterized by >100 colorectal adenomatous polyps, typically appearing in adolescence with polyposis by age 20-30. Without prophylactic colectomy, colorectal cancer develops by age 40 on average. Caused by mutations in the mutation cluster region (MCR) of APC.																																																								"{""description"": ""Characterized by >100 colorectal adenomatous polyps, typically appearing in adolescence with polyposis by age 20-30. Without prophylactic colectomy, colorectal cancer develops by age 40 on average. Caused by mutations in the mutation cluster region (MCR) of APC."", ""name"": ""Classic FAP""}"	{}	"{""description"": ""Characterized by >100 colorectal adenomatous polyps, typically appearing in adolescence with polyposis by age 20-30. Without prophylactic colectomy, colorectal cancer develops by age 40 on average. Caused by mutations in the mutation cluster region (MCR) of APC."", ""name"": ""Classic FAP""}"
2597	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	has_subtypes	1	Attenuated FAP (AFAP)	Milder phenotype with fewer polyps (10-100), later onset of polyposis, right-sided colon predominance, and delayed colorectal cancer risk (average age 50-55). Associated with mutations at the 5' or 3' ends of APC or in the alternatively spliced region of exon 9.																																																								"{""description"": ""Milder phenotype with fewer polyps (10-100), later onset of polyposis, right-sided colon predominance, and delayed colorectal cancer risk (average age 50-55). Associated with mutations at the 5' or 3' ends of APC or in the alternatively spliced region of exon 9."", ""name"": ""Attenuated FAP (AFAP)""}"	{}	"{""description"": ""Milder phenotype with fewer polyps (10-100), later onset of polyposis, right-sided colon predominance, and delayed colorectal cancer risk (average age 50-55). Associated with mutations at the 5' or 3' ends of APC or in the alternatively spliced region of exon 9."", ""name"": ""Attenuated FAP (AFAP)""}"
2598	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	has_subtypes	2	Gardner Syndrome	FAP variant with prominent extracolonic manifestations including osteomas (especially mandible and skull), epidermoid cysts, desmoid tumors, and dental abnormalities. Historically considered separate but now recognized as FAP with variable expressivity.																																																								"{""description"": ""FAP variant with prominent extracolonic manifestations including osteomas (especially mandible and skull), epidermoid cysts, desmoid tumors, and dental abnormalities. Historically considered separate but now recognized as FAP with variable expressivity."", ""name"": ""Gardner Syndrome""}"	{}	"{""description"": ""FAP variant with prominent extracolonic manifestations including osteomas (especially mandible and skull), epidermoid cysts, desmoid tumors, and dental abnormalities. Historically considered separate but now recognized as FAP with variable expressivity."", ""name"": ""Gardner Syndrome""}"
2622	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	0	Type 1	Classic form presenting with recurrent episodes of fever and serositis.																																																								"{""description"": ""Classic form presenting with recurrent episodes of fever and serositis."", ""name"": ""Type 1""}"	{}	"{""description"": ""Classic form presenting with recurrent episodes of fever and serositis."", ""evidence"": [{""explanation"": ""Although the literature describes Familial Mediterranean Fever having episodic fever and serositis, it does not define subtypes or a 'Type 1' specifically."", ""reference"": ""PMID:25649364"", ""snippet"": ""Familial Mediterranean Fever is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""There is a general discussion of Familial Mediterranean Fever but no mention of subtypes or a classification system involving the term 'Type 1'."", ""reference"": ""PMID:23823268"", ""snippet"": ""Periodic fevers are acquired or inherited disorders of innate immunity, which were first described in the 1940s. ... This clinical review focuses on a sample of autoinflammatory disorders including familial Mediterranean fever..."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study discusses the gene mutations associated with FMF but does not describe subtypes of the disease."", ""reference"": ""PMID:36889987"", ""snippet"": ""MEFV gene mutation spectrum in patients with familial mediterranean fever."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Type 1""}"
2623	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	1	Type 2	A variant characterized by continuous subclinical inflammation, leading to amyloidosis without overt episodes.																																																								"{""description"": ""A variant characterized by continuous subclinical inflammation, leading to amyloidosis without overt episodes."", ""name"": ""Type 2""}"	{}	"{""description"": ""A variant characterized by continuous subclinical inflammation, leading to amyloidosis without overt episodes."", ""evidence"": [{""explanation"": ""The literature directly states that FMF type 2 is characterized by amyloidosis without prior overt inflammatory episodes, aligning with the given statement."", ""reference"": ""PMID:21358337"", ""snippet"": ""Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this states Type 2 can involve amyloidosis without typical attacks, it does not directly mention continuous subclinical inflammation."", ""reference"": ""PMID:11053071"", ""snippet"": ""Phenotype II in familial Mediterranean fever (FMF) is the onset of amyloidosis before the onset of FMF with its typical attacks, or as an isolated finding in a member of an FMF family."", ""supports"": ""PARTIAL""}, {""explanation"": ""Reference to subclinical inflammation in amyloidosis supports part of the statement, but does not specifically mention Type 2 FMF."", ""reference"": ""PMID:36161616"", ""snippet"": ""Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis."", ""supports"": ""PARTIAL""}, {""explanation"": ""Though it implies a relationship between FMF and amyloidosis, it does not clearly distinguish between subtypes or mention continuous subclinical inflammation."", ""reference"": ""PMID:37496356"", ""snippet"": ""Recent studies have shown that cases of amyloidosis in patients with familial Mediterranean fever are decreasing"", ""supports"": ""PARTIAL""}], ""name"": ""Type 2""}"
2677	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	0	Core Complex Subtypes	FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT/UBE2T) encode the E3 ubiquitin ligase complex that monoubiquitinates the FANCD2-FANCI heterodimer. Patients with core complex mutations generally have a later age of cancer onset compared to downstream pathway defects.													pathway_tier																																											"{""classification"": ""pathway_tier"", ""description"": ""FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT/UBE2T) encode the E3 ubiquitin ligase complex that monoubiquitinates the FANCD2-FANCI heterodimer. Patients with core complex mutations generally have a later age of cancer onset compared to downstream pathway defects."", ""name"": ""Core Complex Subtypes""}"	"{""children"": [""FA-A"", ""FA-B"", ""FA-C"", ""FA-E"", ""FA-F"", ""FA-G"", ""FA-L"", ""FA-T""]}"	"{""children"": [""FA-A"", ""FA-B"", ""FA-C"", ""FA-E"", ""FA-F"", ""FA-G"", ""FA-L"", ""FA-T""], ""classification"": ""pathway_tier"", ""description"": ""FA core complex genes (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT/UBE2T) encode the E3 ubiquitin ligase complex that monoubiquitinates the FANCD2-FANCI heterodimer. Patients with core complex mutations generally have a later age of cancer onset compared to downstream pathway defects."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort demonstrates later cancer onset in core complex (FANCA) vs downstream gene mutations."", ""reference"": ""PMID:31558676"", ""snippet"": ""Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"", ""supports"": ""SUPPORT""}], ""name"": ""Core Complex Subtypes""}"
2678	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	1	ID Complex Subtypes	The FANCD2-FANCI heterodimer is monoubiquitinated by the core complex and recruited to DNA damage sites. Mutations in these genes cause intermediate-severity FA phenotypes.													pathway_tier																																											"{""classification"": ""pathway_tier"", ""description"": ""The FANCD2-FANCI heterodimer is monoubiquitinated by the core complex and recruited to DNA damage sites. Mutations in these genes cause intermediate-severity FA phenotypes."", ""name"": ""ID Complex Subtypes""}"	"{""children"": [""FA-D2"", ""FA-I""]}"	"{""children"": [""FA-D2"", ""FA-I""], ""classification"": ""pathway_tier"", ""description"": ""The FANCD2-FANCI heterodimer is monoubiquitinated by the core complex and recruited to DNA damage sites. Mutations in these genes cause intermediate-severity FA phenotypes."", ""name"": ""ID Complex Subtypes""}"
2679	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	2	Downstream Effector Subtypes	Downstream effector genes (BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS, SLX4/FANCP, ERCC4/FANCQ, XRCC2/FANCU, MAD2L2/FANCV, RFWD3/FANCW) mediate homologous recombination repair downstream of FANCD2-FANCI. Patients with FANCD1/BRCA2 and FANCN/PALB2 mutations have notably earlier cancer onset and increased risk of childhood solid tumors including medulloblastoma and Wilms tumor.													pathway_tier																																											"{""classification"": ""pathway_tier"", ""description"": ""Downstream effector genes (BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS, SLX4/FANCP, ERCC4/FANCQ, XRCC2/FANCU, MAD2L2/FANCV, RFWD3/FANCW) mediate homologous recombination repair downstream of FANCD2-FANCI. Patients with FANCD1/BRCA2 and FANCN/PALB2 mutations have notably earlier cancer onset and increased risk of childhood solid tumors including medulloblastoma and Wilms tumor."", ""name"": ""Downstream Effector Subtypes""}"	"{""children"": [""FA-D1"", ""FA-J"", ""FA-N"", ""FA-O"", ""FA-P"", ""FA-Q"", ""FA-R"", ""FA-S"", ""FA-U"", ""FA-V"", ""FA-W""]}"	"{""children"": [""FA-D1"", ""FA-J"", ""FA-N"", ""FA-O"", ""FA-P"", ""FA-Q"", ""FA-R"", ""FA-S"", ""FA-U"", ""FA-V"", ""FA-W""], ""classification"": ""pathway_tier"", ""description"": ""Downstream effector genes (BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS, SLX4/FANCP, ERCC4/FANCQ, XRCC2/FANCU, MAD2L2/FANCV, RFWD3/FANCW) mediate homologous recombination repair downstream of FANCD2-FANCI. Patients with FANCD1/BRCA2 and FANCN/PALB2 mutations have notably earlier cancer onset and increased risk of childhood solid tumors including medulloblastoma and Wilms tumor."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort demonstrates more severe congenital anomaly profile in downstream pathway gene mutations."", ""reference"": ""PMID:31558676"", ""snippet"": ""Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."", ""supports"": ""SUPPORT""}], ""name"": ""Downstream Effector Subtypes""}"
2680	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	3	FA-A	Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes.													complementation_group																																							60-70%				"{""classification"": ""complementation_group"", ""description"": ""Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes."", ""name"": ""FA-A"", ""subtype_frequency"": ""60-70%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Most common complementation group, accounting for 60-70% of all FA cases. FANCA is a component of the FA core complex. Patients tend to develop cancer at a later age compared to other FA subtypes."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort confirms FANCA accounts for approximately 60-70% of FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""two-thirds of genetically diagnosed patients had biallelic FANCA mutations. These numbers are similar to the International Fanconi Anemia Registry, in which 60% of the diagnosed patients had FANCA mutations"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCA causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCA"", ""term"": {""id"": ""hgnc:3582"", ""label"": ""FANCA""}}], ""name"": ""FA-A"", ""subtype_frequency"": ""60-70%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group A"", ""term"": {""id"": ""MONDO:0009215"", ""label"": ""Fanconi anemia complementation group A""}}}"
2681	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	4	FA-B	X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association."", ""name"": ""FA-B"", ""subtype_frequency"": ""<1%""}"	"{""inheritance"": [{""name"": ""X-linked recessive""}]}"	"{""classification"": ""complementation_group"", ""description"": ""X-linked FA subtype caused by hemizygous FANCB mutations. FANCB is part of the FA core complex. Affected males may have more severe congenital anomalies including VACTERL association."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCB causes X-linked Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""a hemizygous pathogenic variant in FANCB known to cause X-linked FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCB"", ""term"": {""id"": ""hgnc:3583"", ""label"": ""FANCB""}}], ""inheritance"": [{""name"": ""X-linked recessive""}], ""name"": ""FA-B"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group B"", ""term"": {""id"": ""MONDO:0010351"", ""label"": ""Fanconi anemia complementation group B""}}}"
2682	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	5	FA-C	Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T).													complementation_group																																							~10-15%				"{""classification"": ""complementation_group"", ""description"": ""Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T)."", ""name"": ""FA-C"", ""subtype_frequency"": ""~10-15%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Second or third most common FA complementation group depending on population. FANCC is a component of the FA core complex. Common Ashkenazi Jewish founder mutation (IVS4+4A>T)."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort shows FANCC accounts for 13% of genetically diagnosed FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCC"", ""term"": {""id"": ""hgnc:3584"", ""label"": ""FANCC""}}], ""name"": ""FA-C"", ""subtype_frequency"": ""~10-15%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group C"", ""term"": {""id"": ""MONDO:0009213"", ""label"": ""Fanconi anemia complementation group C""}}}"
2683	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	6	FA-D1	Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer.													complementation_group																																							~2%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer."", ""name"": ""FA-D1"", ""subtype_frequency"": ""~2%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic BRCA2 mutations. Associated with very early-onset malignancies including medulloblastoma, Wilms tumor, and AML, typically before age 5. Distinct from heterozygous BRCA2 carriers who develop breast/ovarian cancer."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms early-onset solid tumors in FANCD1/BRCA2 patients."", ""reference"": ""PMID:31558676"", ""snippet"": ""one patient with a FANCD1 mutation developed medulloblastoma at the age of 3 years. Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""BRCA2"", ""term"": {""id"": ""hgnc:1101"", ""label"": ""BRCA2""}}], ""name"": ""FA-D1"", ""subtype_frequency"": ""~2%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group D1"", ""term"": {""id"": ""MONDO:0011584"", ""label"": ""Fanconi anemia complementation group D1""}}}"
2684	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	7	FA-D2	FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype.													complementation_group																																							~3%				"{""classification"": ""complementation_group"", ""description"": ""FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype."", ""name"": ""FA-D2"", ""subtype_frequency"": ""~3%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""FANCD2 is one of two components of the ID complex that is monoubiquitinated by the core complex. FANCD2 mutations cause a moderate FA phenotype."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCD2 causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCD2"", ""term"": {""id"": ""hgnc:3585"", ""label"": ""FANCD2""}}], ""name"": ""FA-D2"", ""subtype_frequency"": ""~3%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group D2"", ""term"": {""id"": ""MONDO:0009214"", ""label"": ""Fanconi anemia complementation group D2""}}}"
2685	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	8	FA-E	FANCE is a component of the FA core complex that directly interacts with FANCD2.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""FANCE is a component of the FA core complex that directly interacts with FANCD2."", ""name"": ""FA-E"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""FANCE is a component of the FA core complex that directly interacts with FANCD2."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCE causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCE"", ""term"": {""id"": ""hgnc:3586"", ""label"": ""FANCE""}}], ""name"": ""FA-E"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group E"", ""term"": {""id"": ""MONDO:0010953"", ""label"": ""Fanconi anemia complementation group E""}}}"
2686	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	9	FA-F	FANCF is a core complex adaptor protein required for complex assembly and stability.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""FANCF is a core complex adaptor protein required for complex assembly and stability."", ""name"": ""FA-F"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""FANCF is a core complex adaptor protein required for complex assembly and stability."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCF causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCF"", ""term"": {""id"": ""hgnc:3587"", ""label"": ""FANCF""}}], ""name"": ""FA-F"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group F"", ""term"": {""id"": ""MONDO:0011325"", ""label"": ""Fanconi anemia complementation group F""}}}"
2687	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	10	FA-G	Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex.													complementation_group																																							~10%				"{""classification"": ""complementation_group"", ""description"": ""Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex."", ""name"": ""FA-G"", ""subtype_frequency"": ""~10%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Third most common complementation group in some populations, accounting for up to 14% of cases. FANCG/XRCC9 is a component of the FA core complex."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort shows FANCG accounts for 14% of genetically diagnosed FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCG"", ""term"": {""id"": ""hgnc:3588"", ""label"": ""FANCG""}}], ""name"": ""FA-G"", ""subtype_frequency"": ""~10%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group G"", ""term"": {""id"": ""MONDO:0013565"", ""label"": ""Fanconi anemia complementation group G""}}}"
2688	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	11	FA-I	FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks."", ""name"": ""FA-I"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""FANCI forms the ID heterodimer with FANCD2. The complex is monoubiquitinated by the core complex and recruited to sites of DNA interstrand crosslinks."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCI causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCI"", ""term"": {""id"": ""hgnc:25568"", ""label"": ""FANCI""}}], ""name"": ""FA-I"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group I"", ""term"": {""id"": ""MONDO:0012186"", ""label"": ""Fanconi anemia complementation group I""}}}"
2689	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	12	FA-J	Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk.													complementation_group																																							~3%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk."", ""name"": ""FA-J"", ""subtype_frequency"": ""~3%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic mutations in BRIP1 (BACH1), a BRCA1-interacting helicase involved in homologous recombination repair. Heterozygous BRIP1 mutations confer increased breast cancer risk."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort shows FANCJ accounts for 3% of genetically diagnosed FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""BRIP1"", ""term"": {""id"": ""hgnc:20473"", ""label"": ""BRIP1""}}], ""name"": ""FA-J"", ""subtype_frequency"": ""~3%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group J"", ""term"": {""id"": ""MONDO:0012187"", ""label"": ""Fanconi anemia complementation group J""}}}"
2690	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	13	FA-L	FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI."", ""name"": ""FA-L"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""FANCL is the E3 ubiquitin ligase of the FA core complex responsible for monoubiquitinating FANCD2 and FANCI."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCL causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""FANCL"", ""term"": {""id"": ""hgnc:20748"", ""label"": ""FANCL""}}], ""name"": ""FA-L"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group L"", ""term"": {""id"": ""MONDO:0013566"", ""label"": ""Fanconi anemia complementation group L""}}}"
2691	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	14	FA-N	Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele."", ""name"": ""FA-N"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic PALB2 mutations. Like FA-D1 (BRCA2), associated with very early-onset childhood malignancies. Heterozygous PALB2 mutations are a moderate-penetrance breast cancer susceptibility allele."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms PALB2/FANCN causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""PALB2"", ""term"": {""id"": ""hgnc:26144"", ""label"": ""PALB2""}}], ""name"": ""FA-N"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group N"", ""term"": {""id"": ""MONDO:0012565"", ""label"": ""Fanconi anemia complementation group N""}}}"
2692	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	15	FA-O	Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility."", ""name"": ""FA-O"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic RAD51C mutations. RAD51C functions in homologous recombination downstream of FANCD2. Heterozygous RAD51C mutations confer ovarian cancer susceptibility."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RAD51C/FANCO causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""RAD51C"", ""term"": {""id"": ""hgnc:9820"", ""label"": ""RAD51C""}}], ""name"": ""FA-O"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group O"", ""term"": {""id"": ""MONDO:0013248"", ""label"": ""Fanconi anemia complementation group O""}}}"
2693	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	16	FA-P	Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair."", ""name"": ""FA-P"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic SLX4 mutations. SLX4 is a scaffold protein that coordinates multiple structure-specific endonucleases for interstrand crosslink repair."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms SLX4/FANCP causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""SLX4"", ""term"": {""id"": ""hgnc:23845"", ""label"": ""SLX4""}}], ""name"": ""FA-P"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group P"", ""term"": {""id"": ""MONDO:0013499"", ""label"": ""Fanconi anemia complementation group P""}}}"
2694	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	17	FA-Q	Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome."", ""name"": ""FA-Q"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic ERCC4/XPF mutations. ERCC4 is a structure-specific endonuclease also implicated in nucleotide excision repair, creating a phenotypic overlap with xeroderma pigmentosum and Cockayne syndrome."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms ERCC4/FANCQ causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""ERCC4"", ""term"": {""id"": ""hgnc:3436"", ""label"": ""ERCC4""}}], ""name"": ""FA-Q"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group Q"", ""term"": {""id"": ""MONDO:0014108"", ""label"": ""Fanconi anemia complementation group Q""}}}"
2695	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	18	FA-R	Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo."", ""name"": ""FA-R"", ""subtype_frequency"": ""<1%""}"	"{""inheritance"": [{""name"": ""Autosomal dominant""}]}"	"{""classification"": ""complementation_group"", ""description"": ""Caused by heterozygous dominant-negative RAD51 mutations. The only autosomal dominant form of FA. All reported cases arise de novo."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RAD51/FANCR causes autosomal dominant FA via de novo mutations."", ""reference"": ""PMID:20301575"", ""snippet"": ""a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""RAD51"", ""term"": {""id"": ""hgnc:9817"", ""label"": ""RAD51""}}], ""inheritance"": [{""name"": ""Autosomal dominant""}], ""name"": ""FA-R"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group R"", ""term"": {""id"": ""MONDO:0014986"", ""label"": ""Fanconi anemia complementation group R""}}}"
2696	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	19	FA-S	Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk."", ""name"": ""FA-S"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic BRCA1 mutations. Extremely rare, with phenotypic overlap with both FA and hereditary breast/ovarian cancer syndrome. Heterozygous BRCA1 carriers have high breast and ovarian cancer risk."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms BRCA1/FANCS causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""BRCA1"", ""term"": {""id"": ""hgnc:1100"", ""label"": ""BRCA1""}}], ""name"": ""FA-S"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia, complementation group S"", ""term"": {""id"": ""MONDO:0054748"", ""label"": ""Fanconi anemia, complementation group S""}}}"
2697	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	20	FA-T	Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex."", ""name"": ""FA-T"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic UBE2T mutations. UBE2T is the E2 ubiquitin-conjugating enzyme that works with the FANCL E3 ligase to monoubiquitinate the ID complex."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms UBE2T/FANCT causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""UBE2T"", ""term"": {""id"": ""hgnc:25009"", ""label"": ""UBE2T""}}], ""name"": ""FA-T"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group T"", ""term"": {""id"": ""MONDO:0014638"", ""label"": ""Fanconi anemia complementation group T""}}}"
2698	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	21	FA-U	Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair."", ""name"": ""FA-U"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic XRCC2 mutations. XRCC2 is a RAD51 paralog involved in homologous recombination repair."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms XRCC2/FANCU causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""XRCC2"", ""term"": {""id"": ""hgnc:12829"", ""label"": ""XRCC2""}}], ""name"": ""FA-U"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group U"", ""term"": {""id"": ""MONDO:0014987"", ""label"": ""Fanconi anemia complementation group U""}}}"
2699	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	22	FA-V	Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling."", ""name"": ""FA-V"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic MAD2L2/REV7 mutations. MAD2L2 functions in translesion synthesis and also plays roles in mitotic checkpoint signaling."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms MAD2L2/FANCV causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""MAD2L2"", ""term"": {""id"": ""hgnc:6764"", ""label"": ""MAD2L2""}}], ""name"": ""FA-V"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia complementation group V"", ""term"": {""id"": ""MONDO:0014985"", ""label"": ""Fanconi anemia complementation group V""}}}"
2700	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	23	FA-W	Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination.													complementation_group																																							<1%				"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination."", ""name"": ""FA-W"", ""subtype_frequency"": ""<1%""}"	{}	"{""classification"": ""complementation_group"", ""description"": ""Caused by biallelic RFWD3 mutations. RFWD3 is an E3 ubiquitin ligase that ubiquitinates RPA at stalled replication forks to promote homologous recombination."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RFWD3/FANCW causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}], ""genes"": [{""preferred_term"": ""RFWD3"", ""term"": {""id"": ""hgnc:25539"", ""label"": ""RFWD3""}}], ""name"": ""FA-W"", ""subtype_frequency"": ""<1%"", ""subtype_term"": {""preferred_term"": ""Fanconi anemia, complementation group W"", ""term"": {""id"": ""MONDO:0044325"", ""label"": ""Fanconi anemia, complementation group W""}}}"
2892	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	has_subtypes	0	Full Mutation	More than 200 CGG repeats with methylation, full syndrome expression in males.																																																								"{""description"": ""More than 200 CGG repeats with methylation, full syndrome expression in males."", ""name"": ""Full Mutation""}"	{}	"{""description"": ""More than 200 CGG repeats with methylation, full syndrome expression in males."", ""name"": ""Full Mutation""}"
2893	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	has_subtypes	1	Premutation Carrier	55-200 CGG repeats, risk for FXTAS (tremor-ataxia) and FXPOI in carriers.																																																								"{""description"": ""55-200 CGG repeats, risk for FXTAS (tremor-ataxia) and FXPOI in carriers."", ""name"": ""Premutation Carrier""}"	{}	"{""description"": ""55-200 CGG repeats, risk for FXTAS (tremor-ataxia) and FXPOI in carriers."", ""name"": ""Premutation Carrier""}"
2925	122	Galactosemia	Galactosemia.yaml	has_subtypes	0	Classic Galactosemia (GALT deficiency)	"Most common and severe form caused by GALT deficiency. Presents in neonates with life-threatening illness if untreated.
"																																																								"{""description"": ""Most common and severe form caused by GALT deficiency. Presents in neonates with life-threatening illness if untreated.\n"", ""name"": ""Classic Galactosemia (GALT deficiency)""}"	{}	"{""description"": ""Most common and severe form caused by GALT deficiency. Presents in neonates with life-threatening illness if untreated.\n"", ""name"": ""Classic Galactosemia (GALT deficiency)"", ""subtype_term"": {""preferred_term"": ""classic galactosemia"", ""term"": {""id"": ""MONDO:0009258"", ""label"": ""classic galactosemia""}}}"
2926	122	Galactosemia	Galactosemia.yaml	has_subtypes	1	Galactokinase Deficiency	"Milder form caused by GALK1 deficiency. Primary manifestation is cataracts without the systemic toxicity of classic galactosemia.
"																																																								"{""description"": ""Milder form caused by GALK1 deficiency. Primary manifestation is cataracts without the systemic toxicity of classic galactosemia.\n"", ""name"": ""Galactokinase Deficiency""}"	{}	"{""description"": ""Milder form caused by GALK1 deficiency. Primary manifestation is cataracts without the systemic toxicity of classic galactosemia.\n"", ""name"": ""Galactokinase Deficiency""}"
2927	122	Galactosemia	Galactosemia.yaml	has_subtypes	2	Epimerase Deficiency	"Caused by GALE deficiency. Phenotype ranges from benign peripheral form to severe generalized form resembling classic galactosemia.
"																																																								"{""description"": ""Caused by GALE deficiency. Phenotype ranges from benign peripheral form to severe generalized form resembling classic galactosemia.\n"", ""name"": ""Epimerase Deficiency""}"	{}	"{""description"": ""Caused by GALE deficiency. Phenotype ranges from benign peripheral form to severe generalized form resembling classic galactosemia.\n"", ""name"": ""Epimerase Deficiency""}"
2950	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	has_subtypes	0	Intestinal-Type Adenocarcinoma	Well-to-moderately differentiated tumors with glandular architecture, arising through the classic Correa pathway of atrophic gastritis to intestinal metaplasia to dysplasia to carcinoma. More common in high- incidence regions and associated with H. pylori infection.																																																								"{""description"": ""Well-to-moderately differentiated tumors with glandular architecture, arising through the classic Correa pathway of atrophic gastritis to intestinal metaplasia to dysplasia to carcinoma. More common in high- incidence regions and associated with H. pylori infection."", ""name"": ""Intestinal-Type Adenocarcinoma""}"	{}	"{""description"": ""Well-to-moderately differentiated tumors with glandular architecture, arising through the classic Correa pathway of atrophic gastritis to intestinal metaplasia to dysplasia to carcinoma. More common in high- incidence regions and associated with H. pylori infection."", ""name"": ""Intestinal-Type Adenocarcinoma""}"
2951	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	has_subtypes	1	Diffuse-Type Adenocarcinoma	Poorly differentiated tumors with scattered single cells or small clusters infiltrating the gastric wall (signet ring cell carcinoma). Associated with CDH1/E-cadherin loss. Can also arise in H. pylori-infected mucosa but does not require intestinal metaplasia.																																																								"{""description"": ""Poorly differentiated tumors with scattered single cells or small clusters infiltrating the gastric wall (signet ring cell carcinoma). Associated with CDH1/E-cadherin loss. Can also arise in H. pylori-infected mucosa but does not require intestinal metaplasia."", ""name"": ""Diffuse-Type Adenocarcinoma""}"	{}	"{""description"": ""Poorly differentiated tumors with scattered single cells or small clusters infiltrating the gastric wall (signet ring cell carcinoma). Associated with CDH1/E-cadherin loss. Can also arise in H. pylori-infected mucosa but does not require intestinal metaplasia."", ""name"": ""Diffuse-Type Adenocarcinoma""}"
3002	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	has_subtypes	0	KIT-mutant GIST	Approximately 85% of GISTs harbor activating mutations in KIT, most commonly in exon 11 (juxtamembrane domain) but also in exons 9, 13, and 17. Different mutations confer variable sensitivity to tyrosine kinase inhibitors.																																																								"{""description"": ""Approximately 85% of GISTs harbor activating mutations in KIT, most commonly in exon 11 (juxtamembrane domain) but also in exons 9, 13, and 17. Different mutations confer variable sensitivity to tyrosine kinase inhibitors."", ""name"": ""KIT-mutant GIST""}"	{}	"{""description"": ""Approximately 85% of GISTs harbor activating mutations in KIT, most commonly in exon 11 (juxtamembrane domain) but also in exons 9, 13, and 17. Different mutations confer variable sensitivity to tyrosine kinase inhibitors."", ""name"": ""KIT-mutant GIST""}"
3003	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	has_subtypes	1	PDGFRA-mutant GIST	Approximately 10% of GISTs harbor PDGFRA mutations, typically exon 18 D842V which is resistant to imatinib. These tumors often arise in the stomach and have an epithelioid morphology.																																																								"{""description"": ""Approximately 10% of GISTs harbor PDGFRA mutations, typically exon 18 D842V which is resistant to imatinib. These tumors often arise in the stomach and have an epithelioid morphology."", ""name"": ""PDGFRA-mutant GIST""}"	{}	"{""description"": ""Approximately 10% of GISTs harbor PDGFRA mutations, typically exon 18 D842V which is resistant to imatinib. These tumors often arise in the stomach and have an epithelioid morphology."", ""name"": ""PDGFRA-mutant GIST""}"
3004	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	has_subtypes	2	Wild-type GIST	Approximately 10-15% of GISTs lack KIT or PDGFRA mutations. This group includes SDH-deficient GISTs (pediatric/young adult), NF1-associated GISTs, and GISTs with BRAF, RAS, or receptor tyrosine kinase fusions.																																																								"{""description"": ""Approximately 10-15% of GISTs lack KIT or PDGFRA mutations. This group includes SDH-deficient GISTs (pediatric/young adult), NF1-associated GISTs, and GISTs with BRAF, RAS, or receptor tyrosine kinase fusions."", ""name"": ""Wild-type GIST""}"	{}	"{""description"": ""Approximately 10-15% of GISTs lack KIT or PDGFRA mutations. This group includes SDH-deficient GISTs (pediatric/young adult), NF1-associated GISTs, and GISTs with BRAF, RAS, or receptor tyrosine kinase fusions."", ""name"": ""Wild-type GIST""}"
3023	127	Gaucher Disease	Gaucher_Disease.yaml	has_subtypes	0	Type 1 (Non-neuronopathic)	Most common (95%), no CNS involvement, hepatosplenomegaly, bone disease, variable onset.																																																								"{""description"": ""Most common (95%), no CNS involvement, hepatosplenomegaly, bone disease, variable onset."", ""name"": ""Type 1 (Non-neuronopathic)""}"	{}	"{""description"": ""Most common (95%), no CNS involvement, hepatosplenomegaly, bone disease, variable onset."", ""name"": ""Type 1 (Non-neuronopathic)""}"
3024	127	Gaucher Disease	Gaucher_Disease.yaml	has_subtypes	1	Type 2 (Acute neuronopathic)	Severe infantile neurodegeneration, death by age 2-4 years.																																																								"{""description"": ""Severe infantile neurodegeneration, death by age 2-4 years."", ""name"": ""Type 2 (Acute neuronopathic)""}"	{}	"{""description"": ""Severe infantile neurodegeneration, death by age 2-4 years."", ""name"": ""Type 2 (Acute neuronopathic)""}"
3025	127	Gaucher Disease	Gaucher_Disease.yaml	has_subtypes	2	Type 3 (Chronic neuronopathic)	Intermediate, systemic and neurological involvement, slower progression than Type 2.																																																								"{""description"": ""Intermediate, systemic and neurological involvement, slower progression than Type 2."", ""name"": ""Type 3 (Chronic neuronopathic)""}"	{}	"{""description"": ""Intermediate, systemic and neurological involvement, slower progression than Type 2."", ""name"": ""Type 3 (Chronic neuronopathic)""}"
3097	130	Glaucoma	Glaucoma.yaml	has_subtypes	0	Primary Open-Angle Glaucoma	Most common form, gradual onset with open drainage angle.																																																								"{""description"": ""Most common form, gradual onset with open drainage angle."", ""name"": ""Primary Open-Angle Glaucoma""}"	{}	"{""description"": ""Most common form, gradual onset with open drainage angle."", ""name"": ""Primary Open-Angle Glaucoma""}"
3098	130	Glaucoma	Glaucoma.yaml	has_subtypes	1	Angle-Closure Glaucoma	Blocked drainage angle, can be acute or chronic.																																																								"{""description"": ""Blocked drainage angle, can be acute or chronic."", ""name"": ""Angle-Closure Glaucoma""}"	{}	"{""description"": ""Blocked drainage angle, can be acute or chronic."", ""name"": ""Angle-Closure Glaucoma""}"
3099	130	Glaucoma	Glaucoma.yaml	has_subtypes	2	Normal-Tension Glaucoma	Optic nerve damage despite normal IOP.																																																								"{""description"": ""Optic nerve damage despite normal IOP."", ""name"": ""Normal-Tension Glaucoma""}"	{}	"{""description"": ""Optic nerve damage despite normal IOP."", ""name"": ""Normal-Tension Glaucoma""}"
3100	130	Glaucoma	Glaucoma.yaml	has_subtypes	3	Secondary Glaucoma	Due to other conditions (trauma, steroids, uveitis).																																																								"{""description"": ""Due to other conditions (trauma, steroids, uveitis)."", ""name"": ""Secondary Glaucoma""}"	{}	"{""description"": ""Due to other conditions (trauma, steroids, uveitis)."", ""name"": ""Secondary Glaucoma""}"
3126	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	has_subtypes	0	Giant Cell Glioblastoma	Histological variant characterized by numerous bizarre multinucleated giant cells. May have slightly better prognosis than conventional glioblastoma. Often shows TP53 mutations.																																																								"{""description"": ""Histological variant characterized by numerous bizarre multinucleated giant cells. May have slightly better prognosis than conventional glioblastoma. Often shows TP53 mutations."", ""name"": ""Giant Cell Glioblastoma""}"	{}	"{""description"": ""Histological variant characterized by numerous bizarre multinucleated giant cells. May have slightly better prognosis than conventional glioblastoma. Often shows TP53 mutations."", ""name"": ""Giant Cell Glioblastoma""}"
3127	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	has_subtypes	1	Gliosarcoma	Variant with biphasic pattern showing areas of glial differentiation and malignant mesenchymal (sarcomatous) component. Similar prognosis to conventional glioblastoma. Sarcomatous component often shows divergent molecular features.																																																								"{""description"": ""Variant with biphasic pattern showing areas of glial differentiation and malignant mesenchymal (sarcomatous) component. Similar prognosis to conventional glioblastoma. Sarcomatous component often shows divergent molecular features."", ""name"": ""Gliosarcoma""}"	{}	"{""description"": ""Variant with biphasic pattern showing areas of glial differentiation and malignant mesenchymal (sarcomatous) component. Similar prognosis to conventional glioblastoma. Sarcomatous component often shows divergent molecular features."", ""name"": ""Gliosarcoma""}"
3128	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	has_subtypes	2	Epithelioid Glioblastoma	Aggressive variant with epithelioid morphology, frequent BRAF V600E mutations, and loss of INI1 expression. Often occurs in younger patients and may have worse prognosis than conventional glioblastoma.																																																								"{""description"": ""Aggressive variant with epithelioid morphology, frequent BRAF V600E mutations, and loss of INI1 expression. Often occurs in younger patients and may have worse prognosis than conventional glioblastoma."", ""name"": ""Epithelioid Glioblastoma""}"	{}	"{""description"": ""Aggressive variant with epithelioid morphology, frequent BRAF V600E mutations, and loss of INI1 expression. Often occurs in younger patients and may have worse prognosis than conventional glioblastoma."", ""name"": ""Epithelioid Glioblastoma""}"
3327	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	has_subtypes	0	Diffuse Intrinsic Pontine Glioma (DIPG)	The most common form, arising in the pons with characteristic diffuse infiltration of pontine structures. Presents with classic triad of cranial nerve deficits, ataxia, and long tract signs. Diagnosis often made on imaging without biopsy. Median survival 9-11 months.																																																								"{""description"": ""The most common form, arising in the pons with characteristic diffuse infiltration of pontine structures. Presents with classic triad of cranial nerve deficits, ataxia, and long tract signs. Diagnosis often made on imaging without biopsy. Median survival 9-11 months."", ""name"": ""Diffuse Intrinsic Pontine Glioma (DIPG)""}"	{}	"{""description"": ""The most common form, arising in the pons with characteristic diffuse infiltration of pontine structures. Presents with classic triad of cranial nerve deficits, ataxia, and long tract signs. Diagnosis often made on imaging without biopsy. Median survival 9-11 months."", ""name"": ""Diffuse Intrinsic Pontine Glioma (DIPG)""}"
3328	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	has_subtypes	1	Thalamic H3 K27M-Mutant Glioma	H3 K27-altered glioma arising in the thalamus. May present with hemiparesis, hydrocephalus, or cognitive changes. Bilateral thalamic involvement can occur. Slightly better prognosis than DIPG in some series.																																																								"{""description"": ""H3 K27-altered glioma arising in the thalamus. May present with hemiparesis, hydrocephalus, or cognitive changes. Bilateral thalamic involvement can occur. Slightly better prognosis than DIPG in some series."", ""name"": ""Thalamic H3 K27M-Mutant Glioma""}"	{}	"{""description"": ""H3 K27-altered glioma arising in the thalamus. May present with hemiparesis, hydrocephalus, or cognitive changes. Bilateral thalamic involvement can occur. Slightly better prognosis than DIPG in some series."", ""name"": ""Thalamic H3 K27M-Mutant Glioma""}"
3329	139	Diffuse Midline Glioma, H3 K27-Altered	H3_K27_Altered_Diffuse_Midline_Glioma.yaml	has_subtypes	2	Spinal Cord H3 K27M-Mutant Glioma	H3 K27-altered glioma arising in the spinal cord. Presents with progressive myelopathy. May have better prognosis than pontine tumors, particularly with focal disease amenable to radiation.																																																								"{""description"": ""H3 K27-altered glioma arising in the spinal cord. Presents with progressive myelopathy. May have better prognosis than pontine tumors, particularly with focal disease amenable to radiation."", ""name"": ""Spinal Cord H3 K27M-Mutant Glioma""}"	{}	"{""description"": ""H3 K27-altered glioma arising in the spinal cord. Presents with progressive myelopathy. May have better prognosis than pontine tumors, particularly with focal disease amenable to radiation."", ""name"": ""Spinal Cord H3 K27M-Mutant Glioma""}"
3435	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	has_subtypes	0	Oral Cavity Squamous Cell Carcinoma	Carcinoma arising from the mucosal lining of the oral cavity including the lips, buccal mucosa, floor of mouth, oral tongue, hard palate, and retromolar trigone. Strongly associated with tobacco and alcohol.																																																								"{""description"": ""Carcinoma arising from the mucosal lining of the oral cavity including the lips, buccal mucosa, floor of mouth, oral tongue, hard palate, and retromolar trigone. Strongly associated with tobacco and alcohol."", ""name"": ""Oral Cavity Squamous Cell Carcinoma""}"	{}	"{""description"": ""Carcinoma arising from the mucosal lining of the oral cavity including the lips, buccal mucosa, floor of mouth, oral tongue, hard palate, and retromolar trigone. Strongly associated with tobacco and alcohol."", ""name"": ""Oral Cavity Squamous Cell Carcinoma""}"
3436	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	has_subtypes	1	Laryngeal Squamous Cell Carcinoma	Carcinoma of the larynx (voice box) affecting the glottic, supraglottic, or subglottic regions. Smoking is the dominant risk factor. Presents early with hoarseness when affecting the vocal cords.																																																								"{""description"": ""Carcinoma of the larynx (voice box) affecting the glottic, supraglottic, or subglottic regions. Smoking is the dominant risk factor. Presents early with hoarseness when affecting the vocal cords."", ""name"": ""Laryngeal Squamous Cell Carcinoma""}"	{}	"{""description"": ""Carcinoma of the larynx (voice box) affecting the glottic, supraglottic, or subglottic regions. Smoking is the dominant risk factor. Presents early with hoarseness when affecting the vocal cords."", ""name"": ""Laryngeal Squamous Cell Carcinoma""}"
3437	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	has_subtypes	2	Hypopharyngeal Squamous Cell Carcinoma	Carcinoma of the hypopharynx (lower throat), including pyriform sinuses, posterior pharyngeal wall, and postcricoid region. Often presents at advanced stage with poor prognosis.																																																								"{""description"": ""Carcinoma of the hypopharynx (lower throat), including pyriform sinuses, posterior pharyngeal wall, and postcricoid region. Often presents at advanced stage with poor prognosis."", ""name"": ""Hypopharyngeal Squamous Cell Carcinoma""}"	{}	"{""description"": ""Carcinoma of the hypopharynx (lower throat), including pyriform sinuses, posterior pharyngeal wall, and postcricoid region. Often presents at advanced stage with poor prognosis."", ""name"": ""Hypopharyngeal Squamous Cell Carcinoma""}"
3459	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	has_subtypes	0	Tonsillar Squamous Cell Carcinoma	The most common site for HPV-positive oropharyngeal carcinoma, arising from the palatine tonsils within the specialized lymphoepithelium of the tonsillar crypts.																																																								"{""description"": ""The most common site for HPV-positive oropharyngeal carcinoma, arising from the palatine tonsils within the specialized lymphoepithelium of the tonsillar crypts."", ""name"": ""Tonsillar Squamous Cell Carcinoma""}"	{}	"{""description"": ""The most common site for HPV-positive oropharyngeal carcinoma, arising from the palatine tonsils within the specialized lymphoepithelium of the tonsillar crypts."", ""name"": ""Tonsillar Squamous Cell Carcinoma""}"
3460	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	has_subtypes	1	Base of Tongue Squamous Cell Carcinoma	HPV-positive carcinoma arising from the lingual tonsils at the base of the tongue, another major site of oropharyngeal involvement.																																																								"{""description"": ""HPV-positive carcinoma arising from the lingual tonsils at the base of the tongue, another major site of oropharyngeal involvement."", ""name"": ""Base of Tongue Squamous Cell Carcinoma""}"	{}	"{""description"": ""HPV-positive carcinoma arising from the lingual tonsils at the base of the tongue, another major site of oropharyngeal involvement."", ""name"": ""Base of Tongue Squamous Cell Carcinoma""}"
3509	147	Heart Failure	Heart_Failure.yaml	has_subtypes	0	Heart Failure with Reduced Ejection Fraction (HFrEF)	Left ventricular ejection fraction less than 40%, systolic dysfunction predominates.																																																								"{""description"": ""Left ventricular ejection fraction less than 40%, systolic dysfunction predominates."", ""name"": ""Heart Failure with Reduced Ejection Fraction (HFrEF)""}"	{}	"{""description"": ""Left ventricular ejection fraction less than 40%, systolic dysfunction predominates."", ""name"": ""Heart Failure with Reduced Ejection Fraction (HFrEF)""}"
3510	147	Heart Failure	Heart_Failure.yaml	has_subtypes	1	Heart Failure with Preserved Ejection Fraction (HFpEF)	Left ventricular ejection fraction 50% or greater, diastolic dysfunction predominates.																																																								"{""description"": ""Left ventricular ejection fraction 50% or greater, diastolic dysfunction predominates."", ""name"": ""Heart Failure with Preserved Ejection Fraction (HFpEF)""}"	{}	"{""description"": ""Left ventricular ejection fraction 50% or greater, diastolic dysfunction predominates."", ""name"": ""Heart Failure with Preserved Ejection Fraction (HFpEF)""}"
3511	147	Heart Failure	Heart_Failure.yaml	has_subtypes	2	Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)	Left ventricular ejection fraction 41-49%, intermediate phenotype.																																																								"{""description"": ""Left ventricular ejection fraction 41-49%, intermediate phenotype."", ""name"": ""Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)""}"	{}	"{""description"": ""Left ventricular ejection fraction 41-49%, intermediate phenotype."", ""name"": ""Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)""}"
3553	149	Hemophilia A	Hemophilia_A.yaml	has_subtypes	0	Severe Hemophilia A	Factor VIII activity less than 1%, spontaneous bleeding episodes.																																																								"{""description"": ""Factor VIII activity less than 1%, spontaneous bleeding episodes."", ""name"": ""Severe Hemophilia A""}"	{}	"{""description"": ""Factor VIII activity less than 1%, spontaneous bleeding episodes."", ""name"": ""Severe Hemophilia A""}"
3554	149	Hemophilia A	Hemophilia_A.yaml	has_subtypes	1	Moderate Hemophilia A	Factor VIII activity 1-5%, bleeding with minor trauma.																																																								"{""description"": ""Factor VIII activity 1-5%, bleeding with minor trauma."", ""name"": ""Moderate Hemophilia A""}"	{}	"{""description"": ""Factor VIII activity 1-5%, bleeding with minor trauma."", ""name"": ""Moderate Hemophilia A""}"
3555	149	Hemophilia A	Hemophilia_A.yaml	has_subtypes	2	Mild Hemophilia A	Factor VIII activity 5-40%, bleeding with surgery or major trauma.																																																								"{""description"": ""Factor VIII activity 5-40%, bleeding with surgery or major trauma."", ""name"": ""Mild Hemophilia A""}"	{}	"{""description"": ""Factor VIII activity 5-40%, bleeding with surgery or major trauma."", ""name"": ""Mild Hemophilia A""}"
3626	152	Hepatitis C	Hepatitis_C.yaml	has_subtypes	0	Acute Hepatitis C	Initial HCV infection within the first 6 months, often asymptomatic but may present with jaundice and elevated transaminases.																																																								"{""description"": ""Initial HCV infection within the first 6 months, often asymptomatic but may present with jaundice and elevated transaminases."", ""name"": ""Acute Hepatitis C""}"	{}	"{""description"": ""Initial HCV infection within the first 6 months, often asymptomatic but may present with jaundice and elevated transaminases."", ""name"": ""Acute Hepatitis C""}"
3627	152	Hepatitis C	Hepatitis_C.yaml	has_subtypes	1	Chronic Hepatitis C	Persistent HCV infection beyond 6 months, affecting 75-85% of infected individuals and leading to progressive liver damage.																																																								"{""description"": ""Persistent HCV infection beyond 6 months, affecting 75-85% of infected individuals and leading to progressive liver damage."", ""name"": ""Chronic Hepatitis C""}"	{}	"{""description"": ""Persistent HCV infection beyond 6 months, affecting 75-85% of infected individuals and leading to progressive liver damage."", ""name"": ""Chronic Hepatitis C""}"
3650	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	has_subtypes	0	Viral Hepatitis-Associated HCC	HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly oncogenic through viral integration, while HCV promotes HCC primarily through cirrhosis and chronic inflammation.																																																								"{""description"": ""HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly oncogenic through viral integration, while HCV promotes HCC primarily through cirrhosis and chronic inflammation."", ""name"": ""Viral Hepatitis-Associated HCC""}"	{}	"{""description"": ""HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly oncogenic through viral integration, while HCV promotes HCC primarily through cirrhosis and chronic inflammation."", ""name"": ""Viral Hepatitis-Associated HCC""}"
3651	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	has_subtypes	1	Alcohol-Related HCC	HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific molecular features and generally presents at more advanced stage.																																																								"{""description"": ""HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific molecular features and generally presents at more advanced stage."", ""name"": ""Alcohol-Related HCC""}"	{}	"{""description"": ""HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific molecular features and generally presents at more advanced stage."", ""name"": ""Alcohol-Related HCC""}"
3652	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	has_subtypes	2	MASLD-Associated HCC	HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH). Increasingly common subtype that can occur even without cirrhosis. May have distinct immune microenvironment features affecting immunotherapy response.																																																								"{""description"": ""HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH). Increasingly common subtype that can occur even without cirrhosis. May have distinct immune microenvironment features affecting immunotherapy response."", ""name"": ""MASLD-Associated HCC""}"	{}	"{""description"": ""HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH). Increasingly common subtype that can occur even without cirrhosis. May have distinct immune microenvironment features affecting immunotherapy response."", ""name"": ""MASLD-Associated HCC""}"
3653	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	has_subtypes	3	Fibrolamellar HCC	Rare variant occurring in younger patients without cirrhosis. Characterized by DNAJB1-PRKACA fusion. Distinct clinical behavior and treatment considerations.																																																								"{""description"": ""Rare variant occurring in younger patients without cirrhosis. Characterized by DNAJB1-PRKACA fusion. Distinct clinical behavior and treatment considerations."", ""name"": ""Fibrolamellar HCC""}"	{}	"{""description"": ""Rare variant occurring in younger patients without cirrhosis. Characterized by DNAJB1-PRKACA fusion. Distinct clinical behavior and treatment considerations."", ""name"": ""Fibrolamellar HCC""}"
3681	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	has_subtypes	0	BRCA1-Associated HBOC	Associated with germline BRCA1 mutations. Higher lifetime risk of breast cancer (70-80%) and ovarian cancer (40-50%). Breast cancers often triple-negative (ER-/PR-/HER2-) and high grade. Higher risk of ovarian cancer than BRCA2.																																																								"{""description"": ""Associated with germline BRCA1 mutations. Higher lifetime risk of breast cancer (70-80%) and ovarian cancer (40-50%). Breast cancers often triple-negative (ER-/PR-/HER2-) and high grade. Higher risk of ovarian cancer than BRCA2."", ""name"": ""BRCA1-Associated HBOC""}"	{}	"{""description"": ""Associated with germline BRCA1 mutations. Higher lifetime risk of breast cancer (70-80%) and ovarian cancer (40-50%). Breast cancers often triple-negative (ER-/PR-/HER2-) and high grade. Higher risk of ovarian cancer than BRCA2."", ""name"": ""BRCA1-Associated HBOC""}"
3682	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	has_subtypes	1	BRCA2-Associated HBOC	Associated with germline BRCA2 mutations. Significant lifetime risk of breast cancer (60-70%) and ovarian cancer (15-30%). Higher risk of male breast cancer and pancreatic cancer than BRCA1. Also associated with increased prostate cancer risk.																																																								"{""description"": ""Associated with germline BRCA2 mutations. Significant lifetime risk of breast cancer (60-70%) and ovarian cancer (15-30%). Higher risk of male breast cancer and pancreatic cancer than BRCA1. Also associated with increased prostate cancer risk."", ""name"": ""BRCA2-Associated HBOC""}"	{}	"{""description"": ""Associated with germline BRCA2 mutations. Significant lifetime risk of breast cancer (60-70%) and ovarian cancer (15-30%). Higher risk of male breast cancer and pancreatic cancer than BRCA1. Also associated with increased prostate cancer risk."", ""name"": ""BRCA2-Associated HBOC""}"
3697	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	0	Type 1 von Willebrand Disease	Partial quantitative deficiency of von Willebrand factor.																																																								"{""description"": ""Partial quantitative deficiency of von Willebrand factor."", ""name"": ""Type 1 von Willebrand Disease""}"	{}	"{""description"": ""Partial quantitative deficiency of von Willebrand factor."", ""evidence"": [{""explanation"": ""The abstract notes type 1 as a quantitative subtype."", ""reference"": ""PMID:21289515"", ""snippet"": ""There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:"", ""supports"": ""SUPPORT""}], ""name"": ""Type 1 von Willebrand Disease""}"
3698	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	1	Type 2 von Willebrand Disease	Qualitative defects of von Willebrand factor with impaired function.																																																								"{""description"": ""Qualitative defects of von Willebrand factor with impaired function."", ""name"": ""Type 2 von Willebrand Disease""}"	{}	"{""description"": ""Qualitative defects of von Willebrand factor with impaired function."", ""evidence"": [{""explanation"": ""The abstract notes type 2 as a qualitative subtype group."", ""reference"": ""PMID:21289515"", ""snippet"": ""There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:"", ""supports"": ""SUPPORT""}], ""name"": ""Type 2 von Willebrand Disease""}"
3699	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	2	Type 2N von Willebrand Disease	Defect in von Willebrand factor binding to factor VIII.																																																								"{""description"": ""Defect in von Willebrand factor binding to factor VIII."", ""name"": ""Type 2N von Willebrand Disease""}"	{}	"{""description"": ""Defect in von Willebrand factor binding to factor VIII."", ""evidence"": [{""explanation"": ""The abstract describes type 2N as a qualitative defect affecting FVIII binding."", ""reference"": ""PMID:33497541"", ""snippet"": ""Type 2N VWD is an uncommon recessive disorder that results from gene mutations located in the region coding for the binding site of VWF for factor VIII (FVIII)."", ""supports"": ""SUPPORT""}], ""name"": ""Type 2N von Willebrand Disease""}"
3700	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	3	Type 3 von Willebrand Disease	Severe quantitative deficiency of von Willebrand factor.																																																								"{""description"": ""Severe quantitative deficiency of von Willebrand factor."", ""name"": ""Type 3 von Willebrand Disease""}"	{}	"{""description"": ""Severe quantitative deficiency of von Willebrand factor."", ""evidence"": [{""explanation"": ""The abstract notes type 3 as a quantitative subtype."", ""reference"": ""PMID:21289515"", ""snippet"": ""There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:"", ""supports"": ""SUPPORT""}], ""name"": ""Type 3 von Willebrand Disease""}"
3720	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	0	Short-Segment Hirschsprung Disease	Affects the rectum and a short segment of the distal colon.																																																								"{""description"": ""Affects the rectum and a short segment of the distal colon."", ""name"": ""Short-Segment Hirschsprung Disease""}"	{}	"{""description"": ""Affects the rectum and a short segment of the distal colon."", ""evidence"": [{""explanation"": ""This statement directly supports that short-segment Hirschsprung Disease (HD) affects the rectum and a short segment of the distal colon."", ""reference"": ""PMID:9269974"", ""snippet"": ""The extent of aganglionosis was as follows: short segment restricted to the rectosigmoid or descending colon (n = 44, 75%)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt confirms that short-segment HD involves the rectosigmoid area, supporting the claim that it affects the rectum and a short segment of the distal colon."", ""reference"": ""PMID:24168728"", ""snippet"": ""Analysis of a series of rectosigmoid resections from patients with short-segment (>2-cm aganglionic, n  =  9) and very short-segment (</=2-cm aganglionic, n  =  9) Hirschsprung disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature discusses the differences in subtypes of Hirschsprung Disease, including short-segment HSCR involving the rectosigmoid colon, thus supporting the statement."", ""reference"": ""PMID:22985835"", ""snippet"": ""Moreover, it reviews current outcomes to find consensus on management."", ""supports"": ""SUPPORT""}], ""name"": ""Short-Segment Hirschsprung Disease""}"
3721	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	1	Long-Segment Hirschsprung Disease	Affects a longer segment of the colon beyond the rectum.																																																								"{""description"": ""Affects a longer segment of the colon beyond the rectum."", ""name"": ""Long-Segment Hirschsprung Disease""}"	{}	"{""description"": ""Affects a longer segment of the colon beyond the rectum."", ""evidence"": [{""explanation"": ""This reference supports the classification of long-segment Hirschsprung Disease, indicating that it involves a longer segment of the colon beyond the rectum."", ""reference"": ""PMID:22985835"", ""snippet"": ""Total colonic aganglionosis (TCA) is a relatively uncommon form of Hirschsprung disease (HSCR)... It can probably be classified as TCA (defined as aganglionosis extending from the anus to at least the ileocecal valve, but not >50 cm proximal to the ileocecal valve) and total colonic and small bowel aganglionosis, which may involve a very long segment of aganglionosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference explicitly defines long-segment Hirschsprung's disease as affecting a longer segment of the colon beyond the rectum."", ""reference"": ""PMID:1514906"", ""snippet"": ""We identified 21 children...with long-segment Hirschsprung's disease defined as aganglionosis extending proximal to the ileocecal valve."", ""supports"": ""SUPPORT""}], ""name"": ""Long-Segment Hirschsprung Disease""}"
3722	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	2	Total Colonic Aganglionosis	Affects the entire colon and sometimes the small intestine.																																																								"{""description"": ""Affects the entire colon and sometimes the small intestine."", ""name"": ""Total Colonic Aganglionosis""}"	{}	"{""description"": ""Affects the entire colon and sometimes the small intestine."", ""evidence"": [{""explanation"": ""This reference indicates that Total Colonic Aganglionosis (TCA) affects the entire colon and sometimes extends into the small intestine, supporting the statement."", ""reference"": ""PMID:25367097"", ""snippet"": ""Total colonic aganglionosis is a relatively uncommon form of Hirschsprung's disease (HSCR). It occurs in approximately 2-13 % of HSCR cases and involves the entire colon which is aganglionic but may extend proximally into varying lengths of small bowel."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the component of the statement indicating that the condition can involve the small intestine."", ""reference"": ""PMID:10745745"", ""snippet"": ""Absence of ganglion cells in the small intestine, a rare form of Hirschsprung's disease, is a condition found in newborns and associated with increased morbidity and mortality."", ""supports"": ""SUPPORT""}], ""name"": ""Total Colonic Aganglionosis""}"
3779	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	0	Juvenile Huntington's Disease	A rare, early-onset form that begins in childhood or adolescence and progresses more rapidly than typical forms.																																																								"{""description"": ""A rare, early-onset form that begins in childhood or adolescence and progresses more rapidly than typical forms."", ""name"": ""Juvenile Huntington's Disease""}"	{}	"{""description"": ""A rare, early-onset form that begins in childhood or adolescence and progresses more rapidly than typical forms."", ""evidence"": [{""explanation"": ""The abstract describes a case of childhood-onset Huntington's disease that progresses rapidly, supporting the statement."", ""reference"": ""PMID:26557176"", ""snippet"": ""Huntington's disease (HD) is a rare dominantly inherited neurodegenerative disorder... As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract confirms that Juvenile Huntington's Disease is rare, begins early, and progresses rapidly, supporting the statement."", ""reference"": ""PMID:36318082"", ""snippet"": ""Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years... The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract acknowledges the existence of juvenile Huntington's disease, which supports the statement."", ""reference"": ""PMID:14584235"", ""snippet"": ""The presentation of juvenile Huntington's disease can cause diagnostic difficulties. The genetics and pathogenesis of the condition are discussed."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract discusses juvenile Huntington's disease and its characteristics, supporting the statement."", ""reference"": ""PMID:2942452"", ""snippet"": ""Of 195 cases of juvenile Huntington disease gathered from case descriptions... It is argued that juvenile Huntington disease should not be regarded as a separate clinical entity, but as a manifestation of the rigid variant of the disease."", ""supports"": ""SUPPORT""}], ""name"": ""Juvenile Huntington's Disease""}"
3780	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	1	Late-Onset Huntington's Disease	Typically begins after the age of 50 and may have a slower progression.																																																								"{""description"": ""Typically begins after the age of 50 and may have a slower progression."", ""name"": ""Late-Onset Huntington's Disease""}"	{}	"{""description"": ""Typically begins after the age of 50 and may have a slower progression."", ""evidence"": [{""explanation"": ""The statement that Huntington's Disease typically begins after the age of 50 is not entirely accurate. While late-onset Huntington's Disease (LoHD) does occur, the typical age of onset for HD is in the fourth decade. However, the statement is partially supported by the fact that some individuals do experience late onset, and LoHD may have a slower progression."", ""reference"": ""PMID:28671137"", ""snippet"": ""BACKGROUND: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference refutes the statement that Huntington's Disease typically begins after the age of 50. It states that HD most typically manifests between the ages of 35 and 45 years."", ""reference"": ""PMID:17390259"", ""snippet"": ""Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment."", ""supports"": ""REFUTE""}, {""explanation"": ""This reference discusses Juvenile-onset Huntington's Disease, which is not relevant to the claim about typical onset after the age of 50."", ""reference"": ""PMID:36318082"", ""snippet"": ""Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference does not provide information relevant to the typical age of onset or progression of Huntington's Disease."", ""reference"": ""PMID:28087720"", ""snippet"": ""Following predictive testing for Huntington disease (HD), knowledge of one's carrier status may have consequences on disease onset."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Late-Onset Huntington's Disease""}"
3808	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	0	Left Ventricular Hypertrophy	Thickening of the heart's main pumping chamber (left ventricle) in response to high blood pressure.																																																								"{""description"": ""Thickening of the heart's main pumping chamber (left ventricle) in response to high blood pressure."", ""name"": ""Left Ventricular Hypertrophy""}"	{}	"{""description"": ""Thickening of the heart's main pumping chamber (left ventricle) in response to high blood pressure."", ""evidence"": [{""explanation"": ""The reference indicates that left ventricular hypertrophy (LVH) is a manifestation of hypertensive heart disease, but it does not explicitly state that LVH is a subtype of hypertensive heart disease. However, since it implies a direct relationship, partial support is inferred."", ""reference"": ""PMID:16097361"", ""snippet"": ""Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are the early manifestations of cardiovascular target organ damage in patients with arterial hypertension and signify hypertensive heart disease."", ""supports"": ""PARTIAL""}], ""name"": ""Left Ventricular Hypertrophy""}"
3809	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	1	Coronary Artery Disease	Narrowing of the blood vessels that supply the heart, worsened by hypertension.																																																								"{""description"": ""Narrowing of the blood vessels that supply the heart, worsened by hypertension."", ""name"": ""Coronary Artery Disease""}"	{}	"{""description"": ""Narrowing of the blood vessels that supply the heart, worsened by hypertension."", ""evidence"": [{""explanation"": ""The literature explicitly mentions the contribution of hypertension to the development of coronary artery disease, which involves narrowing of the blood vessels that supply the heart."", ""reference"": ""PMID:37739329"", ""snippet"": ""Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque, endothelial dysfunction, altered intramyocardial coronary circulation, hypertension-mediated cardiac and vascular damage and the relationship between arterial stiffness and coronary perfusion."", ""supports"": ""SUPPORT""}], ""name"": ""Coronary Artery Disease""}"
3810	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	2	Heart Failure	Weakening of the heart muscle, leading to reduced pumping efficiency, often as a result of long-standing hypertension.																																																								"{""description"": ""Weakening of the heart muscle, leading to reduced pumping efficiency, often as a result of long-standing hypertension."", ""name"": ""Heart Failure""}"	{}	"{""description"": ""Weakening of the heart muscle, leading to reduced pumping efficiency, often as a result of long-standing hypertension."", ""evidence"": [{""explanation"": ""The abstract indicates that heart failure can develop as part of hypertensive heart disease."", ""reference"": ""PMID:31472888"", ""snippet"": ""Hypertensive heart disease represents a spectrum of illnesses from uncontrolled hypertension to heart failure."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the presence of heart failure as an outcome of hypertensive heart disease."", ""reference"": ""PMID:36030347"", ""snippet"": ""Current evidence, based on cross-sectional and longitudinal observational studies as well as real-world registries and randomized controlled trials, suggests that women are more at risk of developing (and maintaining) LVH, concentric remodeling and subclinical LV dysfunction, namely the morpho-functional features of heart failure with preserved ejection fraction."", ""supports"": ""SUPPORT""}, {""explanation"": ""Heart failure as a result of hypertension is explicitly mentioned."", ""reference"": ""PMID:35679365"", ""snippet"": ""Several factors chronically lead to HF, including cardiac volume and pressure overload that may result from hypertension."", ""supports"": ""SUPPORT""}, {""explanation"": ""Hypertension leading to heart failure is supported via the mechanism of LV diastolic dysfunction."", ""reference"": ""PMID:27884237"", ""snippet"": ""Left ventricular (LV) diastolic dysfunction (LVDD) is characterized by alterations in LV diastolic filling, and is a strong predictor of cardiovascular events and heart failure. Hypertension is the most important risk factor for LVDD in the community and promotes LVDD through several mechanisms."", ""supports"": ""SUPPORT""}], ""name"": ""Heart Failure""}"
3856	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	0	Obstructive HCM	The thickened heart muscle obstructs blood flow out of the left ventricle.																																																								"{""description"": ""The thickened heart muscle obstructs blood flow out of the left ventricle."", ""name"": ""Obstructive HCM""}"	{}	"{""description"": ""The thickened heart muscle obstructs blood flow out of the left ventricle."", ""evidence"": [{""explanation"": ""The provided literature states that obstruction occurs in approximately 60% of HCM patients, indicating that not all HCM cases are obstructive. Thus, the statement that the thickened heart muscle obstructs blood flow out of the left ventricle can be recognized as a subtype known as obstructive HCM but does not apply to all HCM patients."", ""reference"": ""PMID:38368032"", ""snippet"": ""Obstruction to left ventricular outflow occurs in approximately 60% of patients."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature indicates that LV hypertrophy (LVH) occurs in HCM alongside various conditions. However, it characterizes different forms, not solely obstructive HCM, thereby acknowledging the partial correctness of the subtype Obstructive HCM but not exclusively."", ""reference"": ""PMID:35555885"", ""snippet"": ""Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)..."", ""supports"": ""PARTIAL""}, {""explanation"": ""This specific literature confirms that left ventricular outflow tract obstruction (LVOTO) is a defining feature of HCM, thereby supporting the statement regarding the thickened heart muscle obstructing blood flow out of the left ventricle."", ""reference"": ""PMID:20560010"", ""snippet"": ""Left ventricular outflow tract obstruction (LVOTO) is one of the defining features of hypertrophic cardiomyopathy (HCM)..."", ""supports"": ""SUPPORT""}], ""name"": ""Obstructive HCM""}"
3857	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	1	Non-Obstructive HCM	The heart muscle is thickened, but blood flow is not significantly obstructed.																																																								"{""description"": ""The heart muscle is thickened, but blood flow is not significantly obstructed."", ""name"": ""Non-Obstructive HCM""}"	{}	"{""description"": ""The heart muscle is thickened, but blood flow is not significantly obstructed."", ""evidence"": [{""explanation"": ""The reference describes non-obstructive hypertrophic cardiomyopathy (HCM) as a subtype of HCM characterized by different clinical subtypes based on cardiac morphology and function, supporting the statement that non-obstructive HCM involves thickened heart muscle without significant obstruction of blood flow."", ""reference"": ""PMID:34126727"", ""snippet"": ""Patients with non-obstructive HCM... According to the characteristics of cardiac morphology and function shown by echocardiography, the patients were divided into common type, dilated type, restricted type and reduced ejection fraction type."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by acknowledging that hypertrophic cardiomyopathy can include conditions with thickened heart muscle where the histological features differ, indicating diverse subtypes including non-obstructive forms."", ""reference"": ""PMID:35555885"", ""snippet"": ""Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...Although various diseases share LV wall thickening as a common feature, the histologic changes that underscore each disease are distinct."", ""supports"": ""SUPPORT""}], ""name"": ""Non-Obstructive HCM""}"
3908	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	has_subtypes	0	IDH1-Mutated AML	AML with mutations in cytoplasmic IDH1, most commonly R132H. IDH1 mutations occur in 6-10% of AML cases and are targetable with ivosidenib. Often co-occurs with NPM1 and DNMT3A mutations.																																																								"{""description"": ""AML with mutations in cytoplasmic IDH1, most commonly R132H. IDH1 mutations occur in 6-10% of AML cases and are targetable with ivosidenib. Often co-occurs with NPM1 and DNMT3A mutations."", ""name"": ""IDH1-Mutated AML""}"	{}	"{""description"": ""AML with mutations in cytoplasmic IDH1, most commonly R132H. IDH1 mutations occur in 6-10% of AML cases and are targetable with ivosidenib. Often co-occurs with NPM1 and DNMT3A mutations."", ""name"": ""IDH1-Mutated AML""}"
3909	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	has_subtypes	1	IDH2-Mutated AML	AML with mutations in mitochondrial IDH2, either R140Q (more common) or R172K. IDH2 mutations occur in 8-12% of AML cases and are targetable with enasidenib. R172K mutations may have different clinical features than R140Q.																																																								"{""description"": ""AML with mutations in mitochondrial IDH2, either R140Q (more common) or R172K. IDH2 mutations occur in 8-12% of AML cases and are targetable with enasidenib. R172K mutations may have different clinical features than R140Q."", ""name"": ""IDH2-Mutated AML""}"	{}	"{""description"": ""AML with mutations in mitochondrial IDH2, either R140Q (more common) or R172K. IDH2 mutations occur in 8-12% of AML cases and are targetable with enasidenib. R172K mutations may have different clinical features than R140Q."", ""name"": ""IDH2-Mutated AML""}"
3932	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	has_subtypes	0	IDH-Mutant Astrocytoma Grade 2	Low-grade diffuse astrocytoma with IDH mutation. Characterized by low cellularity, mild nuclear atypia, and absence of mitotic activity, microvascular proliferation, or necrosis. Patients typically present with seizures and have favorable prognosis with median survival of 10-15 years.																																																								"{""description"": ""Low-grade diffuse astrocytoma with IDH mutation. Characterized by low cellularity, mild nuclear atypia, and absence of mitotic activity, microvascular proliferation, or necrosis. Patients typically present with seizures and have favorable prognosis with median survival of 10-15 years."", ""name"": ""IDH-Mutant Astrocytoma Grade 2""}"	{}	"{""description"": ""Low-grade diffuse astrocytoma with IDH mutation. Characterized by low cellularity, mild nuclear atypia, and absence of mitotic activity, microvascular proliferation, or necrosis. Patients typically present with seizures and have favorable prognosis with median survival of 10-15 years."", ""name"": ""IDH-Mutant Astrocytoma Grade 2""}"
3933	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	has_subtypes	1	IDH-Mutant Astrocytoma Grade 3	Anaplastic astrocytoma with IDH mutation. Shows increased cellularity, nuclear atypia, and mitotic activity but lacks microvascular proliferation and necrosis. Median survival approximately 5-7 years.																																																								"{""description"": ""Anaplastic astrocytoma with IDH mutation. Shows increased cellularity, nuclear atypia, and mitotic activity but lacks microvascular proliferation and necrosis. Median survival approximately 5-7 years."", ""name"": ""IDH-Mutant Astrocytoma Grade 3""}"	{}	"{""description"": ""Anaplastic astrocytoma with IDH mutation. Shows increased cellularity, nuclear atypia, and mitotic activity but lacks microvascular proliferation and necrosis. Median survival approximately 5-7 years."", ""name"": ""IDH-Mutant Astrocytoma Grade 3""}"
3934	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	has_subtypes	2	IDH-Mutant Astrocytoma Grade 4	Astrocytoma with IDH mutation and either microvascular proliferation, necrosis, or homozygous CDKN2A/B deletion. Previously termed secondary glioblastoma. Despite grade 4 histology, prognosis is better than IDH-wildtype glioblastoma.																																																								"{""description"": ""Astrocytoma with IDH mutation and either microvascular proliferation, necrosis, or homozygous CDKN2A/B deletion. Previously termed secondary glioblastoma. Despite grade 4 histology, prognosis is better than IDH-wildtype glioblastoma."", ""name"": ""IDH-Mutant Astrocytoma Grade 4""}"	{}	"{""description"": ""Astrocytoma with IDH mutation and either microvascular proliferation, necrosis, or homozygous CDKN2A/B deletion. Previously termed secondary glioblastoma. Despite grade 4 histology, prognosis is better than IDH-wildtype glioblastoma."", ""name"": ""IDH-Mutant Astrocytoma Grade 4""}"
3977	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	has_subtypes	0	Oligodendroglioma Grade 2	Low-grade oligodendroglioma with IDH mutation and 1p/19q codeletion. Characterized by uniform round nuclei, perinuclear halos (fried egg appearance), delicate branching capillaries (chicken-wire vasculature), and low mitotic activity. Median survival exceeds 15 years with appropriate treatment.																																																								"{""description"": ""Low-grade oligodendroglioma with IDH mutation and 1p/19q codeletion. Characterized by uniform round nuclei, perinuclear halos (fried egg appearance), delicate branching capillaries (chicken-wire vasculature), and low mitotic activity. Median survival exceeds 15 years with appropriate treatment."", ""name"": ""Oligodendroglioma Grade 2""}"	{}	"{""description"": ""Low-grade oligodendroglioma with IDH mutation and 1p/19q codeletion. Characterized by uniform round nuclei, perinuclear halos (fried egg appearance), delicate branching capillaries (chicken-wire vasculature), and low mitotic activity. Median survival exceeds 15 years with appropriate treatment."", ""name"": ""Oligodendroglioma Grade 2""}"
3978	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	has_subtypes	1	Oligodendroglioma Grade 3 (Anaplastic)	Anaplastic oligodendroglioma with IDH mutation and 1p/19q codeletion. Shows increased cellularity, mitotic activity, microvascular proliferation, and/or necrosis. Despite high-grade features, chemosensitivity is retained and median survival is 10-15 years with combined chemoradiation.																																																								"{""description"": ""Anaplastic oligodendroglioma with IDH mutation and 1p/19q codeletion. Shows increased cellularity, mitotic activity, microvascular proliferation, and/or necrosis. Despite high-grade features, chemosensitivity is retained and median survival is 10-15 years with combined chemoradiation."", ""name"": ""Oligodendroglioma Grade 3 (Anaplastic)""}"	{}	"{""description"": ""Anaplastic oligodendroglioma with IDH mutation and 1p/19q codeletion. Shows increased cellularity, mitotic activity, microvascular proliferation, and/or necrosis. Despite high-grade features, chemosensitivity is retained and median survival is 10-15 years with combined chemoradiation."", ""name"": ""Oligodendroglioma Grade 3 (Anaplastic)""}"
4087	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	has_subtypes	0	Eyelid Myoclonia with Absences (EMA)	The most common presentation, characterized by eyelid myoclonia with or without absences.																																																								"{""description"": ""The most common presentation, characterized by eyelid myoclonia with or without absences."", ""name"": ""Eyelid Myoclonia with Absences (EMA)""}"	{}	"{""description"": ""The most common presentation, characterized by eyelid myoclonia with or without absences."", ""evidence"": [{""explanation"": ""The criteria for diagnosing Jeavons syndrome include eyelid myoclonia with or without absences, supporting the statement's description."", ""reference"": ""PMID:30082241"", ""snippet"": ""Criteria for Jeavons syndrome included all of the following: (1) eyelid myoclonia with or without absences..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The consensus specifies that absence seizures can be typically or occasionally seen in patients with Jeavons syndrome, supporting the statement."", ""reference"": ""PMID:37329145"", ""snippet"": ""There was consensus that generalized tonic-clonic and absence seizures are typically or occasionally seen in patients."", ""supports"": ""SUPPORT""}], ""name"": ""Eyelid Myoclonia with Absences (EMA)""}"
4088	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	has_subtypes	1	Eyelid Myoclonia with Absences and Photosensitivity (EMA+)	Eyelid myoclonia with absences that are consistently provoked by photic stimulation.																																																								"{""description"": ""Eyelid myoclonia with absences that are consistently provoked by photic stimulation."", ""name"": ""Eyelid Myoclonia with Absences and Photosensitivity (EMA+)""}"	{}	"{""description"": ""Eyelid myoclonia with absences that are consistently provoked by photic stimulation."", ""evidence"": [{""explanation"": ""This reference confirms that EMA, a defining feature of Jeavons Syndrome, includes photosensitivity as well as eyelid myoclonia and absences."", ""reference"": ""PMID:35394968"", ""snippet"": ""Epilepsy with eyelid myoclonia (EMA) is characterized by eyelid myoclonia, eyelid closure sensitivity, and photosensitivity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case report discusses a patient with Jeavons Syndrome exhibiting eyelid myoclonia with absences and severe photosensitivity, supporting the subtype EMA+ described in the statement."", ""reference"": ""PMID:29722743"", ""snippet"": ""Eyelid myoclonia with absences, generalized tonic-clonic seizures, and severe photosensitivity accompanied by eyelid myoclonia."", ""supports"": ""SUPPORT""}], ""name"": ""Eyelid Myoclonia with Absences and Photosensitivity (EMA+)""}"
4111	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	has_subtypes	0	Acral KIT-Mutant Melanoma	Melanoma arising on acral surfaces (palms, soles, subungual regions) with KIT mutation. Represents the most common anatomic site for KIT-mutant melanoma. Not associated with sun exposure.																																																								"{""description"": ""Melanoma arising on acral surfaces (palms, soles, subungual regions) with KIT mutation. Represents the most common anatomic site for KIT-mutant melanoma. Not associated with sun exposure."", ""name"": ""Acral KIT-Mutant Melanoma""}"	{}	"{""description"": ""Melanoma arising on acral surfaces (palms, soles, subungual regions) with KIT mutation. Represents the most common anatomic site for KIT-mutant melanoma. Not associated with sun exposure."", ""name"": ""Acral KIT-Mutant Melanoma""}"
4112	174	KIT Mutant Melanoma	KIT_Mutant_Melanoma.yaml	has_subtypes	1	Mucosal KIT-Mutant Melanoma	Melanoma arising from mucosal surfaces (oral, nasal, genital, anorectal) with KIT mutation. Associated with poor prognosis due to delayed diagnosis and limited surgical options.																																																								"{""description"": ""Melanoma arising from mucosal surfaces (oral, nasal, genital, anorectal) with KIT mutation. Associated with poor prognosis due to delayed diagnosis and limited surgical options."", ""name"": ""Mucosal KIT-Mutant Melanoma""}"	{}	"{""description"": ""Melanoma arising from mucosal surfaces (oral, nasal, genital, anorectal) with KIT mutation. Associated with poor prognosis due to delayed diagnosis and limited surgical options."", ""name"": ""Mucosal KIT-Mutant Melanoma""}"
4129	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	has_subtypes	0	KRAS G12C Adenocarcinoma	The majority of KRAS G12C NSCLC presents as adenocarcinoma histology. Associated with smoking history in most cases.																																																								"{""description"": ""The majority of KRAS G12C NSCLC presents as adenocarcinoma histology. Associated with smoking history in most cases."", ""name"": ""KRAS G12C Adenocarcinoma""}"	{}	"{""description"": ""The majority of KRAS G12C NSCLC presents as adenocarcinoma histology. Associated with smoking history in most cases."", ""name"": ""KRAS G12C Adenocarcinoma""}"
4130	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	has_subtypes	1	KRAS G12C with STK11/LKB1 Co-mutation	Co-occurring STK11/LKB1 inactivation is common (~20-30%) and associated with worse prognosis and reduced immunotherapy response. May still respond to KRAS G12C inhibitors.																																																								"{""description"": ""Co-occurring STK11/LKB1 inactivation is common (~20-30%) and associated with worse prognosis and reduced immunotherapy response. May still respond to KRAS G12C inhibitors."", ""name"": ""KRAS G12C with STK11/LKB1 Co-mutation""}"	{}	"{""description"": ""Co-occurring STK11/LKB1 inactivation is common (~20-30%) and associated with worse prognosis and reduced immunotherapy response. May still respond to KRAS G12C inhibitors."", ""name"": ""KRAS G12C with STK11/LKB1 Co-mutation""}"
4131	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	has_subtypes	2	KRAS G12C with KEAP1 Co-mutation	Co-occurring KEAP1 mutations (~15-20%) are associated with worse outcomes and may confer resistance to KRAS G12C inhibitors.																																																								"{""description"": ""Co-occurring KEAP1 mutations (~15-20%) are associated with worse outcomes and may confer resistance to KRAS G12C inhibitors."", ""name"": ""KRAS G12C with KEAP1 Co-mutation""}"	{}	"{""description"": ""Co-occurring KEAP1 mutations (~15-20%) are associated with worse outcomes and may confer resistance to KRAS G12C inhibitors."", ""name"": ""KRAS G12C with KEAP1 Co-mutation""}"
4148	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	has_subtypes	0	Classic Kaposi Sarcoma	Indolent form occurring in elderly men of Mediterranean, Eastern European, or Middle Eastern descent. Typically confined to lower extremities with slow progression over years to decades. Not associated with immunosuppression.																																																								"{""description"": ""Indolent form occurring in elderly men of Mediterranean, Eastern European, or Middle Eastern descent. Typically confined to lower extremities with slow progression over years to decades. Not associated with immunosuppression."", ""name"": ""Classic Kaposi Sarcoma""}"	{}	"{""description"": ""Indolent form occurring in elderly men of Mediterranean, Eastern European, or Middle Eastern descent. Typically confined to lower extremities with slow progression over years to decades. Not associated with immunosuppression."", ""name"": ""Classic Kaposi Sarcoma""}"
4149	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	has_subtypes	1	Endemic Kaposi Sarcoma	Occurs in sub-Saharan Africa, predating the HIV epidemic. Includes a lymphadenopathic variant affecting children that is rapidly progressive and often fatal. More aggressive than classic form.																																																								"{""description"": ""Occurs in sub-Saharan Africa, predating the HIV epidemic. Includes a lymphadenopathic variant affecting children that is rapidly progressive and often fatal. More aggressive than classic form."", ""name"": ""Endemic Kaposi Sarcoma""}"	{}	"{""description"": ""Occurs in sub-Saharan Africa, predating the HIV epidemic. Includes a lymphadenopathic variant affecting children that is rapidly progressive and often fatal. More aggressive than classic form."", ""name"": ""Endemic Kaposi Sarcoma""}"
4150	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	has_subtypes	2	Iatrogenic Kaposi Sarcoma	Occurs in organ transplant recipients and others on immunosuppressive therapy. May regress with reduction of immunosuppression. Risk correlates with degree of T-cell immunosuppression.																																																								"{""description"": ""Occurs in organ transplant recipients and others on immunosuppressive therapy. May regress with reduction of immunosuppression. Risk correlates with degree of T-cell immunosuppression."", ""name"": ""Iatrogenic Kaposi Sarcoma""}"	{}	"{""description"": ""Occurs in organ transplant recipients and others on immunosuppressive therapy. May regress with reduction of immunosuppression. Risk correlates with degree of T-cell immunosuppression."", ""name"": ""Iatrogenic Kaposi Sarcoma""}"
4151	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	has_subtypes	3	AIDS-Associated Kaposi Sarcoma	Most common malignancy in AIDS patients, particularly in men who have sex with men. More aggressive with visceral involvement. Incidence has declined dramatically with effective antiretroviral therapy but remains an AIDS-defining illness.																																																								"{""description"": ""Most common malignancy in AIDS patients, particularly in men who have sex with men. More aggressive with visceral involvement. Incidence has declined dramatically with effective antiretroviral therapy but remains an AIDS-defining illness."", ""name"": ""AIDS-Associated Kaposi Sarcoma""}"	{}	"{""description"": ""Most common malignancy in AIDS patients, particularly in men who have sex with men. More aggressive with visceral involvement. Incidence has declined dramatically with effective antiretroviral therapy but remains an AIDS-defining illness."", ""name"": ""AIDS-Associated Kaposi Sarcoma""}"
4221	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	has_subtypes	0	Classic Vohwinkel Syndrome	"The classic form caused by GJB2 mutations, featuring the complete triad of palmoplantar keratoderma, pseudoainhum, and sensorineural hearing loss.
"																																																								"{""description"": ""The classic form caused by GJB2 mutations, featuring the complete triad of palmoplantar keratoderma, pseudoainhum, and sensorineural hearing loss.\n"", ""name"": ""Classic Vohwinkel Syndrome""}"	{}	"{""description"": ""The classic form caused by GJB2 mutations, featuring the complete triad of palmoplantar keratoderma, pseudoainhum, and sensorineural hearing loss.\n"", ""evidence"": [{""explanation"": ""This landmark paper identified the D66H mutation in GJB2 as causative for classic Vohwinkel syndrome with the characteristic triad."", ""reference"": ""PMID:10369869"", ""snippet"": ""VS is characterized by papular and honeycomb keratoderma associated with constrictions of digits leading to autoamputation, distinctive starfish-like acral keratoses and moderate degrees of deafness.\n"", ""supports"": ""SUPPORT""}], ""name"": ""Classic Vohwinkel Syndrome""}"
4222	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	has_subtypes	1	Loricrin Keratoderma (Variant Vohwinkel Syndrome)	"A variant form caused by LOR gene mutations, featuring keratoderma and pseudoainhum but with ichthyosis instead of hearing loss. Also known as Camisa variant.
"																																																								"{""description"": ""A variant form caused by LOR gene mutations, featuring keratoderma and pseudoainhum but with ichthyosis instead of hearing loss. Also known as Camisa variant.\n"", ""name"": ""Loricrin Keratoderma (Variant Vohwinkel Syndrome)""}"	{}	"{""description"": ""A variant form caused by LOR gene mutations, featuring keratoderma and pseudoainhum but with ichthyosis instead of hearing loss. Also known as Camisa variant.\n"", ""evidence"": [{""explanation"": ""This paper established that loricrin mutations cause the ichthyotic variant without hearing loss."", ""reference"": ""PMID:9326398"", ""snippet"": ""Vohwinkel's keratoderma is thus clinically and genetically heterogeneous. Only the variant with ichthyosis appears to be due to loricrin mutation.\n"", ""supports"": ""SUPPORT""}, {""explanation"": ""Confirms loricrin mutations underlie the ichthyotic variant of Vohwinkel syndrome."", ""reference"": ""PMID:12072018"", ""snippet"": ""Functional studies in transgenic mice have shown that the accumulation of mutant loricrin in the nucleus appears to interfere with the later stages of epidermal differentiation, thereby explaining the clinical manifestations of ichthyosis, keratoderma and pseudoainhum.\n"", ""supports"": ""SUPPORT""}], ""name"": ""Loricrin Keratoderma (Variant Vohwinkel Syndrome)""}"
4331	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	0	Type 0 (interarytenoid cleft)	Interarytenoid notch above the vocal folds without extension into the cricoid cartilage.																																																								"{""description"": ""Interarytenoid notch above the vocal folds without extension into the cricoid cartilage."", ""name"": ""Type 0 (interarytenoid cleft)""}"	{}	"{""description"": ""Interarytenoid notch above the vocal folds without extension into the cricoid cartilage."", ""name"": ""Type 0 (interarytenoid cleft)"", ""subtype_term"": {""preferred_term"": ""laryngotracheoesophageal cleft type 0"", ""term"": {""id"": ""MONDO:0017220"", ""label"": ""laryngotracheoesophageal cleft type 0""}}}"
4332	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	1	Type I	Supraglottic cleft extending to, but not through, the cricoid cartilage.																																																								"{""description"": ""Supraglottic cleft extending to, but not through, the cricoid cartilage."", ""name"": ""Type I""}"	{}	"{""description"": ""Supraglottic cleft extending to, but not through, the cricoid cartilage."", ""name"": ""Type I"", ""subtype_term"": {""preferred_term"": ""laryngotracheoesophageal cleft type 1"", ""term"": {""id"": ""MONDO:0019761"", ""label"": ""laryngotracheoesophageal cleft type 1""}}}"
4333	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	2	Type II	Cleft extends through the cricoid cartilage into the cervical trachea.																																																								"{""description"": ""Cleft extends through the cricoid cartilage into the cervical trachea."", ""name"": ""Type II""}"	{}	"{""description"": ""Cleft extends through the cricoid cartilage into the cervical trachea."", ""name"": ""Type II"", ""subtype_term"": {""preferred_term"": ""laryngotracheoesophageal cleft type 2"", ""term"": {""id"": ""MONDO:0019762"", ""label"": ""laryngotracheoesophageal cleft type 2""}}}"
4334	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	3	Type III	Cleft extends into the thoracic trachea.																																																								"{""description"": ""Cleft extends into the thoracic trachea."", ""name"": ""Type III""}"	{}	"{""description"": ""Cleft extends into the thoracic trachea."", ""name"": ""Type III"", ""subtype_term"": {""preferred_term"": ""laryngotracheoesophageal cleft type 3"", ""term"": {""id"": ""MONDO:0019763"", ""label"": ""laryngotracheoesophageal cleft type 3""}}}"
4335	182	Laryngotracheoesophageal Cleft	Laryngotracheoesophageal_Cleft.yaml	has_subtypes	4	Type IV	Cleft extends to the carina and may involve a mainstem bronchus.																																																								"{""description"": ""Cleft extends to the carina and may involve a mainstem bronchus."", ""name"": ""Type IV""}"	{}	"{""description"": ""Cleft extends to the carina and may involve a mainstem bronchus."", ""name"": ""Type IV"", ""subtype_term"": {""preferred_term"": ""laryngotracheoesophageal cleft type 4"", ""term"": {""id"": ""MONDO:0019764"", ""label"": ""laryngotracheoesophageal cleft type 4""}}}"
4362	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	0	Visceral leishmaniasis																																																									"{""name"": ""Visceral leishmaniasis""}"	{}	"{""evidence"": [{""explanation"": ""The review lists visceral leishmaniasis as a main clinical form."", ""reference"": ""PMID:19634705"", ""snippet"": ""It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)"", ""supports"": ""SUPPORT""}], ""name"": ""Visceral leishmaniasis"", ""subtype_term"": {""preferred_term"": ""visceral leishmaniasis"", ""term"": {""id"": ""MONDO:0005445"", ""label"": ""visceral leishmaniasis""}}}"
4363	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	1	Cutaneous leishmaniasis																																																									"{""name"": ""Cutaneous leishmaniasis""}"	{}	"{""evidence"": [{""explanation"": ""The review lists cutaneous leishmaniasis as a main clinical form."", ""reference"": ""PMID:19634705"", ""snippet"": ""It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)"", ""supports"": ""SUPPORT""}], ""name"": ""Cutaneous leishmaniasis"", ""subtype_term"": {""preferred_term"": ""cutaneous leishmaniasis"", ""term"": {""id"": ""MONDO:0005446"", ""label"": ""cutaneous leishmaniasis""}}}"
4364	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	2	Mucocutaneous leishmaniasis																																																									"{""name"": ""Mucocutaneous leishmaniasis""}"	{}	"{""evidence"": [{""explanation"": ""The review lists mucocutaneous leishmaniasis as a main clinical form."", ""reference"": ""PMID:19634705"", ""snippet"": ""It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)"", ""supports"": ""SUPPORT""}], ""name"": ""Mucocutaneous leishmaniasis"", ""subtype_term"": {""preferred_term"": ""mucocutaneous leishmaniasis"", ""term"": {""id"": ""MONDO:0005859"", ""label"": ""mucocutaneous leishmaniasis""}}}"
4379	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	has_subtypes	0	Classic Li-Fraumeni Syndrome	Defined by classic clinical criteria: proband with sarcoma before age 45, first-degree relative with cancer before 45, and another first- or second-degree relative with cancer before 45 or sarcoma at any age.																																																								"{""description"": ""Defined by classic clinical criteria: proband with sarcoma before age 45, first-degree relative with cancer before 45, and another first- or second-degree relative with cancer before 45 or sarcoma at any age."", ""name"": ""Classic Li-Fraumeni Syndrome""}"	{}	"{""description"": ""Defined by classic clinical criteria: proband with sarcoma before age 45, first-degree relative with cancer before 45, and another first- or second-degree relative with cancer before 45 or sarcoma at any age."", ""name"": ""Classic Li-Fraumeni Syndrome""}"
4380	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	has_subtypes	1	Li-Fraumeni-Like Syndrome	Families meeting relaxed criteria (Birch or Eeles) who have germline TP53 mutations but do not fulfill classic LFS criteria. May have later onset or fewer affected family members.																																																								"{""description"": ""Families meeting relaxed criteria (Birch or Eeles) who have germline TP53 mutations but do not fulfill classic LFS criteria. May have later onset or fewer affected family members."", ""name"": ""Li-Fraumeni-Like Syndrome""}"	{}	"{""description"": ""Families meeting relaxed criteria (Birch or Eeles) who have germline TP53 mutations but do not fulfill classic LFS criteria. May have later onset or fewer affected family members."", ""name"": ""Li-Fraumeni-Like Syndrome""}"
4412	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	has_subtypes	0	Alcoholic Cirrhosis	Cirrhosis due to chronic alcohol abuse.																																																								"{""description"": ""Cirrhosis due to chronic alcohol abuse."", ""name"": ""Alcoholic Cirrhosis""}"	{}	"{""description"": ""Cirrhosis due to chronic alcohol abuse."", ""name"": ""Alcoholic Cirrhosis""}"
4413	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	has_subtypes	1	Viral Cirrhosis	Cirrhosis from chronic hepatitis B or C infection.																																																								"{""description"": ""Cirrhosis from chronic hepatitis B or C infection."", ""name"": ""Viral Cirrhosis""}"	{}	"{""description"": ""Cirrhosis from chronic hepatitis B or C infection."", ""name"": ""Viral Cirrhosis""}"
4414	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	has_subtypes	2	Non-Alcoholic Steatohepatitis Cirrhosis	Cirrhosis from metabolic-associated fatty liver disease.																																																								"{""description"": ""Cirrhosis from metabolic-associated fatty liver disease."", ""name"": ""Non-Alcoholic Steatohepatitis Cirrhosis""}"	{}	"{""description"": ""Cirrhosis from metabolic-associated fatty liver disease."", ""name"": ""Non-Alcoholic Steatohepatitis Cirrhosis""}"
4415	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	has_subtypes	3	Primary Biliary Cholangitis	Autoimmune destruction of intrahepatic bile ducts.																																																								"{""description"": ""Autoimmune destruction of intrahepatic bile ducts."", ""name"": ""Primary Biliary Cholangitis""}"	{}	"{""description"": ""Autoimmune destruction of intrahepatic bile ducts."", ""name"": ""Primary Biliary Cholangitis""}"
4416	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	has_subtypes	4	Primary Sclerosing Cholangitis	Chronic inflammation and fibrosis of bile ducts.																																																								"{""description"": ""Chronic inflammation and fibrosis of bile ducts."", ""name"": ""Primary Sclerosing Cholangitis""}"	{}	"{""description"": ""Chronic inflammation and fibrosis of bile ducts."", ""name"": ""Primary Sclerosing Cholangitis""}"
4510	190	Lung Carcinoma	Lung_Carcinoma.yaml	has_subtypes	0	Small Cell Lung Cancer	High-grade neuroendocrine carcinoma accounting for a minority of lung cancers, often treated with systemic chemotherapy.																																																								"{""description"": ""High-grade neuroendocrine carcinoma accounting for a minority of lung cancers, often treated with systemic chemotherapy."", ""name"": ""Small Cell Lung Cancer""}"	{}	"{""description"": ""High-grade neuroendocrine carcinoma accounting for a minority of lung cancers, often treated with systemic chemotherapy."", ""evidence"": [{""explanation"": ""The abstract identifies small cell lung cancer as a major subtype and notes chemotherapy treatment."", ""reference"": ""PMID:19445746"", ""snippet"": ""Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""Small Cell Lung Cancer""}"
4511	190	Lung Carcinoma	Lung_Carcinoma.yaml	has_subtypes	1	Lung Adenocarcinoma (NSCLC)	The most common non-small cell lung carcinoma histology, often treated initially with surgery when resectable.																																																								"{""description"": ""The most common non-small cell lung carcinoma histology, often treated initially with surgery when resectable."", ""name"": ""Lung Adenocarcinoma (NSCLC)""}"	{}	"{""description"": ""The most common non-small cell lung carcinoma histology, often treated initially with surgery when resectable."", ""evidence"": [{""explanation"": ""The abstract notes adenocarcinoma as the main NSCLC subtype and its initial surgical treatment."", ""reference"": ""PMID:19445746"", ""snippet"": ""Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery."", ""supports"": ""SUPPORT""}], ""name"": ""Lung Adenocarcinoma (NSCLC)""}"
4539	191	Lyme Disease	Lyme_Disease.yaml	has_subtypes	0	Early Localized Lyme Disease	Initial stage within weeks of tick bite, characterized by erythema migrans and flu-like symptoms.																																																								"{""description"": ""Initial stage within weeks of tick bite, characterized by erythema migrans and flu-like symptoms."", ""name"": ""Early Localized Lyme Disease""}"	{}	"{""description"": ""Initial stage within weeks of tick bite, characterized by erythema migrans and flu-like symptoms."", ""name"": ""Early Localized Lyme Disease""}"
4540	191	Lyme Disease	Lyme_Disease.yaml	has_subtypes	1	Early Disseminated Lyme Disease	Hematogenous spread within weeks to months, with multiple erythema migrans, neurological, or cardiac involvement.																																																								"{""description"": ""Hematogenous spread within weeks to months, with multiple erythema migrans, neurological, or cardiac involvement."", ""name"": ""Early Disseminated Lyme Disease""}"	{}	"{""description"": ""Hematogenous spread within weeks to months, with multiple erythema migrans, neurological, or cardiac involvement."", ""name"": ""Early Disseminated Lyme Disease""}"
4541	191	Lyme Disease	Lyme_Disease.yaml	has_subtypes	2	Late Disseminated Lyme Disease	Months to years after infection, characterized by Lyme arthritis or chronic neurological manifestations.																																																								"{""description"": ""Months to years after infection, characterized by Lyme arthritis or chronic neurological manifestations."", ""name"": ""Late Disseminated Lyme Disease""}"	{}	"{""description"": ""Months to years after infection, characterized by Lyme arthritis or chronic neurological manifestations."", ""name"": ""Late Disseminated Lyme Disease""}"
4542	191	Lyme Disease	Lyme_Disease.yaml	has_subtypes	3	Post-Treatment Lyme Disease Syndrome	Persistent symptoms after appropriate antibiotic therapy, occurring in 10-20% of treated patients.																																																								"{""description"": ""Persistent symptoms after appropriate antibiotic therapy, occurring in 10-20% of treated patients."", ""name"": ""Post-Treatment Lyme Disease Syndrome""}"	{}	"{""description"": ""Persistent symptoms after appropriate antibiotic therapy, occurring in 10-20% of treated patients."", ""name"": ""Post-Treatment Lyme Disease Syndrome""}"
4569	193	Lymphoma	Lymphoma.yaml	has_subtypes	0	Non-Hodgkin Lymphoma	Broad category of lymphoid malignancies distinct from Hodgkin lymphoma.																																																								"{""description"": ""Broad category of lymphoid malignancies distinct from Hodgkin lymphoma."", ""name"": ""Non-Hodgkin Lymphoma""}"	{}	"{""description"": ""Broad category of lymphoid malignancies distinct from Hodgkin lymphoma."", ""evidence"": [{""explanation"": ""The abstract states lymphoma is classified as non-Hodgkin or Hodgkin."", ""reference"": ""PMID:31894937"", ""snippet"": ""It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma."", ""supports"": ""SUPPORT""}], ""name"": ""Non-Hodgkin Lymphoma""}"
4570	193	Lymphoma	Lymphoma.yaml	has_subtypes	1	Hodgkin Lymphoma	Lymphoma subtype classified separately from non-Hodgkin lymphoma.																																																								"{""description"": ""Lymphoma subtype classified separately from non-Hodgkin lymphoma."", ""name"": ""Hodgkin Lymphoma""}"	{}	"{""description"": ""Lymphoma subtype classified separately from non-Hodgkin lymphoma."", ""evidence"": [{""explanation"": ""The abstract states lymphoma is classified as non-Hodgkin or Hodgkin."", ""reference"": ""PMID:31894937"", ""snippet"": ""It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma."", ""supports"": ""SUPPORT""}], ""name"": ""Hodgkin Lymphoma""}"
4592	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	0	MLH1 Mutation	Caused by a mutation in the MLH1 gene, which is involved in DNA mismatch repair.																																																								"{""description"": ""Caused by a mutation in the MLH1 gene, which is involved in DNA mismatch repair."", ""name"": ""MLH1 Mutation""}"	{}	"{""description"": ""Caused by a mutation in the MLH1 gene, which is involved in DNA mismatch repair."", ""evidence"": [{""explanation"": ""The literature confirms that Lynch Syndrome is caused by germline mutations in DNA mismatch repair genes, including MLH1."", ""reference"": ""PMID:19466295"", ""snippet"": ""Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes"", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature discusses MLH1 gene involvement in Lynch Syndrome, supporting its significant role."", ""reference"": ""PMID:38003003"", ""snippet"": ""MLH1 hypermethylation is an epigenetic alteration in the tumorigenesis of colorectal cancer (CRC) and endometrial cancer (EC), causing gene silencing, and, as a consequence, microsatellite instability."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract confirms that mutations in the MLH1 gene are a significant cause of Lynch Syndrome."", ""reference"": ""PMID:34091457"", ""snippet"": ""Deleterious heterozygous mutation of the MLH1 gene is an important cause of Lynch syndrome (LS), an autosomal dominant cancer caused by functional defects in the DNA mismatch repair (MMR) complex."", ""supports"": ""SUPPORT""}], ""name"": ""MLH1 Mutation""}"
4593	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	1	MSH2 Mutation	Caused by a mutation in the MSH2 gene, which is involved in DNA mismatch repair.																																																								"{""description"": ""Caused by a mutation in the MSH2 gene, which is involved in DNA mismatch repair."", ""name"": ""MSH2 Mutation""}"	{}	"{""description"": ""Caused by a mutation in the MSH2 gene, which is involved in DNA mismatch repair."", ""evidence"": [{""explanation"": ""The literature indicates that MSH2 is one of the genes whose mutation is correlated with susceptibility to Lynch syndrome."", ""reference"": ""PMID:19466295"", ""snippet"": ""Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes. Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This directly supports the statement that Lynch syndrome subtypes include those caused by mutations in the MSH2 gene."", ""reference"": ""PMID:34302852"", ""snippet"": ""Lynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2."", ""supports"": ""SUPPORT""}, {""explanation"": ""This provides further confirmation that mutations in MSH2 can cause Lynch syndrome, supporting the statement."", ""reference"": ""PMID:36434153"", ""snippet"": ""Patients with the heritable cancer disease, Lynch syndrome, carry germline variants in the MLH1, MSH2, MSH6 and PMS2 genes, encoding the central components of the DNA mismatch repair system."", ""supports"": ""SUPPORT""}], ""name"": ""MSH2 Mutation""}"
4594	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	2	MSH6 Mutation	Caused by a mutation in the MSH6 gene, which is involved in DNA mismatch repair.																																																								"{""description"": ""Caused by a mutation in the MSH6 gene, which is involved in DNA mismatch repair."", ""name"": ""MSH6 Mutation""}"	{}	"{""description"": ""Caused by a mutation in the MSH6 gene, which is involved in DNA mismatch repair."", ""evidence"": [{""explanation"": ""The literature confirms that Lynch syndrome can be caused by mutations in the MSH6 gene, which is involved in DNA mismatch repair."", ""reference"": ""PMID:19466295"", ""snippet"": ""Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies MSH6 as one of the genes with mutations found in Lynch syndrome patients."", ""reference"": ""PMID:25430799"", ""snippet"": ""Sixty-seven (59%) families had mutations in MSH2, 20 (18%) in MSH6, 19 (17%) in MLH1 and 7 (6%) in PMS2."", ""supports"": ""SUPPORT""}], ""name"": ""MSH6 Mutation""}"
4595	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	3	PMS2 Mutation	Caused by a mutation in the PMS2 gene, which is involved in DNA mismatch repair.																																																								"{""description"": ""Caused by a mutation in the PMS2 gene, which is involved in DNA mismatch repair."", ""name"": ""PMS2 Mutation""}"	{}	"{""description"": ""Caused by a mutation in the PMS2 gene, which is involved in DNA mismatch repair."", ""evidence"": [{""explanation"": ""Further detail is provided in the study focusing on PMS2 gene's role in MMR and its link to Lynch Syndrome."", ""reference"": ""PMID:24027009"", ""snippet"": ""Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation in one of four DNA mismatch repair (MMR) genes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms PMS2 mutations contribute to Lynch Syndrome."", ""reference"": ""PMID:18602922"", ""snippet"": ""Although the clinical phenotype of Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) has been well described, little is known about disease in PMS2 mutation carriers."", ""supports"": ""SUPPORT""}], ""name"": ""PMS2 Mutation""}"
4596	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	4	EPCAM Deletion	Caused by a deletion in the EPCAM gene, which can lead to silencing of the MSH2 gene.																																																								"{""description"": ""Caused by a deletion in the EPCAM gene, which can lead to silencing of the MSH2 gene."", ""name"": ""EPCAM Deletion""}"	{}	"{""description"": ""Caused by a deletion in the EPCAM gene, which can lead to silencing of the MSH2 gene."", ""evidence"": [{""explanation"": ""This reference describes the mechanism by which EPCAM gene deletion causes epigenetic inactivation of the MSH2 gene, supporting the statement."", ""reference"": ""PMID:23411950"", ""snippet"": ""Germline mutations of 4 MMR genes, e.g., MLH1, MSH2, MSH6 and PMS2, had been identified as the cause of this disease, however, a novel mechanism, epigenetic inactivation of MSH2 gene due to hypermethylation of promotor region by the deletion of 3'part of epithelial cell adhesion molecule(EPCAM) gene which is located upstream of the MSH2 gene, has been reported in recent years."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference further supports the statement by specifying that deletions of the EPCAM gene silence the MSH2 gene, leading to Lynch syndrome."", ""reference"": ""PMID:30461124"", ""snippet"": ""Monoallelic deletions of the 3' end of EPCAM that silence the downstream gene, MSH2, cause a form of Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mismatch repair."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference describes the specific mechanism by which EPCAM deletions lead to the inactivation of MSH2, supporting the statement."", ""reference"": ""PMID:23264089"", ""snippet"": ""These patients carry deletions of the 3' end of the EPCAM gene, including its polyadenylation signal. Due to concomitant transcriptional read-through of EPCAM, the promoter of MSH2 15 kb further downstream becomes inactivated through hypermethylation."", ""supports"": ""SUPPORT""}], ""name"": ""EPCAM Deletion""}"
4629	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	has_subtypes	0	METex14 Splice Site Mutation	Point mutations at splice donor or acceptor sites flanking exon 14 are the most common mechanism, causing exon 14 exclusion during mRNA splicing.																																																								"{""description"": ""Point mutations at splice donor or acceptor sites flanking exon 14 are the most common mechanism, causing exon 14 exclusion during mRNA splicing."", ""name"": ""METex14 Splice Site Mutation""}"	{}	"{""description"": ""Point mutations at splice donor or acceptor sites flanking exon 14 are the most common mechanism, causing exon 14 exclusion during mRNA splicing."", ""name"": ""METex14 Splice Site Mutation""}"
4630	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	has_subtypes	1	METex14 Whole Exon Deletion	Genomic deletion of the entire exon 14 region, a less common mechanism of exon 14 loss.																																																								"{""description"": ""Genomic deletion of the entire exon 14 region, a less common mechanism of exon 14 loss."", ""name"": ""METex14 Whole Exon Deletion""}"	{}	"{""description"": ""Genomic deletion of the entire exon 14 region, a less common mechanism of exon 14 loss."", ""name"": ""METex14 Whole Exon Deletion""}"
4631	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	has_subtypes	2	METex14 with MET Amplification	A subset of METex14-positive tumors also harbor MET gene amplification, which may increase oncogenic drive and affect inhibitor sensitivity.																																																								"{""description"": ""A subset of METex14-positive tumors also harbor MET gene amplification, which may increase oncogenic drive and affect inhibitor sensitivity."", ""name"": ""METex14 with MET Amplification""}"	{}	"{""description"": ""A subset of METex14-positive tumors also harbor MET gene amplification, which may increase oncogenic drive and affect inhibitor sensitivity."", ""name"": ""METex14 with MET Amplification""}"
4654	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	has_subtypes	0	Lynch Syndrome-Associated MSI-H CRC	Hereditary MSI-H colorectal cancer caused by germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) or EPCAM deletions affecting MSH2. Accounts for approximately 3% of all CRC. Younger age at onset, right-sided predominance, and risk of synchronous/metachronous cancers.																																																								"{""description"": ""Hereditary MSI-H colorectal cancer caused by germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) or EPCAM deletions affecting MSH2. Accounts for approximately 3% of all CRC. Younger age at onset, right-sided predominance, and risk of synchronous/metachronous cancers."", ""name"": ""Lynch Syndrome-Associated MSI-H CRC""}"	{}	"{""description"": ""Hereditary MSI-H colorectal cancer caused by germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) or EPCAM deletions affecting MSH2. Accounts for approximately 3% of all CRC. Younger age at onset, right-sided predominance, and risk of synchronous/metachronous cancers."", ""evidence"": [{""explanation"": ""Study confirms that MSI-H colorectal cancers can arise from hereditary (HNPCC/Lynch syndrome) or sporadic causes."", ""reference"": ""PMID:15340260"", ""snippet"": ""Colorectal cancers resulting from defective DNA mismatch repair can occur in both hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting."", ""supports"": ""SUPPORT""}], ""name"": ""Lynch Syndrome-Associated MSI-H CRC""}"
4655	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	has_subtypes	1	Sporadic MSI-H CRC	Non-hereditary MSI-H colorectal cancer caused by biallelic MLH1 promoter hypermethylation, often with concurrent BRAF V600E mutation. Typically occurs in older patients, predominantly female, with right-sided tumors.																																																								"{""description"": ""Non-hereditary MSI-H colorectal cancer caused by biallelic MLH1 promoter hypermethylation, often with concurrent BRAF V600E mutation. Typically occurs in older patients, predominantly female, with right-sided tumors."", ""name"": ""Sporadic MSI-H CRC""}"	{}	"{""description"": ""Non-hereditary MSI-H colorectal cancer caused by biallelic MLH1 promoter hypermethylation, often with concurrent BRAF V600E mutation. Typically occurs in older patients, predominantly female, with right-sided tumors."", ""evidence"": [{""explanation"": ""Study demonstrates that BRAF mutations distinguish sporadic MSI-H CRC from Lynch syndrome-associated tumors."", ""reference"": ""PMID:15340260"", ""snippet"": ""BRAF mutations were detected in 74% of sporadic tumours but none of the HNPCC cancers tested."", ""supports"": ""SUPPORT""}], ""name"": ""Sporadic MSI-H CRC""}"
4678	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	has_subtypes	0	Lynch Syndrome-Associated Endometrial Cancer	Germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) cause Lynch syndrome with substantially increased lifetime risk of endometrial cancer. Regular surveillance and risk-reducing surgery may be considered.																																																								"{""description"": ""Germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) cause Lynch syndrome with substantially increased lifetime risk of endometrial cancer. Regular surveillance and risk-reducing surgery may be considered."", ""name"": ""Lynch Syndrome-Associated Endometrial Cancer""}"	{}	"{""description"": ""Germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) cause Lynch syndrome with substantially increased lifetime risk of endometrial cancer. Regular surveillance and risk-reducing surgery may be considered."", ""evidence"": [{""explanation"": ""This study establishes that MMR-deficient cancers can arise from hereditary (Lynch syndrome) or sporadic causes, applicable to endometrial cancer as well."", ""reference"": ""PMID:15340260"", ""snippet"": ""Colorectal cancers resulting from defective DNA mismatch repair can occur in both hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting."", ""supports"": ""SUPPORT""}], ""name"": ""Lynch Syndrome-Associated Endometrial Cancer""}"
4679	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	has_subtypes	1	Sporadic MSI-H Endometrial Cancer	Most common subtype caused by somatic MLH1 promoter hypermethylation leading to loss of MLH1/PMS2 expression. Not associated with germline mutations or increased cancer risk in family members.																																																								"{""description"": ""Most common subtype caused by somatic MLH1 promoter hypermethylation leading to loss of MLH1/PMS2 expression. Not associated with germline mutations or increased cancer risk in family members."", ""name"": ""Sporadic MSI-H Endometrial Cancer""}"	{}	"{""description"": ""Most common subtype caused by somatic MLH1 promoter hypermethylation leading to loss of MLH1/PMS2 expression. Not associated with germline mutations or increased cancer risk in family members."", ""evidence"": [{""explanation"": ""Study demonstrates that sporadic MSI-H tumors are characterized by promoter hypermethylation, distinguishing them from Lynch syndrome cases."", ""reference"": ""PMID:15340260"", ""snippet"": ""significant differences can be demonstrated at the molecular level including widespread promoter hypermethylation and BRAF -activating mutations which occur significantly less often in HNPCC"", ""supports"": ""SUPPORT""}], ""name"": ""Sporadic MSI-H Endometrial Cancer""}"
4702	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	has_subtypes	0	Melancholic Depression	Characterized by anhedonia, psychomotor changes, and diurnal variation.																																																								"{""description"": ""Characterized by anhedonia, psychomotor changes, and diurnal variation."", ""name"": ""Melancholic Depression""}"	{}	"{""description"": ""Characterized by anhedonia, psychomotor changes, and diurnal variation."", ""name"": ""Melancholic Depression""}"
4703	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	has_subtypes	1	Atypical Depression	Features mood reactivity, hypersomnia, hyperphagia, and rejection sensitivity.																																																								"{""description"": ""Features mood reactivity, hypersomnia, hyperphagia, and rejection sensitivity."", ""name"": ""Atypical Depression""}"	{}	"{""description"": ""Features mood reactivity, hypersomnia, hyperphagia, and rejection sensitivity."", ""name"": ""Atypical Depression""}"
4704	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	has_subtypes	2	Psychotic Depression	Depression with hallucinations or delusions.																																																								"{""description"": ""Depression with hallucinations or delusions."", ""name"": ""Psychotic Depression""}"	{}	"{""description"": ""Depression with hallucinations or delusions."", ""name"": ""Psychotic Depression""}"
4705	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	has_subtypes	3	Seasonal Affective Disorder	Depression recurring in winter months.																																																								"{""description"": ""Depression recurring in winter months."", ""name"": ""Seasonal Affective Disorder""}"	{}	"{""description"": ""Depression recurring in winter months."", ""name"": ""Seasonal Affective Disorder""}"
4706	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	has_subtypes	4	Peripartum Depression	Depression during pregnancy or postpartum period.																																																								"{""description"": ""Depression during pregnancy or postpartum period."", ""name"": ""Peripartum Depression""}"	{}	"{""description"": ""Depression during pregnancy or postpartum period."", ""name"": ""Peripartum Depression""}"
4732	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	has_subtypes	0	Epithelioid Mesothelioma	The most common subtype (50-70%), characterized by polygonal cells with abundant cytoplasm arranged in tubulo-papillary, trabecular, or solid patterns. Has the best prognosis among mesothelioma subtypes.																																																								"{""description"": ""The most common subtype (50-70%), characterized by polygonal cells with abundant cytoplasm arranged in tubulo-papillary, trabecular, or solid patterns. Has the best prognosis among mesothelioma subtypes."", ""name"": ""Epithelioid Mesothelioma""}"	{}	"{""description"": ""The most common subtype (50-70%), characterized by polygonal cells with abundant cytoplasm arranged in tubulo-papillary, trabecular, or solid patterns. Has the best prognosis among mesothelioma subtypes."", ""name"": ""Epithelioid Mesothelioma""}"
4733	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	has_subtypes	1	Sarcomatoid Mesothelioma	Accounts for 10-20% of cases. Composed of spindle cells arranged in fascicles resembling fibrosarcoma. Has the worst prognosis with median survival less than one year.																																																								"{""description"": ""Accounts for 10-20% of cases. Composed of spindle cells arranged in fascicles resembling fibrosarcoma. Has the worst prognosis with median survival less than one year."", ""name"": ""Sarcomatoid Mesothelioma""}"	{}	"{""description"": ""Accounts for 10-20% of cases. Composed of spindle cells arranged in fascicles resembling fibrosarcoma. Has the worst prognosis with median survival less than one year."", ""name"": ""Sarcomatoid Mesothelioma""}"
4734	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	has_subtypes	2	Biphasic Mesothelioma	Contains both epithelioid and sarcomatoid components, each comprising at least 10% of the tumor. Prognosis intermediate between the pure subtypes.																																																								"{""description"": ""Contains both epithelioid and sarcomatoid components, each comprising at least 10% of the tumor. Prognosis intermediate between the pure subtypes."", ""name"": ""Biphasic Mesothelioma""}"	{}	"{""description"": ""Contains both epithelioid and sarcomatoid components, each comprising at least 10% of the tumor. Prognosis intermediate between the pure subtypes."", ""name"": ""Biphasic Mesothelioma""}"
4756	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	has_subtypes	0	Classical Mantle Cell Lymphoma	The predominant form characterized by monotonous small to medium-sized lymphocytes with irregular nuclear contours. Typically presents with widespread nodal and extranodal disease. Aggressive clinical course requiring treatment.																																																								"{""description"": ""The predominant form characterized by monotonous small to medium-sized lymphocytes with irregular nuclear contours. Typically presents with widespread nodal and extranodal disease. Aggressive clinical course requiring treatment."", ""name"": ""Classical Mantle Cell Lymphoma""}"	{}	"{""description"": ""The predominant form characterized by monotonous small to medium-sized lymphocytes with irregular nuclear contours. Typically presents with widespread nodal and extranodal disease. Aggressive clinical course requiring treatment."", ""name"": ""Classical Mantle Cell Lymphoma""}"
4757	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	has_subtypes	1	Leukemic Non-Nodal Mantle Cell Lymphoma	Indolent variant presenting with splenomegaly, bone marrow involvement, and peripheral blood disease without significant lymphadenopathy. Often SOX11-negative with IGHV mutations. May be managed with observation initially.																																																								"{""description"": ""Indolent variant presenting with splenomegaly, bone marrow involvement, and peripheral blood disease without significant lymphadenopathy. Often SOX11-negative with IGHV mutations. May be managed with observation initially."", ""name"": ""Leukemic Non-Nodal Mantle Cell Lymphoma""}"	{}	"{""description"": ""Indolent variant presenting with splenomegaly, bone marrow involvement, and peripheral blood disease without significant lymphadenopathy. Often SOX11-negative with IGHV mutations. May be managed with observation initially."", ""name"": ""Leukemic Non-Nodal Mantle Cell Lymphoma""}"
4758	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	has_subtypes	2	Blastoid Mantle Cell Lymphoma	Aggressive morphologic variant with blastoid or pleomorphic features, high proliferation rate, and worse prognosis. May arise de novo or from transformation of classical MCL. Often harbors TP53 mutations.																																																								"{""description"": ""Aggressive morphologic variant with blastoid or pleomorphic features, high proliferation rate, and worse prognosis. May arise de novo or from transformation of classical MCL. Often harbors TP53 mutations."", ""name"": ""Blastoid Mantle Cell Lymphoma""}"	{}	"{""description"": ""Aggressive morphologic variant with blastoid or pleomorphic features, high proliferation rate, and worse prognosis. May arise de novo or from transformation of classical MCL. Often harbors TP53 mutations."", ""name"": ""Blastoid Mantle Cell Lymphoma""}"
4792	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	0	Classic MSUD	Most severe form with less than 2% residual enzyme activity, presenting in neonates with acute encephalopathy within days of birth.																																																								"{""description"": ""Most severe form with less than 2% residual enzyme activity, presenting in neonates with acute encephalopathy within days of birth."", ""name"": ""Classic MSUD""}"	{}	"{""description"": ""Most severe form with less than 2% residual enzyme activity, presenting in neonates with acute encephalopathy within days of birth."", ""evidence"": [{""explanation"": ""Confirms classic form has very low residual enzyme activity."", ""reference"": ""PMID:27373929"", ""snippet"": ""In the classic form of MSUD256, BCKDH enzyme only has 25% normal activity."", ""supports"": ""SUPPORT""}], ""name"": ""Classic MSUD""}"
4793	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	1	Intermediate MSUD	Residual enzyme activity 3-30%, variable presentation with developmental delay, may not present until later infancy.																																																								"{""description"": ""Residual enzyme activity 3-30%, variable presentation with developmental delay, may not present until later infancy."", ""name"": ""Intermediate MSUD""}"	{}	"{""description"": ""Residual enzyme activity 3-30%, variable presentation with developmental delay, may not present until later infancy."", ""evidence"": [{""explanation"": ""Confirms intermediate form has higher residual enzyme activity."", ""reference"": ""PMID:27373929"", ""snippet"": ""In addition to the classic form, there are intermediate78 (1525% BCKDH activity), intermittent (asymptomatic until 1016 months or later) and thiamine-responsive910 MSUD diseases."", ""supports"": ""SUPPORT""}], ""name"": ""Intermediate MSUD""}"
4794	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	2	Intermittent MSUD	Normal development with metabolic crises during catabolic stress such as illness, surgery, or fasting.																																																								"{""description"": ""Normal development with metabolic crises during catabolic stress such as illness, surgery, or fasting."", ""name"": ""Intermittent MSUD""}"	{}	"{""description"": ""Normal development with metabolic crises during catabolic stress such as illness, surgery, or fasting."", ""evidence"": [{""explanation"": ""Confirms intermittent form patients are asymptomatic until later in life."", ""reference"": ""PMID:27373929"", ""snippet"": ""In addition to the classic form, there are intermediate78 (1525% BCKDH activity), intermittent (asymptomatic until 1016 months or later) and thiamine-responsive910 MSUD diseases."", ""supports"": ""SUPPORT""}], ""name"": ""Intermittent MSUD""}"
4795	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	3	Thiamine-Responsive MSUD	Responds to high-dose thiamine supplementation due to specific mutations affecting the thiamine binding site.																																																								"{""description"": ""Responds to high-dose thiamine supplementation due to specific mutations affecting the thiamine binding site."", ""name"": ""Thiamine-Responsive MSUD""}"	{}	"{""description"": ""Responds to high-dose thiamine supplementation due to specific mutations affecting the thiamine binding site."", ""evidence"": [{""explanation"": ""Confirms thiamine-responsive form is due to specific mutations affecting thiamine binding."", ""reference"": ""PMID:27373929"", ""snippet"": ""Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction"", ""supports"": ""SUPPORT""}], ""name"": ""Thiamine-Responsive MSUD""}"
4890	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	0	Meckel syndrome, type 1																																																									"{""name"": ""Meckel syndrome, type 1""}"	{}	"{""name"": ""Meckel syndrome, type 1"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 1"", ""term"": {""id"": ""MONDO:0009571"", ""label"": ""Meckel syndrome, type 1""}}}"
4891	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	1	Meckel syndrome, type 2																																																									"{""name"": ""Meckel syndrome, type 2""}"	{}	"{""name"": ""Meckel syndrome, type 2"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 2"", ""term"": {""id"": ""MONDO:0011296"", ""label"": ""Meckel syndrome, type 2""}}}"
4892	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	2	Meckel syndrome, type 3																																																									"{""name"": ""Meckel syndrome, type 3""}"	{}	"{""name"": ""Meckel syndrome, type 3"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 3"", ""term"": {""id"": ""MONDO:0011821"", ""label"": ""Meckel syndrome, type 3""}}}"
4893	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	3	Meckel syndrome, type 4																																																									"{""name"": ""Meckel syndrome, type 4""}"	{}	"{""name"": ""Meckel syndrome, type 4"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 4"", ""term"": {""id"": ""MONDO:0012626"", ""label"": ""Meckel syndrome, type 4""}}}"
4894	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	4	Meckel syndrome, type 5																																																									"{""name"": ""Meckel syndrome, type 5""}"	{}	"{""name"": ""Meckel syndrome, type 5"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 5"", ""term"": {""id"": ""MONDO:0012695"", ""label"": ""Meckel syndrome, type 5""}}}"
4895	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	5	Meckel syndrome, type 6																																																									"{""name"": ""Meckel syndrome, type 6""}"	{}	"{""name"": ""Meckel syndrome, type 6"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 6"", ""term"": {""id"": ""MONDO:0012848"", ""label"": ""Meckel syndrome, type 6""}}}"
4896	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	6	Meckel syndrome, type 8																																																									"{""name"": ""Meckel syndrome, type 8""}"	{}	"{""name"": ""Meckel syndrome, type 8"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 8"", ""term"": {""id"": ""MONDO:0013482"", ""label"": ""Meckel syndrome, type 8""}}}"
4897	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	7	Meckel syndrome, type 9																																																									"{""name"": ""Meckel syndrome, type 9""}"	{}	"{""name"": ""Meckel syndrome, type 9"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 9"", ""term"": {""id"": ""MONDO:0013630"", ""label"": ""Meckel syndrome, type 9""}}}"
4898	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	8	Meckel syndrome, type 10																																																									"{""name"": ""Meckel syndrome, type 10""}"	{}	"{""name"": ""Meckel syndrome, type 10"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 10"", ""term"": {""id"": ""MONDO:0013609"", ""label"": ""Meckel syndrome, type 10""}}}"
4899	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	9	Meckel syndrome, type 11																																																									"{""name"": ""Meckel syndrome, type 11""}"	{}	"{""name"": ""Meckel syndrome, type 11"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome, type 11"", ""term"": {""id"": ""MONDO:0014164"", ""label"": ""Meckel syndrome, type 11""}}}"
4900	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	10	Meckel syndrome 13																																																									"{""name"": ""Meckel syndrome 13""}"	{}	"{""name"": ""Meckel syndrome 13"", ""subtype_term"": {""preferred_term"": ""Meckel syndrome 13"", ""term"": {""id"": ""MONDO:0033044"", ""label"": ""Meckel syndrome 13""}}}"
4901	206	Meckel Syndrome	Meckel_Syndrome.yaml	has_subtypes	11	Meckel syndrome 14																																																									"{""name"": ""Meckel syndrome 14""}"	{}	"{""name"": ""Meckel syndrome 14"", ""subtype_term"": {""preferred_term"": ""meckel syndrome 14"", ""term"": {""id"": ""MONDO:0030819"", ""label"": ""meckel syndrome 14""}}}"
4927	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	has_subtypes	0	Hereditary MTC (MEN2A)	Associated with MEN2A syndrome caused by germline RET mutations in the extracellular cysteine-rich domain. Patients develop MTC, pheochromocytoma, and primary hyperparathyroidism. Prophylactic thyroidectomy is recommended.																																																								"{""description"": ""Associated with MEN2A syndrome caused by germline RET mutations in the extracellular cysteine-rich domain. Patients develop MTC, pheochromocytoma, and primary hyperparathyroidism. Prophylactic thyroidectomy is recommended."", ""name"": ""Hereditary MTC (MEN2A)""}"	{}	"{""description"": ""Associated with MEN2A syndrome caused by germline RET mutations in the extracellular cysteine-rich domain. Patients develop MTC, pheochromocytoma, and primary hyperparathyroidism. Prophylactic thyroidectomy is recommended."", ""name"": ""Hereditary MTC (MEN2A)""}"
4928	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	has_subtypes	1	Hereditary MTC (MEN2B)	Associated with MEN2B syndrome caused by germline RET M918T mutation in the kinase domain. Most aggressive form with mucosal neuromas, marfanoid habitus, and very early MTC onset. Pheochromocytoma also occurs.																																																								"{""description"": ""Associated with MEN2B syndrome caused by germline RET M918T mutation in the kinase domain. Most aggressive form with mucosal neuromas, marfanoid habitus, and very early MTC onset. Pheochromocytoma also occurs."", ""name"": ""Hereditary MTC (MEN2B)""}"	{}	"{""description"": ""Associated with MEN2B syndrome caused by germline RET M918T mutation in the kinase domain. Most aggressive form with mucosal neuromas, marfanoid habitus, and very early MTC onset. Pheochromocytoma also occurs."", ""name"": ""Hereditary MTC (MEN2B)""}"
4929	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	has_subtypes	2	Sporadic MTC	Approximately 75% of MTC cases are sporadic without germline RET mutations. Somatic RET mutations occur in 40-50% of sporadic cases. Generally presents later than hereditary forms.																																																								"{""description"": ""Approximately 75% of MTC cases are sporadic without germline RET mutations. Somatic RET mutations occur in 40-50% of sporadic cases. Generally presents later than hereditary forms."", ""name"": ""Sporadic MTC""}"	{}	"{""description"": ""Approximately 75% of MTC cases are sporadic without germline RET mutations. Somatic RET mutations occur in 40-50% of sporadic cases. Generally presents later than hereditary forms."", ""name"": ""Sporadic MTC""}"
4948	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	has_subtypes	0	SHH-Activated, TP53-Wildtype Medulloblastoma	The majority of SHH-activated medulloblastomas retain wildtype TP53. Prognosis is intermediate between WNT-activated (best) and Group 3 (worst), with approximately 70-80% long-term survival. May respond to SHH pathway inhibitors.																																																								"{""description"": ""The majority of SHH-activated medulloblastomas retain wildtype TP53. Prognosis is intermediate between WNT-activated (best) and Group 3 (worst), with approximately 70-80% long-term survival. May respond to SHH pathway inhibitors."", ""name"": ""SHH-Activated, TP53-Wildtype Medulloblastoma""}"	{}	"{""description"": ""The majority of SHH-activated medulloblastomas retain wildtype TP53. Prognosis is intermediate between WNT-activated (best) and Group 3 (worst), with approximately 70-80% long-term survival. May respond to SHH pathway inhibitors."", ""name"": ""SHH-Activated, TP53-Wildtype Medulloblastoma""}"
4949	208	Medulloblastoma, SHH-Activated	Medulloblastoma_SHH_Activated.yaml	has_subtypes	1	SHH-Activated, TP53-Mutant Medulloblastoma	Approximately 10-15% of SHH-activated medulloblastomas harbor TP53 mutations, often associated with Li-Fraumeni syndrome (germline TP53 mutation). These tumors have significantly worse prognosis (approximately 40-50% survival), often show large cell/anaplastic histology and chromothripsis.																																																								"{""description"": ""Approximately 10-15% of SHH-activated medulloblastomas harbor TP53 mutations, often associated with Li-Fraumeni syndrome (germline TP53 mutation). These tumors have significantly worse prognosis (approximately 40-50% survival), often show large cell/anaplastic histology and chromothripsis."", ""name"": ""SHH-Activated, TP53-Mutant Medulloblastoma""}"	{}	"{""description"": ""Approximately 10-15% of SHH-activated medulloblastomas harbor TP53 mutations, often associated with Li-Fraumeni syndrome (germline TP53 mutation). These tumors have significantly worse prognosis (approximately 40-50% survival), often show large cell/anaplastic histology and chromothripsis."", ""name"": ""SHH-Activated, TP53-Mutant Medulloblastoma""}"
4968	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	has_subtypes	0	WNT-Activated Medulloblastoma with CTNNB1 Mutation	The most common form, with somatic activating mutations in CTNNB1 exon 3 that prevent beta-catenin phosphorylation and degradation. Sporadic, not associated with germline predisposition.																																																								"{""description"": ""The most common form, with somatic activating mutations in CTNNB1 exon 3 that prevent beta-catenin phosphorylation and degradation. Sporadic, not associated with germline predisposition."", ""name"": ""WNT-Activated Medulloblastoma with CTNNB1 Mutation""}"	{}	"{""description"": ""The most common form, with somatic activating mutations in CTNNB1 exon 3 that prevent beta-catenin phosphorylation and degradation. Sporadic, not associated with germline predisposition."", ""name"": ""WNT-Activated Medulloblastoma with CTNNB1 Mutation""}"
4969	209	Medulloblastoma, WNT-Activated	Medulloblastoma_WNT_Activated.yaml	has_subtypes	1	WNT-Activated Medulloblastoma with APC Mutation	Associated with Turcot syndrome (APC germline mutation). APC normally promotes beta-catenin degradation; loss leads to WNT pathway activation. Patients require genetic counseling and screening for colorectal polyposis.																																																								"{""description"": ""Associated with Turcot syndrome (APC germline mutation). APC normally promotes beta-catenin degradation; loss leads to WNT pathway activation. Patients require genetic counseling and screening for colorectal polyposis."", ""name"": ""WNT-Activated Medulloblastoma with APC Mutation""}"	{}	"{""description"": ""Associated with Turcot syndrome (APC germline mutation). APC normally promotes beta-catenin degradation; loss leads to WNT pathway activation. Patients require genetic counseling and screening for colorectal polyposis."", ""name"": ""WNT-Activated Medulloblastoma with APC Mutation""}"
5061	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	has_subtypes	0	MCPyV-Positive Merkel Cell Carcinoma	Virus-driven MCC containing clonally integrated Merkel cell polyomavirus with expression of viral T antigens (small T and truncated large T antigens). Accounts for approximately 80% of MCC cases. Generally has lower tumor mutational burden than virus-negative MCC.																																																								"{""description"": ""Virus-driven MCC containing clonally integrated Merkel cell polyomavirus with expression of viral T antigens (small T and truncated large T antigens). Accounts for approximately 80% of MCC cases. Generally has lower tumor mutational burden than virus-negative MCC."", ""name"": ""MCPyV-Positive Merkel Cell Carcinoma""}"	{}	"{""description"": ""Virus-driven MCC containing clonally integrated Merkel cell polyomavirus with expression of viral T antigens (small T and truncated large T antigens). Accounts for approximately 80% of MCC cases. Generally has lower tumor mutational burden than virus-negative MCC."", ""name"": ""MCPyV-Positive Merkel Cell Carcinoma""}"
5062	213	Merkel Cell Carcinoma	Merkel_Cell_Carcinoma.yaml	has_subtypes	1	MCPyV-Negative Merkel Cell Carcinoma	UV-induced MCC lacking viral integration. Characterized by high tumor mutational burden with UV signature mutations, including frequent RB1 inactivation. Accounts for approximately 20% of MCC cases.																																																								"{""description"": ""UV-induced MCC lacking viral integration. Characterized by high tumor mutational burden with UV signature mutations, including frequent RB1 inactivation. Accounts for approximately 20% of MCC cases."", ""name"": ""MCPyV-Negative Merkel Cell Carcinoma""}"	{}	"{""description"": ""UV-induced MCC lacking viral integration. Characterized by high tumor mutational burden with UV signature mutations, including frequent RB1 inactivation. Accounts for approximately 20% of MCC cases."", ""name"": ""MCPyV-Negative Merkel Cell Carcinoma""}"
5092	214	Migraine	Migraine.yaml	has_subtypes	0	Migraine with Aura	Preceded by transient neurological symptoms (visual, sensory, speech).																																																								"{""description"": ""Preceded by transient neurological symptoms (visual, sensory, speech)."", ""name"": ""Migraine with Aura""}"	{}	"{""description"": ""Preceded by transient neurological symptoms (visual, sensory, speech)."", ""evidence"": [{""explanation"": ""Population study establishes migraine with aura as a distinct subtype with 5% lifetime prevalence."", ""reference"": ""PMID:1525797"", ""snippet"": ""Lifetime prevalence of MA was 5%, male:female ratio 1:2."", ""supports"": ""SUPPORT""}, {""explanation"": ""Visual symptoms are the predominant aura type, occurring in 90% of migraine with aura cases."", ""reference"": ""PMID:1525797"", ""snippet"": ""Visual disturbances were the most common aura phenomenon occurring in 90% of subjects with MA."", ""supports"": ""SUPPORT""}], ""name"": ""Migraine with Aura""}"
5093	214	Migraine	Migraine.yaml	has_subtypes	1	Migraine without Aura	Most common form, no preceding aura.																																																								"{""description"": ""Most common form, no preceding aura."", ""name"": ""Migraine without Aura""}"	{}	"{""description"": ""Most common form, no preceding aura."", ""evidence"": [{""explanation"": ""Migraine without aura is the most common form with 8% lifetime prevalence and strong female predominance."", ""reference"": ""PMID:1525797"", ""snippet"": ""Lifetime prevalence of MO was 8%, M:F ratio 1:7."", ""supports"": ""SUPPORT""}, {""explanation"": ""Migraine without aura shows stronger female predominance than migraine with aura."", ""reference"": ""PMID:1525797"", ""snippet"": ""Women, but not men, were significantly more likely to have MO than MA."", ""supports"": ""SUPPORT""}], ""name"": ""Migraine without Aura""}"
5094	214	Migraine	Migraine.yaml	has_subtypes	2	Chronic Migraine	15 or more headache days per month for >3 months.																																																								"{""description"": ""15 or more headache days per month for >3 months."", ""name"": ""Chronic Migraine""}"	{}	"{""description"": ""15 or more headache days per month for >3 months."", ""evidence"": [{""explanation"": ""Chronic migraine is recognized as a distinct subtype requiring different treatment approaches."", ""reference"": ""PMID:30893319"", ""snippet"": ""For chronic migraine, propranolol was more likely to reduce headaches by at least 50% (RR: 2.0, 95% CI: 1.0-4.3)."", ""supports"": ""SUPPORT""}], ""name"": ""Chronic Migraine""}"
5095	214	Migraine	Migraine.yaml	has_subtypes	3	Vestibular Migraine	Migraine with prominent vestibular symptoms (vertigo).																																																								"{""description"": ""Migraine with prominent vestibular symptoms (vertigo)."", ""name"": ""Vestibular Migraine""}"	{}	"{""description"": ""Migraine with prominent vestibular symptoms (vertigo)."", ""evidence"": [{""explanation"": ""Vestibular migraine is established as a distinct underdiagnosed migraine phenotype."", ""reference"": ""PMID:38619053"", ""snippet"": ""Vestibular migraine is an underdiagnosed migraine phenotype that shares the pathophysiological mechanisms of migraine, with growing interest in recent years."", ""supports"": ""SUPPORT""}], ""name"": ""Vestibular Migraine""}"
5144	216	Monkeypox	Monkeypox.yaml	has_subtypes	0	West African Clade	Typically causes milder illness with lower mortality rates.																																																								"{""description"": ""Typically causes milder illness with lower mortality rates."", ""name"": ""West African Clade""}"	{}	"{""description"": ""Typically causes milder illness with lower mortality rates."", ""evidence"": [{""explanation"": ""The abstract mentions that monkeypox symptoms are milder and fatalities are rare, which aligns with the statement that the West African Clade typically causes milder illness with lower mortality rates."", ""reference"": ""PMID:36607751"", ""snippet"": ""Monkeypox is a variola poxvirus that is related to smallpox, but monkeypox symptoms (fever, painful vesicular or pustular rash, and lymphadenopathy) are milder and fatalities are rare."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the snippet predominantly discusses transmission and general symptomatology, the phrase 'the severity and prevalence of the disease differ' suggests variation among clades, implicitly supporting that the West African Clade, by comparison, is known for milder illness."", ""reference"": ""PMID:36801633"", ""snippet"": ""In addition to identified transmission mediators through animal-to-human and human-to-human, especially sexual transmission among men who have sex with men came to prominence in the 2022 global outbreak. Although the severity and prevalence of the disease differ depending on age and gender, some symptoms are commonly observed."", ""supports"": ""SUPPORT""}, {""explanation"": ""This abstract provides an overview of monkeypox symptoms but does not distinguish between different clades or mention their severity or mortality rates."", ""reference"": ""PMID:36604361"", ""snippet"": ""Monkeypox is a systemic exanthematous viral disease presenting with fever, lymphadenopathy, and vesicular rash."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""West African Clade""}"
5145	216	Monkeypox	Monkeypox.yaml	has_subtypes	1	Central African (Congo Basin) Clade	Generally associated with more severe clinical manifestations and higher mortality rates.																																																								"{""description"": ""Generally associated with more severe clinical manifestations and higher mortality rates."", ""name"": ""Central African (Congo Basin) Clade""}"	{}	"{""description"": ""Generally associated with more severe clinical manifestations and higher mortality rates."", ""evidence"": [{""explanation"": ""The abstract clearly distinguishes the Central African clade as having higher virulence and mortality compared to the West African clade."", ""reference"": ""PMID:36066176"", ""snippet"": ""Despite with a close genetic similarity between the two clades, the Central African strain is comparatively very virulent with high mortality."", ""supports"": ""SUPPORT""}, {""explanation"": ""Clade I corresponds to the Central African clade, and the abstract reports high fatality rates associated with it, supporting the statement."", ""reference"": ""PMID:36328951"", ""snippet"": ""High fatality rates associated with monkeypox virus clade I also are a local and international concern."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference describes the Congo Basin clade (Central African clade) as having a high case fatality rate, supporting the claim about more severe clinical manifestations and higher mortality."", ""reference"": ""PMID:20643162"", ""snippet"": ""the MPXV Congo Basin clade viruses are endemic in the Congo Basin, human illness typically presents with symptoms similar to discrete, ordinary smallpox and has a case fatality rate of approximately 10% in unvaccinated populations"", ""supports"": ""SUPPORT""}], ""name"": ""Central African (Congo Basin) Clade""}"
5196	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	has_subtypes	0	MEN2A	The most common subtype (95% of MEN2), characterized by medullary thyroid carcinoma (95%), pheochromocytoma (50%), and primary hyperparathyroidism (20-30%). Most commonly caused by mutations at codon 634 (Cys634Arg). Penetrance for MTC approaches 100% but varies with specific mutation.																																																								"{""description"": ""The most common subtype (95% of MEN2), characterized by medullary thyroid carcinoma (95%), pheochromocytoma (50%), and primary hyperparathyroidism (20-30%). Most commonly caused by mutations at codon 634 (Cys634Arg). Penetrance for MTC approaches 100% but varies with specific mutation."", ""name"": ""MEN2A""}"	{}	"{""description"": ""The most common subtype (95% of MEN2), characterized by medullary thyroid carcinoma (95%), pheochromocytoma (50%), and primary hyperparathyroidism (20-30%). Most commonly caused by mutations at codon 634 (Cys634Arg). Penetrance for MTC approaches 100% but varies with specific mutation."", ""name"": ""MEN2A""}"
5197	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	has_subtypes	1	MEN2B	The most aggressive subtype (5% of MEN2), characterized by earlier and more aggressive MTC, pheochromocytoma (50%), mucosal neuromas of lips and tongue, intestinal ganglioneuromatosis, and marfanoid habitus. Does not include hyperparathyroidism. Caused by M918T mutation in 95% of cases.																																																								"{""description"": ""The most aggressive subtype (5% of MEN2), characterized by earlier and more aggressive MTC, pheochromocytoma (50%), mucosal neuromas of lips and tongue, intestinal ganglioneuromatosis, and marfanoid habitus. Does not include hyperparathyroidism. Caused by M918T mutation in 95% of cases."", ""name"": ""MEN2B""}"	{}	"{""description"": ""The most aggressive subtype (5% of MEN2), characterized by earlier and more aggressive MTC, pheochromocytoma (50%), mucosal neuromas of lips and tongue, intestinal ganglioneuromatosis, and marfanoid habitus. Does not include hyperparathyroidism. Caused by M918T mutation in 95% of cases."", ""name"": ""MEN2B""}"
5198	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	has_subtypes	2	Familial Medullary Thyroid Carcinoma (FMTC)	MTC without pheochromocytoma or hyperparathyroidism in four or more family members. Now considered a variant of MEN2A with lower penetrance for pheochromocytoma rather than a separate entity. Associated with mutations at codons 609, 611, 618, 620, and 791.																																																								"{""description"": ""MTC without pheochromocytoma or hyperparathyroidism in four or more family members. Now considered a variant of MEN2A with lower penetrance for pheochromocytoma rather than a separate entity. Associated with mutations at codons 609, 611, 618, 620, and 791."", ""name"": ""Familial Medullary Thyroid Carcinoma (FMTC)""}"	{}	"{""description"": ""MTC without pheochromocytoma or hyperparathyroidism in four or more family members. Now considered a variant of MEN2A with lower penetrance for pheochromocytoma rather than a separate entity. Associated with mutations at codons 609, 611, 618, 620, and 791."", ""name"": ""Familial Medullary Thyroid Carcinoma (FMTC)""}"
5331	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	0	AChR Antibody-Positive MG	Most common form (~85%), with antibodies against acetylcholine receptors.																																																								"{""description"": ""Most common form (~85%), with antibodies against acetylcholine receptors."", ""name"": ""AChR Antibody-Positive MG""}"	{}	"{""description"": ""Most common form (~85%), with antibodies against acetylcholine receptors."", ""name"": ""AChR Antibody-Positive MG""}"
5332	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	1	MuSK Antibody-Positive MG	Antibodies against muscle-specific kinase, typically more severe bulbar symptoms.																																																								"{""description"": ""Antibodies against muscle-specific kinase, typically more severe bulbar symptoms."", ""name"": ""MuSK Antibody-Positive MG""}"	{}	"{""description"": ""Antibodies against muscle-specific kinase, typically more severe bulbar symptoms."", ""evidence"": [{""explanation"": ""Large cohort study confirms MuSK-MG has prominent bulbar involvement and female predominance."", ""reference"": ""PMID:21674519"", ""snippet"": ""Eighty-five percent were female, with disease onset typically in the fourth decade. Ocular and/or bulbar symptoms were present at onset in 79% of those studied."", ""supports"": ""SUPPORT""}, {""explanation"": ""MuSK-MG tends to be more severe with higher rates of myasthenic crisis."", ""reference"": ""PMID:21674519"", ""snippet"": ""Eighty-five percent were MGFA class III or greater, and crisis occurred in 28%."", ""supports"": ""SUPPORT""}], ""name"": ""MuSK Antibody-Positive MG""}"
5333	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	2	Seronegative MG	No detectable AChR or MuSK antibodies, may have LRP4 or other antibodies.																																																								"{""description"": ""No detectable AChR or MuSK antibodies, may have LRP4 or other antibodies."", ""name"": ""Seronegative MG""}"	{}	"{""description"": ""No detectable AChR or MuSK antibodies, may have LRP4 or other antibodies."", ""name"": ""Seronegative MG""}"
5334	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	3	Ocular MG	Disease limited to extraocular muscles, may progress to generalized form.																																																								"{""description"": ""Disease limited to extraocular muscles, may progress to generalized form."", ""name"": ""Ocular MG""}"	{}	"{""description"": ""Disease limited to extraocular muscles, may progress to generalized form."", ""name"": ""Ocular MG""}"
5335	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	4	Thymoma-Associated MG	MG associated with thymic tumors, often more severe.																																																								"{""description"": ""MG associated with thymic tumors, often more severe."", ""name"": ""Thymoma-Associated MG""}"	{}	"{""description"": ""MG associated with thymic tumors, often more severe."", ""name"": ""Thymoma-Associated MG""}"
5392	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	has_subtypes	0	NTRK1 Fusion-Positive Cancer	Fusions involving NTRK1 (encoding TRKA) are common in papillary thyroid cancer, lung adenocarcinoma, and colorectal cancer. Common fusion partners include TPM3, TPR, and LMNA.																																																								"{""description"": ""Fusions involving NTRK1 (encoding TRKA) are common in papillary thyroid cancer, lung adenocarcinoma, and colorectal cancer. Common fusion partners include TPM3, TPR, and LMNA."", ""name"": ""NTRK1 Fusion-Positive Cancer""}"	{}	"{""description"": ""Fusions involving NTRK1 (encoding TRKA) are common in papillary thyroid cancer, lung adenocarcinoma, and colorectal cancer. Common fusion partners include TPM3, TPR, and LMNA."", ""name"": ""NTRK1 Fusion-Positive Cancer""}"
5393	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	has_subtypes	1	NTRK2 Fusion-Positive Cancer	Fusions involving NTRK2 (encoding TRKB) are less common than NTRK1 or NTRK3 fusions. Found in various tumor types including gliomas.																																																								"{""description"": ""Fusions involving NTRK2 (encoding TRKB) are less common than NTRK1 or NTRK3 fusions. Found in various tumor types including gliomas."", ""name"": ""NTRK2 Fusion-Positive Cancer""}"	{}	"{""description"": ""Fusions involving NTRK2 (encoding TRKB) are less common than NTRK1 or NTRK3 fusions. Found in various tumor types including gliomas."", ""name"": ""NTRK2 Fusion-Positive Cancer""}"
5394	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	has_subtypes	2	NTRK3 Fusion-Positive Cancer	Fusions involving NTRK3 (encoding TRKC) are characteristic of secretory breast carcinoma and infantile fibrosarcoma. ETV6-NTRK3 is the classic fusion in these tumors.																																																								"{""description"": ""Fusions involving NTRK3 (encoding TRKC) are characteristic of secretory breast carcinoma and infantile fibrosarcoma. ETV6-NTRK3 is the classic fusion in these tumors."", ""name"": ""NTRK3 Fusion-Positive Cancer""}"	{}	"{""description"": ""Fusions involving NTRK3 (encoding TRKC) are characteristic of secretory breast carcinoma and infantile fibrosarcoma. ETV6-NTRK3 is the classic fusion in these tumors."", ""name"": ""NTRK3 Fusion-Positive Cancer""}"
5411	227	Narcolepsy	Narcolepsy.yaml	has_subtypes	0	Narcolepsy Type 1	With cataplexy and orexin/hypocretin deficiency.																																																								"{""description"": ""With cataplexy and orexin/hypocretin deficiency."", ""name"": ""Narcolepsy Type 1""}"	{}	"{""description"": ""With cataplexy and orexin/hypocretin deficiency."", ""name"": ""Narcolepsy Type 1""}"
5412	227	Narcolepsy	Narcolepsy.yaml	has_subtypes	1	Narcolepsy Type 2	Without cataplexy, normal or near-normal orexin levels.																																																								"{""description"": ""Without cataplexy, normal or near-normal orexin levels."", ""name"": ""Narcolepsy Type 2""}"	{}	"{""description"": ""Without cataplexy, normal or near-normal orexin levels."", ""name"": ""Narcolepsy Type 2""}"
5433	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	has_subtypes	0	Non-keratinizing Carcinoma	The most common type (greater than 95% in endemic areas), characterized by poorly differentiated cells without keratinization. Further subdivided into differentiated and undifferentiated subtypes. Virtually always EBV-positive.																																																								"{""description"": ""The most common type (greater than 95% in endemic areas), characterized by poorly differentiated cells without keratinization. Further subdivided into differentiated and undifferentiated subtypes. Virtually always EBV-positive."", ""name"": ""Non-keratinizing Carcinoma""}"	{}	"{""description"": ""The most common type (greater than 95% in endemic areas), characterized by poorly differentiated cells without keratinization. Further subdivided into differentiated and undifferentiated subtypes. Virtually always EBV-positive."", ""name"": ""Non-keratinizing Carcinoma""}"
5434	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	has_subtypes	1	Keratinizing Squamous Cell Carcinoma	A minority subtype (approximately 25% in non-endemic areas) showing squamous differentiation with keratin formation. More similar to other HNSCC, often associated with tobacco and alcohol rather than EBV.																																																								"{""description"": ""A minority subtype (approximately 25% in non-endemic areas) showing squamous differentiation with keratin formation. More similar to other HNSCC, often associated with tobacco and alcohol rather than EBV."", ""name"": ""Keratinizing Squamous Cell Carcinoma""}"	{}	"{""description"": ""A minority subtype (approximately 25% in non-endemic areas) showing squamous differentiation with keratin formation. More similar to other HNSCC, often associated with tobacco and alcohol rather than EBV."", ""name"": ""Keratinizing Squamous Cell Carcinoma""}"
5460	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	0	Infantile Nephronophthisis	Early onset in infancy characterized by rapid progression to end-stage renal disease.																																																								"{""description"": ""Early onset in infancy characterized by rapid progression to end-stage renal disease."", ""name"": ""Infantile Nephronophthisis""}"	{}	"{""description"": ""Early onset in infancy characterized by rapid progression to end-stage renal disease."", ""evidence"": [{""explanation"": ""The source indicates that infantile nephronophthisis is characterized by early onset and rapid progression to end-stage renal disease, supporting the statement."", ""reference"": ""PMID:16966065"", ""snippet"": ""Infantile nephronophtisis is a recessive autosomic tubulo-interstitial nephritis with cortical microcysts which progress to end stage renal failure before age 5."", ""supports"": ""SUPPORT""}], ""name"": ""Infantile Nephronophthisis""}"
5461	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	1	Juvenile Nephronophthisis	Most common form with onset in childhood and progressive renal failure by adolescence.																																																								"{""description"": ""Most common form with onset in childhood and progressive renal failure by adolescence."", ""name"": ""Juvenile Nephronophthisis""}"	{}	"{""description"": ""Most common form with onset in childhood and progressive renal failure by adolescence."", ""evidence"": [{""explanation"": ""The provided excerpt states that juvenile nephronophthisis is the most frequent subtype and typically progresses to end-stage renal failure by adolescence."", ""reference"": ""PMID:16966065"", ""snippet"": ""Juvenile nephronophtisis, the most frequent, progress to end stage renal failure before age 15."", ""supports"": ""SUPPORT""}, {""explanation"": ""The excerpt indicates that juvenile nephronophthisis is a common pediatric kidney failure cause, aligning with 'most common form with onset in childhood'."", ""reference"": ""PMID:35570616"", ""snippet"": ""Nephronophthisis is the most common genetic cause of kidney failure in childhood... outcomes of kidney transplant recipients with primary diagnosis of juvenile nephronophthisis..."", ""supports"": ""SUPPORT""}], ""name"": ""Juvenile Nephronophthisis""}"
5462	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	2	Adolescent Nephronophthisis	Later onset in teenage years with slower progression to renal failure.																																																								"{""description"": ""Later onset in teenage years with slower progression to renal failure."", ""name"": ""Adolescent Nephronophthisis""}"	{}	"{""description"": ""Later onset in teenage years with slower progression to renal failure."", ""evidence"": [{""explanation"": ""The term 'adolescent nephronophthisis' is noted, and it is described as a less frequent form of nephronophthisis which is consistent with later onset."", ""reference"": ""PMID:16966065"", ""snippet"": ""Adolescent nephronophtisis is a less frequent form of nephronophtisis."", ""supports"": ""SUPPORT""}, {""explanation"": ""Medullary cystic disease presents similar signs but progresses later, implying a slower progression to renal failure, corroborating the adolescent nephronophthisis description."", ""reference"": ""PMID:16966065"", ""snippet"": ""Medullary cystic disease is transmitted as an autosomic dominant trait. Clinical and histological signs are similar to nephronophthisis, but the disease progress later to terminal renal failure and is not accompanied by extra-renal symptoms."", ""supports"": ""SUPPORT""}], ""name"": ""Adolescent Nephronophthisis""}"
5497	230	Neuroblastoma	Neuroblastoma.yaml	has_subtypes	0	MYCN-Amplified Neuroblastoma	Approximately 20% of neuroblastomas harbor MYCN gene amplification, associated with rapid tumor progression and poor prognosis. MYCN amplification is one of the earliest oncogene amplifications discovered.																																																								"{""description"": ""Approximately 20% of neuroblastomas harbor MYCN gene amplification, associated with rapid tumor progression and poor prognosis. MYCN amplification is one of the earliest oncogene amplifications discovered."", ""name"": ""MYCN-Amplified Neuroblastoma""}"	{}	"{""description"": ""Approximately 20% of neuroblastomas harbor MYCN gene amplification, associated with rapid tumor progression and poor prognosis. MYCN amplification is one of the earliest oncogene amplifications discovered."", ""name"": ""MYCN-Amplified Neuroblastoma""}"
5498	230	Neuroblastoma	Neuroblastoma.yaml	has_subtypes	1	Stage 4S Neuroblastoma	A special stage occurring in infants under 18 months with primary tumor and metastases limited to skin, liver, and bone marrow. Despite widespread disease, 4S neuroblastoma often undergoes spontaneous regression.																																																								"{""description"": ""A special stage occurring in infants under 18 months with primary tumor and metastases limited to skin, liver, and bone marrow. Despite widespread disease, 4S neuroblastoma often undergoes spontaneous regression."", ""name"": ""Stage 4S Neuroblastoma""}"	{}	"{""description"": ""A special stage occurring in infants under 18 months with primary tumor and metastases limited to skin, liver, and bone marrow. Despite widespread disease, 4S neuroblastoma often undergoes spontaneous regression."", ""name"": ""Stage 4S Neuroblastoma""}"
5499	230	Neuroblastoma	Neuroblastoma.yaml	has_subtypes	2	High-Risk Neuroblastoma	Defined by age over 18 months with metastatic disease, or MYCN amplification at any age. Requires intensive multimodal therapy including chemotherapy, surgery, radiation, autologous stem cell transplant, and immunotherapy.																																																								"{""description"": ""Defined by age over 18 months with metastatic disease, or MYCN amplification at any age. Requires intensive multimodal therapy including chemotherapy, surgery, radiation, autologous stem cell transplant, and immunotherapy."", ""name"": ""High-Risk Neuroblastoma""}"	{}	"{""description"": ""Defined by age over 18 months with metastatic disease, or MYCN amplification at any age. Requires intensive multimodal therapy including chemotherapy, surgery, radiation, autologous stem cell transplant, and immunotherapy."", ""name"": ""High-Risk Neuroblastoma""}"
5545	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	has_subtypes	0	AQP4-IgG Seropositive NMOSD	"The most common form, characterized by presence of antibodies against aquaporin-4 water channels on astrocytes. Associated with more severe attacks and higher relapse rates.
"																																																								"{""description"": ""The most common form, characterized by presence of antibodies against aquaporin-4 water channels on astrocytes. Associated with more severe attacks and higher relapse rates.\n"", ""name"": ""AQP4-IgG Seropositive NMOSD""}"	{}	"{""description"": ""The most common form, characterized by presence of antibodies against aquaporin-4 water channels on astrocytes. Associated with more severe attacks and higher relapse rates.\n"", ""evidence"": [{""explanation"": ""The 2015 international diagnostic criteria formally stratify NMOSD by AQP4-IgG serostatus."", ""reference"": ""PMID:26092914"", ""snippet"": ""The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG)."", ""supports"": ""SUPPORT""}], ""name"": ""AQP4-IgG Seropositive NMOSD""}"
5546	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	has_subtypes	1	MOG-IgG Associated Disease	"Characterized by antibodies against myelin oligodendrocyte glycoprotein. Now recognized as a distinct entity (MOGAD) separate from AQP4+ NMOSD.
"																																																								"{""description"": ""Characterized by antibodies against myelin oligodendrocyte glycoprotein. Now recognized as a distinct entity (MOGAD) separate from AQP4+ NMOSD.\n"", ""name"": ""MOG-IgG Associated Disease""}"	{}	"{""description"": ""Characterized by antibodies against myelin oligodendrocyte glycoprotein. Now recognized as a distinct entity (MOGAD) separate from AQP4+ NMOSD.\n"", ""name"": ""MOG-IgG Associated Disease""}"
5547	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	has_subtypes	2	Seronegative NMOSD	"Meets clinical criteria for NMOSD but lacks detectable AQP4 or MOG antibodies.
"																																																								"{""description"": ""Meets clinical criteria for NMOSD but lacks detectable AQP4 or MOG antibodies.\n"", ""name"": ""Seronegative NMOSD""}"	{}	"{""description"": ""Meets clinical criteria for NMOSD but lacks detectable AQP4 or MOG antibodies.\n"", ""name"": ""Seronegative NMOSD""}"
5579	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	0	Adenosquamous Carcinoma	A rare subtype displaying both adenocarcinoma and squamous cell carcinoma features.																																																								"{""description"": ""A rare subtype displaying both adenocarcinoma and squamous cell carcinoma features."", ""name"": ""Adenosquamous Carcinoma""}"	{}	"{""description"": ""A rare subtype displaying both adenocarcinoma and squamous cell carcinoma features."", ""evidence"": [{""explanation"": ""This excerpt confirms that adenosquamous carcinoma displays features of both adenocarcinoma and squamous cell carcinoma."", ""reference"": ""PMID:37681230"", ""snippet"": ""Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature supports the statement by explaining that adenosquamous carcinoma (ASC) contains both adenocarcinoma (AC) and squamous cell carcinoma (SCC) components."", ""reference"": ""PMID:20004040"", ""snippet"": ""Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC). ASC are morphologically mixed tumours that contain the two cell components AC and SCC."", ""supports"": ""SUPPORT""}], ""name"": ""Adenosquamous Carcinoma""}"
5580	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	1	ALK-rearranged NSCLC	NSCLC with ALK gene rearrangements, responsive to ALK inhibitors.																																																								"{""description"": ""NSCLC with ALK gene rearrangements, responsive to ALK inhibitors."", ""name"": ""ALK-rearranged NSCLC""}"	{}	"{""description"": ""NSCLC with ALK gene rearrangements, responsive to ALK inhibitors."", ""evidence"": [{""explanation"": ""This reference supports that NSCLC with ALK gene rearrangements is a subtype that is responsive to ALK inhibitors."", ""reference"": ""PMID:27637426"", ""snippet"": ""An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article mentions the impact of ALK mutations and the necessity to identify NSCLCs harboring these mutations due to their sensitivity to specific agents like ALK inhibitors."", ""reference"": ""PMID:21233671"", ""snippet"": ""The significance of EGFR and ALK mutations in NSCLC and the impact of these genotypes on pathology and clinical practice are also reviewed."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference discusses the success and approval of ALK inhibitors like Crizotinib and Ceritinib for the treatment of ALK-rearranged NSCLC, supporting the claim."", ""reference"": ""PMID:24998601"", ""snippet"": ""The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development."", ""supports"": ""SUPPORT""}, {""explanation"": ""This indirectly supports that ALK-rearranged NSCLC is a recognized subtype as it compares ROS1+ NSCLC to ALK-positive NSCLC in terms of patient characteristics and histology."", ""reference"": ""PMID:31720561"", ""snippet"": ""Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology."", ""supports"": ""SUPPORT""}, {""explanation"": ""This recent review discusses the targeting of ALK rearrangements as a therapeutic strategy, supporting that ALK-rearranged NSCLC is a recognized subtype responsive to ALK inhibitors."", ""reference"": ""PMID:33387080"", ""snippet"": ""Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy."", ""supports"": ""SUPPORT""}], ""name"": ""ALK-rearranged NSCLC""}"
5581	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	2	EGFR-mutant NSCLC	NSCLC with activating EGFR mutations, responsive to EGFR inhibitors.																																																								"{""description"": ""NSCLC with activating EGFR mutations, responsive to EGFR inhibitors."", ""name"": ""EGFR-mutant NSCLC""}"	{}	"{""description"": ""NSCLC with activating EGFR mutations, responsive to EGFR inhibitors."", ""evidence"": [{""explanation"": ""This excerpt confirms that NSCLC with activating EGFR mutations (such as exon 19 deletions or L858R mutations) are responsive to EGFR TKIs."", ""reference"": ""PMID:28017789"", ""snippet"": ""Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs)..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This statement supports the idea that NSCLC with EGFR mutations are responsive to EGFR inhibitors."", ""reference"": ""PMID:15946581"", ""snippet"": ""A genetic mutation in EGFR has also been correlated with an increase in response."", ""supports"": ""SUPPORT""}, {""explanation"": ""Osimertinib, an EGFR inhibitor, being the standard-of-care for EGFR-mutant NSCLC indicates that this subtype is responsive to EGFR inhibitors."", ""reference"": ""PMID:35993098"", ""snippet"": ""Osimertinib is the current standard-of-care for the first-line treatment of EGFR-mutant NSCLC."", ""supports"": ""SUPPORT""}, {""explanation"": ""This excerpt specifically notes the responsiveness of NSCLC with TKI-sensitizing EGFR mutations to EGFR inhibitors."", ""reference"": ""PMID:24857124"", ""snippet"": ""Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC."", ""supports"": ""SUPPORT""}, {""explanation"": ""This indicates the effectiveness of EGFR inhibitors in treating EGFR-mutant NSCLC."", ""reference"": ""PMID:25145405"", ""snippet"": ""Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy."", ""supports"": ""SUPPORT""}], ""name"": ""EGFR-mutant NSCLC""}"
5610	236	Noonan Syndrome	Noonan_Syndrome.yaml	has_subtypes	0	Noonan Syndrome 1 (PTPN11-related)	Most common form caused by PTPN11 mutations, accounting for approximately 50% of cases.																																																								"{""description"": ""Most common form caused by PTPN11 mutations, accounting for approximately 50% of cases."", ""name"": ""Noonan Syndrome 1 (PTPN11-related)""}"	{}	"{""description"": ""Most common form caused by PTPN11 mutations, accounting for approximately 50% of cases."", ""name"": ""Noonan Syndrome 1 (PTPN11-related)"", ""subtype_term"": {""preferred_term"": ""Noonan syndrome 1"", ""term"": {""id"": ""MONDO:0008104"", ""label"": ""Noonan syndrome 1""}}}"
5611	236	Noonan Syndrome	Noonan_Syndrome.yaml	has_subtypes	1	Noonan Syndrome with Multiple Lentigines	Formerly known as LEOPARD syndrome, characterized by lentigines and hypertrophic cardiomyopathy.																																																								"{""description"": ""Formerly known as LEOPARD syndrome, characterized by lentigines and hypertrophic cardiomyopathy."", ""name"": ""Noonan Syndrome with Multiple Lentigines""}"	{}	"{""description"": ""Formerly known as LEOPARD syndrome, characterized by lentigines and hypertrophic cardiomyopathy."", ""name"": ""Noonan Syndrome with Multiple Lentigines"", ""subtype_term"": {""preferred_term"": ""Noonan syndrome with multiple lentigines"", ""term"": {""id"": ""MONDO:0007893"", ""label"": ""Noonan syndrome with multiple lentigines""}}}"
5722	240	Osteoarthritis	Osteoarthritis.yaml	has_subtypes	0	Primary Osteoarthritis	Age-related degeneration without identifiable cause.																																																								"{""description"": ""Age-related degeneration without identifiable cause."", ""name"": ""Primary Osteoarthritis""}"	{}	"{""description"": ""Age-related degeneration without identifiable cause."", ""name"": ""Primary Osteoarthritis""}"
5723	240	Osteoarthritis	Osteoarthritis.yaml	has_subtypes	1	Secondary Osteoarthritis	Results from injury, obesity, or other joint diseases.																																																								"{""description"": ""Results from injury, obesity, or other joint diseases."", ""name"": ""Secondary Osteoarthritis""}"	{}	"{""description"": ""Results from injury, obesity, or other joint diseases."", ""name"": ""Secondary Osteoarthritis""}"
5724	240	Osteoarthritis	Osteoarthritis.yaml	has_subtypes	2	Erosive Osteoarthritis	Aggressive form affecting hand joints with inflammation.																																																								"{""description"": ""Aggressive form affecting hand joints with inflammation."", ""name"": ""Erosive Osteoarthritis""}"	{}	"{""description"": ""Aggressive form affecting hand joints with inflammation."", ""name"": ""Erosive Osteoarthritis""}"
5925	251	Pars Planitis	Pars_Planitis.yaml	has_subtypes	0	Idiopathic Pars Planitis	Chronic intermediate uveitis with no identifiable underlying systemic disease or infection.																																																								"{""description"": ""Chronic intermediate uveitis with no identifiable underlying systemic disease or infection."", ""name"": ""Idiopathic Pars Planitis""}"	{}	"{""description"": ""Chronic intermediate uveitis with no identifiable underlying systemic disease or infection."", ""evidence"": [{""explanation"": ""This represents the classic form of pars planitis where no underlying cause can be identified."", ""reference"": ""PMID:39360991"", ""snippet"": ""Pars planitis is the term used for idiopathic intermediate uveitis that presents with snowballs and snowbanks."", ""supports"": ""SUPPORT""}], ""name"": ""Idiopathic Pars Planitis""}"
5926	251	Pars Planitis	Pars_Planitis.yaml	has_subtypes	1	Secondary Pars Planitis	Intermediate uveitis with similar features but associated with systemic conditions like multiple sclerosis or sarcoidosis.																																																								"{""description"": ""Intermediate uveitis with similar features but associated with systemic conditions like multiple sclerosis or sarcoidosis."", ""name"": ""Secondary Pars Planitis""}"	{}	"{""description"": ""Intermediate uveitis with similar features but associated with systemic conditions like multiple sclerosis or sarcoidosis."", ""evidence"": [{""explanation"": ""Secondary pars planitis occurs when intermediate uveitis is linked to an underlying systemic or infectious condition."", ""reference"": ""PMID:39360991"", ""snippet"": ""Etiology can be infectious, associated with a systemic disease, neoplastic or idiopathic."", ""supports"": ""SUPPORT""}], ""name"": ""Secondary Pars Planitis""}"
6119	259	Phenylketonuria	Phenylketonuria.yaml	has_subtypes	0	Classic PKU	Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated.																																																								"{""description"": ""Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated."", ""name"": ""Classic PKU""}"	{}	"{""description"": ""Severe PAH deficiency with blood Phe greater than 1200 micromol/L untreated."", ""name"": ""Classic PKU""}"
6120	259	Phenylketonuria	Phenylketonuria.yaml	has_subtypes	1	Mild PKU	Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated.																																																								"{""description"": ""Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated."", ""name"": ""Mild PKU""}"	{}	"{""description"": ""Moderate PAH deficiency with blood Phe 600-1200 micromol/L untreated."", ""name"": ""Mild PKU""}"
6121	259	Phenylketonuria	Phenylketonuria.yaml	has_subtypes	2	BH4-Responsive PKU	Responds to tetrahydrobiopterin supplementation.																																																								"{""description"": ""Responds to tetrahydrobiopterin supplementation."", ""name"": ""BH4-Responsive PKU""}"	{}	"{""description"": ""Responds to tetrahydrobiopterin supplementation."", ""name"": ""BH4-Responsive PKU""}"
6144	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	has_subtypes	0	Pheochromocytoma	Tumors arising from the adrenal medulla chromaffin cells. Most common site of catecholamine-producing paraganglioma. Usually unilateral but bilateral in hereditary syndromes.																																																								"{""description"": ""Tumors arising from the adrenal medulla chromaffin cells. Most common site of catecholamine-producing paraganglioma. Usually unilateral but bilateral in hereditary syndromes."", ""name"": ""Pheochromocytoma""}"	{}	"{""description"": ""Tumors arising from the adrenal medulla chromaffin cells. Most common site of catecholamine-producing paraganglioma. Usually unilateral but bilateral in hereditary syndromes."", ""name"": ""Pheochromocytoma""}"
6145	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	has_subtypes	1	Sympathetic Paraganglioma	Extra-adrenal tumors arising from sympathetic ganglia along the paravertebral axis (thorax, abdomen, pelvis). Often catecholamine-secreting. SDHB mutations associated with high malignancy risk.																																																								"{""description"": ""Extra-adrenal tumors arising from sympathetic ganglia along the paravertebral axis (thorax, abdomen, pelvis). Often catecholamine-secreting. SDHB mutations associated with high malignancy risk."", ""name"": ""Sympathetic Paraganglioma""}"	{}	"{""description"": ""Extra-adrenal tumors arising from sympathetic ganglia along the paravertebral axis (thorax, abdomen, pelvis). Often catecholamine-secreting. SDHB mutations associated with high malignancy risk."", ""name"": ""Sympathetic Paraganglioma""}"
6146	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	has_subtypes	2	Parasympathetic Paraganglioma	Head and neck paragangliomas arising from parasympathetic ganglia (carotid body, jugulotympanic, vagal). Usually non-secreting. SDHD mutations common.																																																								"{""description"": ""Head and neck paragangliomas arising from parasympathetic ganglia (carotid body, jugulotympanic, vagal). Usually non-secreting. SDHD mutations common."", ""name"": ""Parasympathetic Paraganglioma""}"	{}	"{""description"": ""Head and neck paragangliomas arising from parasympathetic ganglia (carotid body, jugulotympanic, vagal). Usually non-secreting. SDHD mutations common."", ""name"": ""Parasympathetic Paraganglioma""}"
6167	261	Pick Disease	Pick_Disease.yaml	has_subtypes	0	Behavioral Variant Frontotemporal Dementia (bvFTD)	Characterized by significant changes in social behavior and conduct, with early emotional blunting and loss of insight.																																																								"{""description"": ""Characterized by significant changes in social behavior and conduct, with early emotional blunting and loss of insight."", ""name"": ""Behavioral Variant Frontotemporal Dementia (bvFTD)""}"	{}	"{""description"": ""Characterized by significant changes in social behavior and conduct, with early emotional blunting and loss of insight."", ""evidence"": [{""explanation"": ""The reference identifies that behavioral variant FTD (bvFTD) is a common presentation of Pick's disease, implying that PiD can be characterized by bvFTD symptoms."", ""reference"": ""PMID:32440921"", ""snippet"": ""Behavioral variant FTD (bvFTD; 12/21) was the most common phenotype... bvFTD and PPA are the most common clinical phenotypes associated with PiD..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms that some patients with corticobasal degeneration (CBD) pathology showing bvFTD symptoms have similar trait overlaps with those having Pick's disease."", ""reference"": ""PMID:21881831"", ""snippet"": ""Some present with behavioral variant frontotemporal dementia (bvFTD)... predominantly apathetic with less florid social disinhibition and eating disturbances, and were more anxious than bvFTD(Pick's) patients."", ""supports"": ""SUPPORT""}], ""name"": ""Behavioral Variant Frontotemporal Dementia (bvFTD)""}"
6168	261	Pick Disease	Pick_Disease.yaml	has_subtypes	1	Language Variant (Primary Progressive Aphasia)	Includes progressive nonfluent aphasia and semantic dementia with prominent language deterioration as the initial symptom.																																																								"{""description"": ""Includes progressive nonfluent aphasia and semantic dementia with prominent language deterioration as the initial symptom."", ""name"": ""Language Variant (Primary Progressive Aphasia)""}"	{}	"{""description"": ""Includes progressive nonfluent aphasia and semantic dementia with prominent language deterioration as the initial symptom."", ""evidence"": [{""explanation"": ""This reference confirms that Pick's disease includes subtypes such as progressive nonfluent aphasia and semantic dementia, which are associated with prominent language deterioration as an initial symptom."", ""reference"": ""PMID:27025090"", ""snippet"": ""Pick's disease is currently defined by the presence of tau-positive Pick bodies... The clinical phenotypes of Pick's disease include behavioral variant FTD (bvFTD), progressive nonfluent aphasia (PNFA) and semantic dementia (SD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference specifies that frontotemporal dementia, which includes Pick's disease, has subtypes including progressive nonfluent aphasia and semantic dementia, both associated with prominent initial language deterioration."", ""reference"": ""PMID:24966676"", ""snippet"": ""Four clinical subtypes characterize the predominant presentations of this illness: behavioral or frontal variant FTD, progressive nonfluent aphasia, semantic dementia, and logopenic primary progressive aphasia."", ""supports"": ""SUPPORT""}], ""name"": ""Language Variant (Primary Progressive Aphasia)""}"
6221	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	has_subtypes	0	Autosomal Dominant PKD (ADPKD)	Most common form, caused by PKD1 or PKD2 mutations, typically presenting in adulthood.																																																								"{""description"": ""Most common form, caused by PKD1 or PKD2 mutations, typically presenting in adulthood."", ""name"": ""Autosomal Dominant PKD (ADPKD)""}"	{}	"{""description"": ""Most common form, caused by PKD1 or PKD2 mutations, typically presenting in adulthood."", ""name"": ""Autosomal Dominant PKD (ADPKD)""}"
6222	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	has_subtypes	1	Autosomal Recessive PKD (ARPKD)	Less common form caused by PKHD1 mutations, presenting in infancy or childhood with more severe phenotype.																																																								"{""description"": ""Less common form caused by PKHD1 mutations, presenting in infancy or childhood with more severe phenotype."", ""name"": ""Autosomal Recessive PKD (ARPKD)""}"	{}	"{""description"": ""Less common form caused by PKHD1 mutations, presenting in infancy or childhood with more severe phenotype."", ""name"": ""Autosomal Recessive PKD (ARPKD)""}"
6411	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	has_subtypes	0	Nonfluent/Agrammatic Variant PPA	Nonfluent/agrammatic primary progressive aphasia phenotype.																																																								"{""description"": ""Nonfluent/agrammatic primary progressive aphasia phenotype."", ""name"": ""Nonfluent/Agrammatic Variant PPA""}"	{}	"{""description"": ""Nonfluent/agrammatic primary progressive aphasia phenotype."", ""evidence"": [{""explanation"": ""The abstract lists nonfluent/agrammatic PPA as a major phenotype."", ""reference"": ""PMID:21666264"", ""snippet"": ""Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic."", ""supports"": ""SUPPORT""}], ""name"": ""Nonfluent/Agrammatic Variant PPA""}"
6412	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	has_subtypes	1	Semantic Variant PPA	Semantic variant primary progressive aphasia phenotype.																																																								"{""description"": ""Semantic variant primary progressive aphasia phenotype."", ""name"": ""Semantic Variant PPA""}"	{}	"{""description"": ""Semantic variant primary progressive aphasia phenotype."", ""evidence"": [{""explanation"": ""The abstract lists semantic PPA as a major phenotype."", ""reference"": ""PMID:21666264"", ""snippet"": ""Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic."", ""supports"": ""SUPPORT""}], ""name"": ""Semantic Variant PPA""}"
6413	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	has_subtypes	2	Logopenic Variant PPA	Logopenic primary progressive aphasia phenotype.																																																								"{""description"": ""Logopenic primary progressive aphasia phenotype."", ""name"": ""Logopenic Variant PPA""}"	{}	"{""description"": ""Logopenic primary progressive aphasia phenotype."", ""evidence"": [{""explanation"": ""The abstract lists logopenic PPA as a major phenotype."", ""reference"": ""PMID:21666264"", ""snippet"": ""Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic."", ""supports"": ""SUPPORT""}], ""name"": ""Logopenic Variant PPA""}"
6528	278	Psoriasis	Psoriasis.yaml	has_subtypes	0	Plaque Psoriasis	Most common form with raised, red, scaly plaques.																																																								"{""description"": ""Most common form with raised, red, scaly plaques."", ""name"": ""Plaque Psoriasis""}"	{}	"{""description"": ""Most common form with raised, red, scaly plaques."", ""name"": ""Plaque Psoriasis""}"
6529	278	Psoriasis	Psoriasis.yaml	has_subtypes	1	Guttate Psoriasis	Small, drop-shaped lesions, often following streptococcal infection.																																																								"{""description"": ""Small, drop-shaped lesions, often following streptococcal infection."", ""name"": ""Guttate Psoriasis""}"	{}	"{""description"": ""Small, drop-shaped lesions, often following streptococcal infection."", ""name"": ""Guttate Psoriasis""}"
6530	278	Psoriasis	Psoriasis.yaml	has_subtypes	2	Inverse Psoriasis	Affects skin folds with smooth, red patches.																																																								"{""description"": ""Affects skin folds with smooth, red patches."", ""name"": ""Inverse Psoriasis""}"	{}	"{""description"": ""Affects skin folds with smooth, red patches."", ""name"": ""Inverse Psoriasis""}"
6531	278	Psoriasis	Psoriasis.yaml	has_subtypes	3	Pustular Psoriasis	Characterized by white pustules surrounded by red skin.																																																								"{""description"": ""Characterized by white pustules surrounded by red skin."", ""name"": ""Pustular Psoriasis""}"	{}	"{""description"": ""Characterized by white pustules surrounded by red skin."", ""name"": ""Pustular Psoriasis""}"
6532	278	Psoriasis	Psoriasis.yaml	has_subtypes	4	Erythrodermic Psoriasis	Severe, widespread inflammation covering most of the body.																																																								"{""description"": ""Severe, widespread inflammation covering most of the body."", ""name"": ""Erythrodermic Psoriasis""}"	{}	"{""description"": ""Severe, widespread inflammation covering most of the body."", ""name"": ""Erythrodermic Psoriasis""}"
6533	278	Psoriasis	Psoriasis.yaml	has_subtypes	5	Psoriatic Arthritis	Joint inflammation associated with psoriasis.																																																								"{""description"": ""Joint inflammation associated with psoriasis."", ""name"": ""Psoriatic Arthritis""}"	{}	"{""description"": ""Joint inflammation associated with psoriasis."", ""name"": ""Psoriatic Arthritis""}"
6573	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	has_subtypes	0	Pulmonary Arterial Hypertension (PAH)	A type of pulmonary hypertension characterized by high blood pressure in the arteries that supply the lungs, often idiopathic or associated with other conditions.																																																								"{""description"": ""A type of pulmonary hypertension characterized by high blood pressure in the arteries that supply the lungs, often idiopathic or associated with other conditions."", ""name"": ""Pulmonary Arterial Hypertension (PAH)""}"	{}	"{""description"": ""A type of pulmonary hypertension characterized by high blood pressure in the arteries that supply the lungs, often idiopathic or associated with other conditions."", ""name"": ""Pulmonary Arterial Hypertension (PAH)"", ""subtype_term"": {""preferred_term"": ""pulmonary arterial hypertension"", ""term"": {""id"": ""MONDO:0015924"", ""label"": ""pulmonary arterial hypertension""}}}"
6574	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	has_subtypes	1	Secondary Pulmonary Hypertension	Pulmonary hypertension that occurs as a result of other diseases such as left heart disease, chronic lung disease, or thromboembolic disease.																																												"MONDO does not have a single term for ""secondary pulmonary hypertension"" as it is a clinical classification. Specific secondary causes have individual terms: MONDO:0013024 (chronic thromboembolic), MONDO:0017157 (due to lung disease/hypoxia)."												"{""description"": ""Pulmonary hypertension that occurs as a result of other diseases such as left heart disease, chronic lung disease, or thromboembolic disease."", ""name"": ""Secondary Pulmonary Hypertension"", ""review_notes"": ""MONDO does not have a single term for \""secondary pulmonary hypertension\"" as it is a clinical classification. Specific secondary causes have individual terms: MONDO:0013024 (chronic thromboembolic), MONDO:0017157 (due to lung disease/hypoxia).""}"	{}	"{""description"": ""Pulmonary hypertension that occurs as a result of other diseases such as left heart disease, chronic lung disease, or thromboembolic disease."", ""name"": ""Secondary Pulmonary Hypertension"", ""review_notes"": ""MONDO does not have a single term for \""secondary pulmonary hypertension\"" as it is a clinical classification. Specific secondary causes have individual terms: MONDO:0013024 (chronic thromboembolic), MONDO:0017157 (due to lung disease/hypoxia).""}"
6600	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	has_subtypes	0	RET/PTC1 (CCDC6-RET)	Most common RET rearrangement in sporadic papillary thyroid cancer, accounting for approximately 60% of RET fusions. The CCDC6 partner provides a coiled-coil dimerization domain.																																																								"{""description"": ""Most common RET rearrangement in sporadic papillary thyroid cancer, accounting for approximately 60% of RET fusions. The CCDC6 partner provides a coiled-coil dimerization domain."", ""name"": ""RET/PTC1 (CCDC6-RET)""}"	{}	"{""description"": ""Most common RET rearrangement in sporadic papillary thyroid cancer, accounting for approximately 60% of RET fusions. The CCDC6 partner provides a coiled-coil dimerization domain."", ""name"": ""RET/PTC1 (CCDC6-RET)""}"
6601	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	has_subtypes	1	RET/PTC3 (NCOA4-RET)	Second most common RET rearrangement, particularly associated with radiation-induced thyroid cancer (Chernobyl). Often associated with solid variant PTC histology.																																																								"{""description"": ""Second most common RET rearrangement, particularly associated with radiation-induced thyroid cancer (Chernobyl). Often associated with solid variant PTC histology."", ""name"": ""RET/PTC3 (NCOA4-RET)""}"	{}	"{""description"": ""Second most common RET rearrangement, particularly associated with radiation-induced thyroid cancer (Chernobyl). Often associated with solid variant PTC histology."", ""name"": ""RET/PTC3 (NCOA4-RET)""}"
6602	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	has_subtypes	2	Other RET Fusions	Multiple other fusion partners have been identified including PRKAR1A, TRIM24, and others. All result in constitutive RET activation.																																																								"{""description"": ""Multiple other fusion partners have been identified including PRKAR1A, TRIM24, and others. All result in constitutive RET activation."", ""name"": ""Other RET Fusions""}"	{}	"{""description"": ""Multiple other fusion partners have been identified including PRKAR1A, TRIM24, and others. All result in constitutive RET activation."", ""name"": ""Other RET Fusions""}"
6618	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	has_subtypes	0	KIF5B-RET NSCLC	KIF5B-RET is the most common RET fusion in NSCLC (~70-90%), resulting from a pericentric inversion on chromosome 10. The kinesin family member provides a coiled-coil dimerization domain.																																																								"{""description"": ""KIF5B-RET is the most common RET fusion in NSCLC (~70-90%), resulting from a pericentric inversion on chromosome 10. The kinesin family member provides a coiled-coil dimerization domain."", ""name"": ""KIF5B-RET NSCLC""}"	{}	"{""description"": ""KIF5B-RET is the most common RET fusion in NSCLC (~70-90%), resulting from a pericentric inversion on chromosome 10. The kinesin family member provides a coiled-coil dimerization domain."", ""name"": ""KIF5B-RET NSCLC""}"
6619	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	has_subtypes	1	CCDC6-RET NSCLC	CCDC6-RET accounts for approximately 15-20% of RET fusions in NSCLC. Also common in papillary thyroid carcinoma (PTC1).																																																								"{""description"": ""CCDC6-RET accounts for approximately 15-20% of RET fusions in NSCLC. Also common in papillary thyroid carcinoma (PTC1)."", ""name"": ""CCDC6-RET NSCLC""}"	{}	"{""description"": ""CCDC6-RET accounts for approximately 15-20% of RET fusions in NSCLC. Also common in papillary thyroid carcinoma (PTC1)."", ""name"": ""CCDC6-RET NSCLC""}"
6620	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	has_subtypes	2	NCOA4-RET NSCLC	NCOA4-RET is a less common fusion variant, also found in thyroid cancer (PTC3).																																																								"{""description"": ""NCOA4-RET is a less common fusion variant, also found in thyroid cancer (PTC3)."", ""name"": ""NCOA4-RET NSCLC""}"	{}	"{""description"": ""NCOA4-RET is a less common fusion variant, also found in thyroid cancer (PTC3)."", ""name"": ""NCOA4-RET NSCLC""}"
6638	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	has_subtypes	0	CD74-ROS1 NSCLC	CD74-ROS1 is the most common ROS1 fusion partner (~40-45%), resulting from a chromosomal rearrangement between chromosomes 5 and 6. CD74 provides the dimerization domain for constitutive ROS1 activation.																																																								"{""description"": ""CD74-ROS1 is the most common ROS1 fusion partner (~40-45%), resulting from a chromosomal rearrangement between chromosomes 5 and 6. CD74 provides the dimerization domain for constitutive ROS1 activation."", ""name"": ""CD74-ROS1 NSCLC""}"	{}	"{""description"": ""CD74-ROS1 is the most common ROS1 fusion partner (~40-45%), resulting from a chromosomal rearrangement between chromosomes 5 and 6. CD74 provides the dimerization domain for constitutive ROS1 activation."", ""name"": ""CD74-ROS1 NSCLC""}"
6639	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	has_subtypes	1	EZR-ROS1 NSCLC	EZR-ROS1 fusion accounts for approximately 15% of ROS1 rearrangements. The ezrin protein provides membrane localization and dimerization for ROS1 activation.																																																								"{""description"": ""EZR-ROS1 fusion accounts for approximately 15% of ROS1 rearrangements. The ezrin protein provides membrane localization and dimerization for ROS1 activation."", ""name"": ""EZR-ROS1 NSCLC""}"	{}	"{""description"": ""EZR-ROS1 fusion accounts for approximately 15% of ROS1 rearrangements. The ezrin protein provides membrane localization and dimerization for ROS1 activation."", ""name"": ""EZR-ROS1 NSCLC""}"
6640	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	has_subtypes	2	SDC4-ROS1 NSCLC	SDC4-ROS1 (syndecan-4) fusion is another common variant, found in approximately 10% of ROS1-positive cases.																																																								"{""description"": ""SDC4-ROS1 (syndecan-4) fusion is another common variant, found in approximately 10% of ROS1-positive cases."", ""name"": ""SDC4-ROS1 NSCLC""}"	{}	"{""description"": ""SDC4-ROS1 (syndecan-4) fusion is another common variant, found in approximately 10% of ROS1-positive cases."", ""name"": ""SDC4-ROS1 NSCLC""}"
6713	287	Retinoblastoma	Retinoblastoma.yaml	has_subtypes	0	Hereditary Retinoblastoma	Caused by germline RB1 mutation (first hit) present in all cells, with somatic loss of the remaining allele in retinal cells. Typically bilateral or multifocal. Patients have 50% chance of passing mutation to offspring and increased lifetime risk of secondary malignancies including osteosarcoma.																																																								"{""description"": ""Caused by germline RB1 mutation (first hit) present in all cells, with somatic loss of the remaining allele in retinal cells. Typically bilateral or multifocal. Patients have 50% chance of passing mutation to offspring and increased lifetime risk of secondary malignancies including osteosarcoma."", ""name"": ""Hereditary Retinoblastoma""}"	{}	"{""description"": ""Caused by germline RB1 mutation (first hit) present in all cells, with somatic loss of the remaining allele in retinal cells. Typically bilateral or multifocal. Patients have 50% chance of passing mutation to offspring and increased lifetime risk of secondary malignancies including osteosarcoma."", ""evidence"": [{""explanation"": ""Knudson's analysis established that hereditary retinoblastoma involves germline inheritance of the first mutation."", ""reference"": ""PMID:5279523"", ""snippet"": ""In the dominantly inherited form, one mutation is inherited via the germinal cells and the second occurs in somatic cells."", ""supports"": ""SUPPORT""}], ""name"": ""Hereditary Retinoblastoma""}"
6714	287	Retinoblastoma	Retinoblastoma.yaml	has_subtypes	1	Sporadic Retinoblastoma	Both RB1 alleles are inactivated by somatic mutations in a single retinal precursor cell. Typically unilateral and unifocal. No increased risk of secondary malignancies and no familial transmission unless mosaicism present.																																																								"{""description"": ""Both RB1 alleles are inactivated by somatic mutations in a single retinal precursor cell. Typically unilateral and unifocal. No increased risk of secondary malignancies and no familial transmission unless mosaicism present."", ""name"": ""Sporadic Retinoblastoma""}"	{}	"{""description"": ""Both RB1 alleles are inactivated by somatic mutations in a single retinal precursor cell. Typically unilateral and unifocal. No increased risk of secondary malignancies and no familial transmission unless mosaicism present."", ""evidence"": [{""explanation"": ""Knudson established that sporadic retinoblastoma requires two somatic mutations in the same cell."", ""reference"": ""PMID:5279523"", ""snippet"": ""In the nonhereditary form, both mutations occur in somatic cells."", ""supports"": ""SUPPORT""}], ""name"": ""Sporadic Retinoblastoma""}"
6740	289	Rett Syndrome	Rett_Syndrome.yaml	has_subtypes	0	Classic Rett Syndrome	Typical presentation with regression, hand stereotypies, gait abnormalities, and acquired microcephaly.																																																								"{""description"": ""Typical presentation with regression, hand stereotypies, gait abnormalities, and acquired microcephaly."", ""name"": ""Classic Rett Syndrome""}"	{}	"{""description"": ""Typical presentation with regression, hand stereotypies, gait abnormalities, and acquired microcephaly."", ""name"": ""Classic Rett Syndrome""}"
6741	289	Rett Syndrome	Rett_Syndrome.yaml	has_subtypes	1	Atypical Rett Syndrome	Variants including preserved speech, early seizure onset, or congenital forms.																																																								"{""description"": ""Variants including preserved speech, early seizure onset, or congenital forms."", ""name"": ""Atypical Rett Syndrome""}"	{}	"{""description"": ""Variants including preserved speech, early seizure onset, or congenital forms."", ""name"": ""Atypical Rett Syndrome""}"
6772	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	0	Seropositive Rheumatoid Arthritis	Characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies.																																																								"{""description"": ""Characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies."", ""name"": ""Seropositive Rheumatoid Arthritis""}"	{}	"{""description"": ""Characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies."", ""evidence"": [{""explanation"": ""The literature indicates that RA can be subdivided into seropositive and seronegative types based on the presence of RF and/or ACPAs in the sera of the patients, which supports the given statement."", ""reference"": ""PMID:28451788"", ""snippet"": ""Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA)... RA can be subdivided into seropositive and seronegative disease."", ""supports"": ""SUPPORT""}], ""name"": ""Seropositive Rheumatoid Arthritis""}"
6773	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	1	Seronegative Rheumatoid Arthritis	Absence of both RF and anti-CCP antibodies, but with typical clinical features of RA.																																																								"{""description"": ""Absence of both RF and anti-CCP antibodies, but with typical clinical features of RA."", ""name"": ""Seronegative Rheumatoid Arthritis""}"	{}	"{""description"": ""Absence of both RF and anti-CCP antibodies, but with typical clinical features of RA."", ""evidence"": [{""explanation"": ""This study discusses SN-RA as a form characterized by the absence of anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), supporting the statement."", ""reference"": ""PMID:33329548"", ""snippet"": ""Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study acknowledges the existence of seronegative RA defined by the absence of RF."", ""reference"": ""PMID:3266362"", ""snippet"": ""We became increasingly concerned with the problem of defining properly patients with seronegative RA. Both the statement of seronegativity with regard to rheumatoid factors (RF), the diagnosis of RA, and particularly the exclusion of cases of seronegative arthritis other than RA were difficult."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the seronegative classification based on the absence of RF and anti-CCP antibodies but points out the complexity and variability within seronegative RA."", ""reference"": ""PMID:32678001"", ""snippet"": ""Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays."", ""supports"": ""PARTIAL""}, {""explanation"": ""Refers to RA without autoantibodies, supporting the statement that such a subtype exists."", ""reference"": ""PMID:38251565"", ""snippet"": ""The subset of rheumatoid arthritis that does not have autoantibodies (such as rheumatoid factor and anti-citrullinated protein autoantibodies) remains less well defined in its pathogenic mechanisms."", ""supports"": ""SUPPORT""}], ""name"": ""Seronegative Rheumatoid Arthritis""}"
6774	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	2	Juvenile Idiopathic Arthritis (JIA)	Onset of arthritis before the age of 16, persisting for at least 6 weeks.																																																								"{""description"": ""Onset of arthritis before the age of 16, persisting for at least 6 weeks."", ""name"": ""Juvenile Idiopathic Arthritis (JIA)""}"	{}	"{""description"": ""Onset of arthritis before the age of 16, persisting for at least 6 weeks."", ""evidence"": [{""explanation"": ""The literature specifies that JIA is defined as arthritis lasting for more than 6 weeks with onset before 16 years, aligning with the statement. However, JIA is not a subtype of Rheumatoid Arthritis but rather a distinct condition."", ""reference"": ""PMID:35087087"", ""snippet"": ""Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study focuses on Juvenile Rheumatoid Arthritis (JRA), a term which is sometimes used synonymously with Juvenile Idiopathic Arthritis (JIA) but does not explicitly define it as a subtype of Rheumatoid Arthritis."", ""reference"": ""PMID:23763801"", ""snippet"": ""To determine the spectrum of clinical presentation, laboratory parameters and drug therapy in patients with Juvenile Rheumatoid Arthritis (JRA)."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This literature mentions that RF-positive juvenile idiopathic arthritis is a type of JIA sharing features with adult RA. It confirms that JIA has clinical overlap with RA but does not support that JIA is a subtype of RA."", ""reference"": ""PMID:37700346"", ""snippet"": ""Childhood-onset rheumatoid arthritis (CORA), known as rheumatoid factor (RF)-positive juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis that shares the same genetic factors and clinical features as adult-onset rheumatoid arthritis."", ""supports"": ""PARTIAL""}, {""explanation"": ""The literature provided does not discuss JIA or its relation as a subtype of RA."", ""reference"": ""PMID:8465574"", ""snippet"": ""Ten to thirty-three per cent of all cases of rheumatoid arthritis (RA) develop after sixty years of age. Late-onset RA patients are more likely to be male, to have faster onset of symptoms..."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Juvenile Idiopathic Arthritis (JIA)""}"
6849	293	Salla Disease	Salla_Disease.yaml	has_subtypes	0	Intermediate-Severe Salla Disease	Intermediate severity variant with onset in infancy, developmental plateau in childhood, followed by progressive neurological regression in adolescence. More severe than classic Salla disease with progressive neurological regression in adolescence. Typically carries different SLC17A5 variants (e.g., splice site mutations). Lifespan extends into adolescence/adulthood but with continued neurological decline.																																																								"{""description"": ""Intermediate severity variant with onset in infancy, developmental plateau in childhood, followed by progressive neurological regression in adolescence. More severe than classic Salla disease with progressive neurological regression in adolescence. Typically carries different SLC17A5 variants (e.g., splice site mutations). Lifespan extends into adolescence/adulthood but with continued neurological decline."", ""name"": ""Intermediate-Severe Salla Disease""}"	{}	"{""description"": ""Intermediate severity variant with onset in infancy, developmental plateau in childhood, followed by progressive neurological regression in adolescence. More severe than classic Salla disease with progressive neurological regression in adolescence. Typically carries different SLC17A5 variants (e.g., splice site mutations). Lifespan extends into adolescence/adulthood but with continued neurological decline."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Longitudinal study characterizes clinical course of intermediate-severe Salla disease as distinct from classic form with progressive regression."", ""reference"": ""PMID:37713976"", ""snippet"": ""Disease onset occurred within the first six months of life in both patients. Early childhood development was delayed with achievement of some milestones followed by a developmental plateau in late childhood. After this, both patients began a slow and progressive neurological regression in adolescence."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive literature review and case report of intermediate-severe Salla disease identifies hypomyelination, developmental delay, and hypotonia as characteristic features, with compound heterozygous SLC17A5 variants. Demonstrates that normal or marginally elevated urine sialic acid cannot exclude this phenotype."", ""reference"": ""PMID:28662915"", ""snippet"": ""Likely pathogenic variants in SLC17A5 results in allelic disorders of free sialic acid metabolism including (1) infantile free sialic acid storage disease with severe global developmental delay, coarse facial features, hepatosplenomegaly, and cardiomegaly; (2) intermediate severe Salla disease with moderate to severe global developmental delay, hypotonia, and hypomyelination with or without coarse facial features, and (3) Salla disease with normal appearance, mild cognitive dysfunction, and spasticity."", ""supports"": ""SUPPORT""}], ""name"": ""Intermediate-Severe Salla Disease""}"
6881	294	Sarcoidosis	Sarcoidosis.yaml	has_subtypes	0	Pulmonary Sarcoidosis	Most common form, affecting lungs and hilar lymph nodes; staged by chest radiograph findings.																																																								"{""description"": ""Most common form, affecting lungs and hilar lymph nodes; staged by chest radiograph findings."", ""name"": ""Pulmonary Sarcoidosis""}"	{}	"{""description"": ""Most common form, affecting lungs and hilar lymph nodes; staged by chest radiograph findings."", ""name"": ""Pulmonary Sarcoidosis""}"
6882	294	Sarcoidosis	Sarcoidosis.yaml	has_subtypes	1	Cardiac Sarcoidosis	Myocardial granulomas causing conduction abnormalities, heart failure, or sudden death.																																																								"{""description"": ""Myocardial granulomas causing conduction abnormalities, heart failure, or sudden death."", ""name"": ""Cardiac Sarcoidosis""}"	{}	"{""description"": ""Myocardial granulomas causing conduction abnormalities, heart failure, or sudden death."", ""name"": ""Cardiac Sarcoidosis""}"
6883	294	Sarcoidosis	Sarcoidosis.yaml	has_subtypes	2	Neurosarcoidosis	CNS involvement causing cranial neuropathies, meningitis, or mass lesions.																																																								"{""description"": ""CNS involvement causing cranial neuropathies, meningitis, or mass lesions."", ""name"": ""Neurosarcoidosis""}"	{}	"{""description"": ""CNS involvement causing cranial neuropathies, meningitis, or mass lesions."", ""name"": ""Neurosarcoidosis""}"
6884	294	Sarcoidosis	Sarcoidosis.yaml	has_subtypes	3	Cutaneous Sarcoidosis	Skin manifestations including erythema nodosum, lupus pernio, and papular lesions.																																																								"{""description"": ""Skin manifestations including erythema nodosum, lupus pernio, and papular lesions."", ""name"": ""Cutaneous Sarcoidosis""}"	{}	"{""description"": ""Skin manifestations including erythema nodosum, lupus pernio, and papular lesions."", ""name"": ""Cutaneous Sarcoidosis""}"
7156	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	has_subtypes	0	Limited-Stage SCLC	Disease confined to one hemithorax that can be encompassed within a tolerable radiation field. Approximately 30% of SCLC presents as limited-stage. Treatment includes concurrent chemoradiation with potential for cure.																																																								"{""description"": ""Disease confined to one hemithorax that can be encompassed within a tolerable radiation field. Approximately 30% of SCLC presents as limited-stage. Treatment includes concurrent chemoradiation with potential for cure."", ""name"": ""Limited-Stage SCLC""}"	{}	"{""description"": ""Disease confined to one hemithorax that can be encompassed within a tolerable radiation field. Approximately 30% of SCLC presents as limited-stage. Treatment includes concurrent chemoradiation with potential for cure."", ""name"": ""Limited-Stage SCLC""}"
7157	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	has_subtypes	1	Extensive-Stage SCLC	Disease beyond a single hemithorax or with distant metastases. Approximately 70% of SCLC presents as extensive-stage. Treated with chemotherapy plus immunotherapy; not curable but can achieve meaningful responses.																																																								"{""description"": ""Disease beyond a single hemithorax or with distant metastases. Approximately 70% of SCLC presents as extensive-stage. Treated with chemotherapy plus immunotherapy; not curable but can achieve meaningful responses."", ""name"": ""Extensive-Stage SCLC""}"	{}	"{""description"": ""Disease beyond a single hemithorax or with distant metastases. Approximately 70% of SCLC presents as extensive-stage. Treated with chemotherapy plus immunotherapy; not curable but can achieve meaningful responses."", ""name"": ""Extensive-Stage SCLC""}"
7158	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	has_subtypes	2	SCLC-A (ASCL1-high)	SCLC subtype defined by high ASCL1 expression. Associated with classic neuroendocrine phenotype and may respond differently to therapy.																																																								"{""description"": ""SCLC subtype defined by high ASCL1 expression. Associated with classic neuroendocrine phenotype and may respond differently to therapy."", ""name"": ""SCLC-A (ASCL1-high)""}"	{}	"{""description"": ""SCLC subtype defined by high ASCL1 expression. Associated with classic neuroendocrine phenotype and may respond differently to therapy."", ""name"": ""SCLC-A (ASCL1-high)""}"
7159	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	has_subtypes	3	SCLC-N (NEUROD1-high)	SCLC subtype defined by high NEUROD1 expression. Variant neuroendocrine phenotype.																																																								"{""description"": ""SCLC subtype defined by high NEUROD1 expression. Variant neuroendocrine phenotype."", ""name"": ""SCLC-N (NEUROD1-high)""}"	{}	"{""description"": ""SCLC subtype defined by high NEUROD1 expression. Variant neuroendocrine phenotype."", ""name"": ""SCLC-N (NEUROD1-high)""}"
7160	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	has_subtypes	4	SCLC-P (POU2F3-high)	SCLC subtype defined by high POU2F3 expression. Tuft cell-like phenotype, may lack classic neuroendocrine markers.																																																								"{""description"": ""SCLC subtype defined by high POU2F3 expression. Tuft cell-like phenotype, may lack classic neuroendocrine markers."", ""name"": ""SCLC-P (POU2F3-high)""}"	{}	"{""description"": ""SCLC subtype defined by high POU2F3 expression. Tuft cell-like phenotype, may lack classic neuroendocrine markers."", ""name"": ""SCLC-P (POU2F3-high)""}"
7161	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	has_subtypes	5	SCLC-Y (YAP1-high)	SCLC subtype with YAP1 activation. Non-neuroendocrine phenotype, may arise from epithelial-mesenchymal transition.																																																								"{""description"": ""SCLC subtype with YAP1 activation. Non-neuroendocrine phenotype, may arise from epithelial-mesenchymal transition."", ""name"": ""SCLC-Y (YAP1-high)""}"	{}	"{""description"": ""SCLC subtype with YAP1 activation. Non-neuroendocrine phenotype, may arise from epithelial-mesenchymal transition."", ""name"": ""SCLC-Y (YAP1-high)""}"
7211	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	has_subtypes	0	SMA Type 1 (Werdnig-Hoffmann)	Most severe, onset before 6 months, never sit independently, death usually by age 2.																																																								"{""description"": ""Most severe, onset before 6 months, never sit independently, death usually by age 2."", ""name"": ""SMA Type 1 (Werdnig-Hoffmann)""}"	{}	"{""description"": ""Most severe, onset before 6 months, never sit independently, death usually by age 2."", ""name"": ""SMA Type 1 (Werdnig-Hoffmann)""}"
7212	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	has_subtypes	1	SMA Type 2	Intermediate, onset 6-18 months, can sit but never walk independently.																																																								"{""description"": ""Intermediate, onset 6-18 months, can sit but never walk independently."", ""name"": ""SMA Type 2""}"	{}	"{""description"": ""Intermediate, onset 6-18 months, can sit but never walk independently."", ""name"": ""SMA Type 2""}"
7213	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	has_subtypes	2	SMA Type 3 (Kugelberg-Welander)	Milder, onset after 18 months, can walk but may lose ability later.																																																								"{""description"": ""Milder, onset after 18 months, can walk but may lose ability later."", ""name"": ""SMA Type 3 (Kugelberg-Welander)""}"	{}	"{""description"": ""Milder, onset after 18 months, can walk but may lose ability later."", ""name"": ""SMA Type 3 (Kugelberg-Welander)""}"
7214	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	has_subtypes	3	SMA Type 4	Adult onset, mildest form, normal lifespan with mild weakness.																																																								"{""description"": ""Adult onset, mildest form, normal lifespan with mild weakness."", ""name"": ""SMA Type 4""}"	{}	"{""description"": ""Adult onset, mildest form, normal lifespan with mild weakness."", ""name"": ""SMA Type 4""}"
7283	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	has_subtypes	0	Classic Stiff Person Syndrome	The prototypical form with stiffness predominantly in truncal and proximal limb muscles, progressive gait disturbance, and lumbar hyperlordosis.																																																								"{""description"": ""The prototypical form with stiffness predominantly in truncal and proximal limb muscles, progressive gait disturbance, and lumbar hyperlordosis."", ""name"": ""Classic Stiff Person Syndrome""}"	{}	"{""description"": ""The prototypical form with stiffness predominantly in truncal and proximal limb muscles, progressive gait disturbance, and lumbar hyperlordosis."", ""evidence"": [{""explanation"": ""The paper defines classic SPS as part of a broader spectrum of GAD antibody-associated disorders with unique clinical phenotypes."", ""reference"": ""PMID:35084720"", ""snippet"": ""GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder. In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability."", ""supports"": ""SUPPORT""}], ""name"": ""Classic Stiff Person Syndrome""}"
7284	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	has_subtypes	1	Stiff Limb Syndrome	A focal variant with stiffness and spasms limited to one or more limbs, often one leg, without significant axial involvement.																																																								"{""description"": ""A focal variant with stiffness and spasms limited to one or more limbs, often one leg, without significant axial involvement."", ""name"": ""Stiff Limb Syndrome""}"	{}	"{""description"": ""A focal variant with stiffness and spasms limited to one or more limbs, often one leg, without significant axial involvement."", ""evidence"": [{""explanation"": ""Clinical heterogeneity in GAD-spectrum disorders includes focal variants like stiff limb syndrome."", ""reference"": ""PMID:35084720"", ""snippet"": ""In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability."", ""supports"": ""SUPPORT""}], ""name"": ""Stiff Limb Syndrome""}"
7285	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	has_subtypes	2	Progressive Encephalomyelitis with Rigidity and Myoclonus	A severe variant with brainstem and spinal cord involvement, featuring rigidity, myoclonus, and autonomic dysfunction, often with a more aggressive course.																																																								"{""description"": ""A severe variant with brainstem and spinal cord involvement, featuring rigidity, myoclonus, and autonomic dysfunction, often with a more aggressive course."", ""name"": ""Progressive Encephalomyelitis with Rigidity and Myoclonus""}"	{}	"{""description"": ""A severe variant with brainstem and spinal cord involvement, featuring rigidity, myoclonus, and autonomic dysfunction, often with a more aggressive course."", ""evidence"": [{""explanation"": ""PERM is explicitly listed as part of the GAD antibody-spectrum disorders."", ""reference"": ""PMID:35084720"", ""snippet"": ""GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder."", ""supports"": ""SUPPORT""}], ""name"": ""Progressive Encephalomyelitis with Rigidity and Myoclonus""}"
7303	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	has_subtypes	0	Biphasic Synovial Sarcoma	Contains both epithelial and spindle cell components with distinct glandular or epithelial differentiation. Accounts for approximately 20-30% of cases.																																																								"{""description"": ""Contains both epithelial and spindle cell components with distinct glandular or epithelial differentiation. Accounts for approximately 20-30% of cases."", ""name"": ""Biphasic Synovial Sarcoma""}"	{}	"{""description"": ""Contains both epithelial and spindle cell components with distinct glandular or epithelial differentiation. Accounts for approximately 20-30% of cases."", ""name"": ""Biphasic Synovial Sarcoma""}"
7304	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	has_subtypes	1	Monophasic Synovial Sarcoma	Composed predominantly of spindle cells without obvious epithelial component. The most common subtype, accounting for 50-60% of cases. Can be more difficult to diagnose histologically.																																																								"{""description"": ""Composed predominantly of spindle cells without obvious epithelial component. The most common subtype, accounting for 50-60% of cases. Can be more difficult to diagnose histologically."", ""name"": ""Monophasic Synovial Sarcoma""}"	{}	"{""description"": ""Composed predominantly of spindle cells without obvious epithelial component. The most common subtype, accounting for 50-60% of cases. Can be more difficult to diagnose histologically."", ""name"": ""Monophasic Synovial Sarcoma""}"
7305	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	has_subtypes	2	Poorly Differentiated Synovial Sarcoma	High-grade variant with round cell or epithelioid morphology. Associated with more aggressive behavior and worse prognosis.																																																								"{""description"": ""High-grade variant with round cell or epithelioid morphology. Associated with more aggressive behavior and worse prognosis."", ""name"": ""Poorly Differentiated Synovial Sarcoma""}"	{}	"{""description"": ""High-grade variant with round cell or epithelioid morphology. Associated with more aggressive behavior and worse prognosis."", ""name"": ""Poorly Differentiated Synovial Sarcoma""}"
7337	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	0	Discoid Lupus Erythematosus	Primarily affects the skin.																																																								"{""description"": ""Primarily affects the skin."", ""name"": ""Discoid Lupus Erythematosus""}"	{}	"{""description"": ""Primarily affects the skin."", ""evidence"": [{""explanation"": ""Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin."", ""reference"": ""PMID:30988213"", ""snippet"": ""The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms that Discoid Lupus Erythematosus primarily affects the skin."", ""reference"": ""PMID:7763220"", ""snippet"": ""Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus."", ""reference"": ""PMID:28941498"", ""snippet"": ""Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types."", ""supports"": ""SUPPORT""}], ""name"": ""Discoid Lupus Erythematosus""}"
7338	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	1	Neonatal Lupus	Affects infants, caused by transplacental transfer of maternal autoantibodies.																																																								"{""description"": ""Affects infants, caused by transplacental transfer of maternal autoantibodies."", ""name"": ""Neonatal Lupus""}"	{}	"{""description"": ""Affects infants, caused by transplacental transfer of maternal autoantibodies."", ""evidence"": [{""explanation"": ""This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies."", ""reference"": ""PMID:9287379"", ""snippet"": ""neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement."", ""reference"": ""PMID:24763535"", ""snippet"": ""Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies."", ""reference"": ""PMID:15744116"", ""snippet"": ""Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors."", ""reference"": ""PMID:3521977"", ""snippet"": ""Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn't explicitly say it's a systemic lupus erythematosus subtype."", ""reference"": ""PMID:22832822"", ""snippet"": ""Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy."", ""supports"": ""PARTIAL""}], ""name"": ""Neonatal Lupus""}"
7339	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	2	Drug-Induced Lupus	Caused by certain medications and usually reversible.																																																								"{""description"": ""Caused by certain medications and usually reversible."", ""name"": ""Drug-Induced Lupus""}"	{}	"{""description"": ""Caused by certain medications and usually reversible."", ""evidence"": [{""explanation"": ""This indicates that there is a distinct subtype of SLE induced by medications."", ""reference"": ""PMID:1356074"", ""snippet"": ""The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE."", ""supports"": ""SUPPORT""}, {""explanation"": ""This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug."", ""reference"": ""PMID:23164669"", ""snippet"": ""Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement."", ""reference"": ""PMID:1751313"", ""snippet"": ""All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself."", ""supports"": ""SUPPORT""}, {""explanation"": ""This article covers drug-induced lupus, affirming the existence of this subtype linked to medications."", ""reference"": ""PMID:25037258"", ""snippet"": ""This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus..."", ""supports"": ""SUPPORT""}], ""name"": ""Drug-Induced Lupus""}"
7422	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	has_subtypes	0	Infantile Tay-Sachs	Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5.																																																								"{""description"": ""Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5."", ""name"": ""Infantile Tay-Sachs""}"	{}	"{""description"": ""Classic form with onset at 3-6 months, rapidly progressive, fatal by age 4-5."", ""name"": ""Infantile Tay-Sachs""}"
7423	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	has_subtypes	1	Juvenile Tay-Sachs	Onset in childhood, slower progression, death in adolescence.																																																								"{""description"": ""Onset in childhood, slower progression, death in adolescence."", ""name"": ""Juvenile Tay-Sachs""}"	{}	"{""description"": ""Onset in childhood, slower progression, death in adolescence."", ""name"": ""Juvenile Tay-Sachs""}"
7424	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	has_subtypes	2	Late-Onset Tay-Sachs	Adult onset, variable progression, compatible with longer survival.																																																								"{""description"": ""Adult onset, variable progression, compatible with longer survival."", ""name"": ""Late-Onset Tay-Sachs""}"	{}	"{""description"": ""Adult onset, variable progression, compatible with longer survival."", ""name"": ""Late-Onset Tay-Sachs""}"
7547	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	0	Basal-like TNBC	The most common TNBC subtype (50-75%), characterized by expression of basal cytokeratins (CK5/6, CK14, CK17), EGFR expression, high proliferation, and frequent TP53 and BRCA1 mutations. Overlaps significantly with BRCA1-associated breast cancer.																																																								"{""description"": ""The most common TNBC subtype (50-75%), characterized by expression of basal cytokeratins (CK5/6, CK14, CK17), EGFR expression, high proliferation, and frequent TP53 and BRCA1 mutations. Overlaps significantly with BRCA1-associated breast cancer."", ""name"": ""Basal-like TNBC""}"	{}	"{""description"": ""The most common TNBC subtype (50-75%), characterized by expression of basal cytokeratins (CK5/6, CK14, CK17), EGFR expression, high proliferation, and frequent TP53 and BRCA1 mutations. Overlaps significantly with BRCA1-associated breast cancer."", ""evidence"": [{""explanation"": ""The Lehmann et al. study identified basal-like subtypes (BL1 and BL2) with high cell cycle and DNA damage response gene expression, consistent with high proliferation and BRCA1 mutations."", ""reference"": ""PMID:21633166"", ""snippet"": ""BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin."", ""supports"": ""SUPPORT""}], ""name"": ""Basal-like TNBC""}"
7548	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	1	Mesenchymal TNBC	Characterized by epithelial-mesenchymal transition features, enrichment in cell motility and differentiation pathways. May respond to PI3K/mTOR inhibition.																																																								"{""description"": ""Characterized by epithelial-mesenchymal transition features, enrichment in cell motility and differentiation pathways. May respond to PI3K/mTOR inhibition."", ""name"": ""Mesenchymal TNBC""}"	{}	"{""description"": ""Characterized by epithelial-mesenchymal transition features, enrichment in cell motility and differentiation pathways. May respond to PI3K/mTOR inhibition."", ""evidence"": [{""explanation"": ""The Lehmann et al. study confirmed mesenchymal subtypes are enriched for EMT and growth factor pathways, responding to PI3K/mTOR inhibition."", ""reference"": ""PMID:21633166"", ""snippet"": ""M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor)."", ""supports"": ""SUPPORT""}], ""name"": ""Mesenchymal TNBC""}"
7549	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	2	Luminal Androgen Receptor (LAR) TNBC	Despite being ER/PR-negative, LAR tumors express androgen receptor and have luminal gene expression patterns. May benefit from androgen receptor-targeted therapy. Often have PIK3CA mutations.																																																								"{""description"": ""Despite being ER/PR-negative, LAR tumors express androgen receptor and have luminal gene expression patterns. May benefit from androgen receptor-targeted therapy. Often have PIK3CA mutations."", ""name"": ""Luminal Androgen Receptor (LAR) TNBC""}"	{}	"{""description"": ""Despite being ER/PR-negative, LAR tumors express androgen receptor and have luminal gene expression patterns. May benefit from androgen receptor-targeted therapy. Often have PIK3CA mutations."", ""evidence"": [{""explanation"": ""The Lehmann et al. study identified the LAR subtype characterized by AR signaling and sensitivity to AR antagonists."", ""reference"": ""PMID:21633166"", ""snippet"": ""The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist)."", ""supports"": ""SUPPORT""}], ""name"": ""Luminal Androgen Receptor (LAR) TNBC""}"
7550	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	3	Immunomodulatory TNBC	Characterized by immune cell infiltration and immune checkpoint expression. Best responders to immune checkpoint inhibitor therapy.																																																								"{""description"": ""Characterized by immune cell infiltration and immune checkpoint expression. Best responders to immune checkpoint inhibitor therapy."", ""name"": ""Immunomodulatory TNBC""}"	{}	"{""description"": ""Characterized by immune cell infiltration and immune checkpoint expression. Best responders to immune checkpoint inhibitor therapy."", ""evidence"": [{""explanation"": ""The Lehmann et al. study identified the immunomodulatory (IM) subtype as one of the six TNBC subtypes with unique gene expression profiles."", ""reference"": ""PMID:21633166"", ""snippet"": ""Cluster analysis identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype."", ""supports"": ""SUPPORT""}], ""name"": ""Immunomodulatory TNBC""}"
7735	336	Uveal Melanoma	Uveal_Melanoma.yaml	has_subtypes	0	Choroidal Melanoma	Melanoma arising from the choroid, the vascular layer between the retina and sclera. Most common uveal melanoma subtype (85-90%). May cause retinal detachment, visual disturbance, or be discovered incidentally.																																																								"{""description"": ""Melanoma arising from the choroid, the vascular layer between the retina and sclera. Most common uveal melanoma subtype (85-90%). May cause retinal detachment, visual disturbance, or be discovered incidentally."", ""name"": ""Choroidal Melanoma""}"	{}	"{""description"": ""Melanoma arising from the choroid, the vascular layer between the retina and sclera. Most common uveal melanoma subtype (85-90%). May cause retinal detachment, visual disturbance, or be discovered incidentally."", ""name"": ""Choroidal Melanoma""}"
7736	336	Uveal Melanoma	Uveal_Melanoma.yaml	has_subtypes	1	Ciliary Body Melanoma	Melanoma arising from the ciliary body, located behind the iris. Less common (5-10%) but associated with higher metastatic risk due to delayed detection and involvement of vascular structures.																																																								"{""description"": ""Melanoma arising from the ciliary body, located behind the iris. Less common (5-10%) but associated with higher metastatic risk due to delayed detection and involvement of vascular structures."", ""name"": ""Ciliary Body Melanoma""}"	{}	"{""description"": ""Melanoma arising from the ciliary body, located behind the iris. Less common (5-10%) but associated with higher metastatic risk due to delayed detection and involvement of vascular structures."", ""name"": ""Ciliary Body Melanoma""}"
7737	336	Uveal Melanoma	Uveal_Melanoma.yaml	has_subtypes	2	Iris Melanoma	Melanoma arising from the iris, the colored portion of the eye. Least common uveal melanoma subtype (3-5%) but often detected earlier due to visible pigmented lesion. Generally better prognosis.																																																								"{""description"": ""Melanoma arising from the iris, the colored portion of the eye. Least common uveal melanoma subtype (3-5%) but often detected earlier due to visible pigmented lesion. Generally better prognosis."", ""name"": ""Iris Melanoma""}"	{}	"{""description"": ""Melanoma arising from the iris, the colored portion of the eye. Least common uveal melanoma subtype (3-5%) but often detected earlier due to visible pigmented lesion. Generally better prognosis."", ""name"": ""Iris Melanoma""}"
7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	Non-Segmental Vitiligo (NSV)	Most common form, characterized by symmetrical depigmented patches on both sides of the body. Includes generalized, acrofacial, and universal variants.																																																								"{""description"": ""Most common form, characterized by symmetrical depigmented patches on both sides of the body. Includes generalized, acrofacial, and universal variants."", ""name"": ""Non-Segmental Vitiligo (NSV)""}"	{}	"{""description"": ""Most common form, characterized by symmetrical depigmented patches on both sides of the body. Includes generalized, acrofacial, and universal variants."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference confirms that Non-Segmental Vitiligo (NSV) is the most common form of vitiligo."", ""reference"": ""PMID:20540698"", ""snippet"": ""Non segmental vitiligo (NSV) is the most common form of the disease: it is usually progressive and may be associated with familiarity and autoimmunity."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference identifies generalized vitiligo as the most common, which is a subtype of NSV, supporting the statement."", ""reference"": ""PMID:22237197"", ""snippet"": ""Generalized vitiligo was the most common type (n=132, 57.4%) followed by focal (n=53, 23%) and acro-facial vitiligo (n=16, 7%)."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference directly states that NSV is the most common type of vitiligo."", ""reference"": ""PMID:33431938"", ""snippet"": ""Non-segmental vitiligo (NSV) is the most common type of vitiligo, which is characterized by chronic and progressive loss of melanocytes."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference indicates the association of autoimmune conditions with NSV, characterizing it as a common subtype."", ""reference"": ""PMID:37062442"", ""snippet"": ""The concomitance of autoimmune disease in vitiligo patients demands the investigation of immune-mediated inner ear disease (IMIED) as a cause of SNHL in NSV."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""OTHER"", ""explanation"": ""This reference mainly discusses lupus erythematosus but indirectly aligns with autoimmune connections similar to NSV."", ""reference"": ""PMID:30988213"", ""snippet"": ""Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE)."", ""supports"": ""PARTIAL""}, {""evidence_source"": ""OTHER"", ""explanation"": ""This reference discusses trichrome vitiligo, which is not directly about NSV or its commonality."", ""reference"": ""PMID:7593796"", ""snippet"": ""The term 'trichrome vitiligo' has been used to describe lesions of vitiligo that have an intermediate level of color between the achromic center and the peripheral unaffected skin."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Non-Segmental Vitiligo (NSV)""}"
7783	338	Vitiligo	Vitiligo.yaml	has_subtypes	1	Segmental Vitiligo (SV)	Patches are restricted to one side of the body or one area, such as a limb or the face. Typically has an earlier onset and progresses for a few years before stabilizing.																																																								"{""description"": ""Patches are restricted to one side of the body or one area, such as a limb or the face. Typically has an earlier onset and progresses for a few years before stabilizing."", ""name"": ""Segmental Vitiligo (SV)""}"	{}	"{""description"": ""Patches are restricted to one side of the body or one area, such as a limb or the face. Typically has an earlier onset and progresses for a few years before stabilizing."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The provided description is consistent with the characterization of segmental vitiligo mentioned in the literature."", ""reference"": ""PMID:28317524"", ""snippet"": ""Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The text mentions segmental vitiligo and supports characteristics such as early onset."", ""reference"": ""PMID:35094387"", ""snippet"": ""Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV) and non-segmental vitiligo (NSV)...As compared to SV, MV had significantly lower mean age of onset of segmental component (SC) (13.33  9.01 vs. 15.70  8.60 years, P = 0.03) and significantly higher proportion of patients with more than 1% body surface involvement by SC (66.2% vs. 51.5%, P = 0.03)"", ""supports"": ""SUPPORT""}], ""name"": ""Segmental Vitiligo (SV)""}"
7784	338	Vitiligo	Vitiligo.yaml	has_subtypes	2	Mixed Vitiligo	A combination of segmental and non-segmental types occurring simultaneously or sequentially in the same individual.																																																								"{""description"": ""A combination of segmental and non-segmental types occurring simultaneously or sequentially in the same individual."", ""name"": ""Mixed Vitiligo""}"	{}	"{""description"": ""A combination of segmental and non-segmental types occurring simultaneously or sequentially in the same individual."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The provided literature discusses cases where segmental and generalized vitiligo occur together in the same individual, which supports the existence of mixed vitiligo."", ""reference"": ""PMID:17241584"", ""snippet"": ""OBSERVATION: We report four more cases of mixed vtiligo, segmental with generalized type"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference discusses overlaps and similarities between segmental and non-segmental vitiligo but does not specifically confirm the simultaneous or sequential occurrence in the same individual."", ""reference"": ""PMID:34780118"", ""snippet"": ""The overlaps between segmental vitiligo (SV) and nonsegmental vitiligo (NSV) suggest the underlying features of SV, which may be helpful for treating SV...The clinical and immunological similarities between SV and M-NSV presented a deeper autoimmune understanding of SV."", ""supports"": ""PARTIAL""}], ""name"": ""Mixed Vitiligo""}"
7807	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	has_subtypes	0	VHL Type 1	Characterized by low risk of pheochromocytoma but high risk of renal cell carcinoma, hemangioblastomas, and pancreatic tumors. Associated with truncating mutations, large deletions, and missense mutations affecting HIF binding.																																																								"{""description"": ""Characterized by low risk of pheochromocytoma but high risk of renal cell carcinoma, hemangioblastomas, and pancreatic tumors. Associated with truncating mutations, large deletions, and missense mutations affecting HIF binding."", ""name"": ""VHL Type 1""}"	{}	"{""description"": ""Characterized by low risk of pheochromocytoma but high risk of renal cell carcinoma, hemangioblastomas, and pancreatic tumors. Associated with truncating mutations, large deletions, and missense mutations affecting HIF binding."", ""name"": ""VHL Type 1""}"
7808	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	has_subtypes	1	VHL Type 2A	Characterized by pheochromocytoma and hemangioblastomas but low risk of renal cell carcinoma. Associated with specific missense mutations.																																																								"{""description"": ""Characterized by pheochromocytoma and hemangioblastomas but low risk of renal cell carcinoma. Associated with specific missense mutations."", ""name"": ""VHL Type 2A""}"	{}	"{""description"": ""Characterized by pheochromocytoma and hemangioblastomas but low risk of renal cell carcinoma. Associated with specific missense mutations."", ""name"": ""VHL Type 2A""}"
7809	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	has_subtypes	2	VHL Type 2B	High risk of all VHL-associated tumors including pheochromocytoma, renal cell carcinoma, and hemangioblastomas. Associated with specific missense mutations.																																																								"{""description"": ""High risk of all VHL-associated tumors including pheochromocytoma, renal cell carcinoma, and hemangioblastomas. Associated with specific missense mutations."", ""name"": ""VHL Type 2B""}"	{}	"{""description"": ""High risk of all VHL-associated tumors including pheochromocytoma, renal cell carcinoma, and hemangioblastomas. Associated with specific missense mutations."", ""name"": ""VHL Type 2B""}"
7810	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	has_subtypes	3	VHL Type 2C	Pheochromocytoma only, without other VHL manifestations. Associated with specific missense mutations that retain some HIF regulatory function.																																																								"{""description"": ""Pheochromocytoma only, without other VHL manifestations. Associated with specific missense mutations that retain some HIF regulatory function."", ""name"": ""VHL Type 2C""}"	{}	"{""description"": ""Pheochromocytoma only, without other VHL manifestations. Associated with specific missense mutations that retain some HIF regulatory function."", ""name"": ""VHL Type 2C""}"
7855	341	Wilms Tumor	Wilms_Tumor.yaml	has_subtypes	0	Favorable Histology Wilms Tumor	Approximately 90% of Wilms tumors have favorable histology without anaplasia. These tumors have excellent outcomes with >90% overall survival using current treatment protocols.																																																								"{""description"": ""Approximately 90% of Wilms tumors have favorable histology without anaplasia. These tumors have excellent outcomes with >90% overall survival using current treatment protocols."", ""name"": ""Favorable Histology Wilms Tumor""}"	{}	"{""description"": ""Approximately 90% of Wilms tumors have favorable histology without anaplasia. These tumors have excellent outcomes with >90% overall survival using current treatment protocols."", ""name"": ""Favorable Histology Wilms Tumor""}"
7856	341	Wilms Tumor	Wilms_Tumor.yaml	has_subtypes	1	Anaplastic Wilms Tumor	Characterized by extreme nuclear enlargement and pleomorphism with atypical mitoses. May be focal or diffuse. Diffuse anaplasia confers significantly worse prognosis and requires treatment intensification.																																																								"{""description"": ""Characterized by extreme nuclear enlargement and pleomorphism with atypical mitoses. May be focal or diffuse. Diffuse anaplasia confers significantly worse prognosis and requires treatment intensification."", ""name"": ""Anaplastic Wilms Tumor""}"	{}	"{""description"": ""Characterized by extreme nuclear enlargement and pleomorphism with atypical mitoses. May be focal or diffuse. Diffuse anaplasia confers significantly worse prognosis and requires treatment intensification."", ""name"": ""Anaplastic Wilms Tumor""}"
7857	341	Wilms Tumor	Wilms_Tumor.yaml	has_subtypes	2	Bilateral Wilms Tumor	Synchronous bilateral tumors occur in approximately 5% of cases and are enriched for germline WT1 mutations. Treatment aims for nephron-sparing approaches to preserve renal function.																																																								"{""description"": ""Synchronous bilateral tumors occur in approximately 5% of cases and are enriched for germline WT1 mutations. Treatment aims for nephron-sparing approaches to preserve renal function."", ""name"": ""Bilateral Wilms Tumor""}"	{}	"{""description"": ""Synchronous bilateral tumors occur in approximately 5% of cases and are enriched for germline WT1 mutations. Treatment aims for nephron-sparing approaches to preserve renal function."", ""name"": ""Bilateral Wilms Tumor""}"
